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 Sjögren’s syndrome (SS) is a complex systemic autoimmune disease hallmarked by 
chronic inflammation of exocrine glands, in particular lacrimal and salivary glands. In 
these glands lymphocytic infiltrates lead to destruction of the excretory tissue resul-
ting in dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia) [1].  Although 
keratoconjunctivitis sicca and xerostomia are the typical symptoms of SS, the disease 
may affect almost all organ systems of the body. Extraglandular manifestations may 
involve skin, joints, lungs, liver, kidneys, thyroid gland, lymph nodes, blood cells, central 
nervous system, vagina and skin, and may cause substantial morbidity to the affected 
individual and interfere with quality of daily life [1-3]. 
SS is one of the most prevalent autoimmune diseases with an estimated prevalence of 
1 to 3% and with a female over male preponderance of 9 : 1 [4, 5]. SS may occur alone 
as primary SS (pSS) or as secondary SS (sSS) in conjunction with other autoimmune 
disease such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) [1, 
6, 7]. 
Brief historical overview
 In 1888, the surgeon Johan Mikulicz (1850-1905) described a case of painless 
bilateral swelling of the lacrimal, parotid and submandibular glands. Surgical specimens 
of the lacrimal and both submaxillar glands contained numerous small round cells 
suggestive of lymphoma (figure 1) [8]. In 1933, during his training of ophthalmology, 
Henrik Sjögren (1899-1987) described a variety of clinical and histopathological 
findings in patients with symptoms of RA, dry eyes and dry mouth. He introduced the 
term “keratoconjunctivitis sicca” and was the first to appreciate the systemic nature of 
SS [9]. 
  The relationship between the case described by Johan Mikulicz and the cases of 
SS described by Henrik Sjögren was clarified by Morgan et al. [10] in 1954 who 
demonstrated that the histologic infiltrate in the salivary gland tissue showed a 
remarkable resemblance between the Mikulicz case and the SS cases described by 
Henrik Sjögren, stating that these cases reflect probably the same entity. Ihrler et 
al.  analysed the Mikulicz case of 1888 and identified a mucosa associated lymphoid 
tissue (MALT)-lymphoma [11]. Indeed subsequent studies confirmed the relationship 
between SS and development of lymphoma [12, 13]. 
Diagnosis
 SS is characterized by a variety of presenting symptoms that may either be rather 
specific for SS or may arise in other autoimmune and related (e.g., HIV, sarcoidosis) 
disorders as well. Thus, over time there have been a number of classification criteria 










Figure 1. Panels A-C show the woodcuts that appeared in the text of Mikulicz’s original article. A, Extensive 
symmetrical swelling of the lacrymal, parotid, submandibular, and sublingual (labelled a) glands. B, Manual lifting of the 
eyelids highlights the extensive swelling of the lacrymal glands. C, Extensive symmetrical swelling of the palatal minor 
salivary glands. Panel D is the original color print that appeared with the article. This panel consists of macroscopic 
and histologic drawings of the left submandibular gland. The external appearance (top) and the transverse section 
(middle) show an enlarged gland with a preserved lobular structure. The microscopic field (bottom) shows a uniform 
cellular infiltrate with 3 mitoses and scattered serous acini with orange secretory granules. Panel E shows the central 
part of the microscopical field of the original color print magnified to 240% revealing the nuclei of the cells of the 
infiltrate to be smaller than the nuclei of the acini. These small to medium-sized nuclei of the cells of the infiltrate are 
irregularly shaped and contain dispersed chromatin without obvious nucleoli. Although the cytoplasm of the infiltrate 
is unstained, the separation between the nuclei indicates that it is abundant. These features are those of lymphocytes of 










Table 1. The 2002 American-European classification criteria for SS [14].
 I. Ocular symptoms: a positive response to at least one of the following questions:
  1.  Have you had daily, persistent, troublesome dry eyes for more than 3 months?
  2. Do you have a recurrent sensation of sand or gravel in the eyes?
  3. Do you use tear substitutes more than 3 times a day?
 II. Oral symptoms: a positive response to at least one of the following questions:
  1. Have you had a daily feeling of dry mouth for more than 3 months?
  2 Have you had recurrently or persistently swollen salivary glands as an adult?
  3. Do you frequently drink liquids to aid in swallowing dry food?
 III. Ocular signs- that is, objective evidence of ocular involvement defined as a positive result for at least one of  
   the following tests:
  1. Schirmer’s test, performed without anaesthesia (<5mm in 5 minutes)
  2. Rose bengal score or other ocular dye score (>4 according to van Bijsterveld’s scoring system)
 IV. Histopathology: in minor salivary glands (obtained through normal-appearing mucosa) focal lymphocytic
   sialoadenitis, evaluated by an expert histopathologist, with a focus score ≥1, defined as a number of
   lymphocytic foci (which are adjacent to normal-appearing mucous acini and contain more than 50
  lymphocytes) per 4 mm2 of glandular tissue.
 V.   Salivary gland involvement: objective evidence of salivary gland involvement defined by a positive result for at  
  least one of the following diagnostic tests:
  1. Unstimulated whole salivary flow (<1.5 ml in 15 minutes)
  2. Parotid sialography showing the presence of diffuse sialectasias (punctuate, cavitary or destructive
   pattern), wihtoud evidence of obstruction in the major ducts
  3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion of tracer
 VI.   Autoantibodies: presence in the serum for autoantibodies to Ro(SSA) or La(SSB) antigens, or both
For primary SS: in patients without any potentially associated disease, primary SS may be defined as follows:
 a.  The presence of any 4 of the 6 items is indicative of primary SS, as long as either item IV    
  (Histopathology) or VI (Serology) is positive or
 b.  The presence of any 3 of the 4 objective criteria items (that is, items III (Ocular signs), 
  IV (Histopathology),  V (Salivary gland involvement), or VI (Serology)).
For secondary SS: in patients with a potentially associated disease (for instance, another well defined conncective tissue 
disease), the presence of item I or item II plus any 2 from among items III, IV and V may be considered as indicative 
of secondary SS. 
Exclusion criteria: past head and neck radiation treatment, hepatitis C infection, acquired immunodeficiency disease 
(AIDS), pre-existing lymphoma, sarcoidosis, graft versus host disease, use of anticholinergic drugs (since a time shorter 
than 4-fold the half life of the drug)
on a set of American/European criteria for SS classification (table 1) [14]; this criteria 
set is currently the most commonly applied criteria set worldwide. These international 
American/European Consensus Group classification (AECG) criteria comprise 
subjective (ocular and oral symptoms) and objective criteria (ocular, histopathological, 
oral and serological signs) [1, 14, 15]. It must be noted that the AECG criteria for SS 
were not developed for clinical purposes but to select cohorts of SS patients for 
performing clinical trials with well-defined SS subjects, e.g., for assessing the effect of a 
particular therapy and for allowing reliable comparison of results of various published 
studies. Nonetheless the AECG criteria are now worldwide accepted as diagnostic 










Table 2. The 2012 American College of Rheumatology criteria for SS [16].
The classification of SS will be met in patients who have at least 2 of the following 3 objective features:
I. Positive serum anti-SSA/Ro and/or anti-SSB/La or (positive rheumatoid factor and ANA titer 1:320)
II.  Labial salivary gland biopsy exhibiting focal lymphocytic sialadenitis with a focus score ≥1 focus/4 mm2
III.  Keratoconjunctivitis sicca with ocular staining score ≥3 (assuming that individual is not currently using   
 daily eye drops for glaucoma and has not had corneal surgery or cosmetic eyelid surgery in the last
 5 years)
Prior diagnosis of any of the following conditions would exclude participation in SS studies or therapeutic trials 
because of overlapping clinical features or interference with criteria tests: history of head and neck radiation treatment, 
hepatitis C infection, acquired immunodeficiency syndrome (AIDS), sarcoidosis, amyloidosis, graft versus host disease, 
IgG4-related disease.
criteria comprise subjective signs and certain salivary and ophthalmologic criteria lack 
specificity [16-18]. In 2012, the American College of Rheumatology (ACR) introduced 
a provisional criteria set (table 2) [16]. The ACR criteria were established, in part, to 
improve the specificity of criteria used for entry of SS patients into clinical trials [16]. 
These recent ACR criteria differ from the AECG criteria by excluding criteria based 
upon symptoms of glandular manifestations (i.e. xerostomia and keratoconjunctivitis 
sicca) and not distinguishing between pSS and sSS. Labial salivary gland biopsies and 
serology, however, remain the main criteria in both criteria sets. 
 Although labial salivary gland biopsies are a main criterion in both the AECG and 
ACR criteria sets, studies comparing labial and parotid gland biopsies have shown that 
incisional parotid gland biopsies were superior to or at least comparable with labial 
biopsies in the diagnostic workup of SS according to the AECG criteria [15, 19, 20]. 
Parotid gland biopsies have advantages over labial biopsies. In both biopsy techniques 
the morbidity is low, but permanent skin hypoesthesia mainly occurs after a labial gland 
biopsy. Another main advantage of parotid gland biopsies relies on the fact that the 
parotid gland can be biopsied more often. Parotid biopsies are, therefore, not only a 
valuable diagnostic asset but also fundamental in monitoring disease treatment at the 
glandular level. With regard to the ACR criteria, the use of the parotid gland biopsy as 
a replacement for the labial salivary gland biopsy has still to be validated.
 In the various studies described in this thesis emphasis is put on what can be learned 
from parotid gland biopsies, both regarding the etiopathogenesis of SS as well as the 
effect of treatment of SS with a biological on a tissue level.
 Pathogenesis
 The etiology of SS remains undefined, although it is believed that the pathogenesis 
of exocrine cell damage is multifactorial, involving viral, genetic, hormonal and 
immunological components.
 Several studies have focused on the etiopathogenic role of viruses in SS [21-24]. 










a direct pathogenic role of viruses in SS has yet been demonstrated. It remains to be 
determined whether viral infection of the affected glands is primary or secondary to 
the development of autoimmunity in pSS (for example Epstein–Barr virus infection 
[25]) or whether certain viruses, such as human T lymphotropic virus type I [26] 
and coxsackievirus [27], may act as triggers in distinct human populations for the 
development of SS.
 A genetic predisposition to SS is probably present since several families involving 
two or more cases of SS have been described including monozygotic twin studies 
[28-31]. Predisposition to pSS in caucasians is associated with an increased frequency 
of the HLA-DR3 gene [32, 33]. HLA-DR3 appears to be more closely associated with 
autoantibody production, exemplified by the notion that patients producing anti-Ro/
SSA or anti-La/SSB autoantibodies are associated with a frequency of 60 to 90 percent 
in HLA-DR3 positive patients [34]. The level of genetic contribution is not yet known.
 The strong female predominance and the menopausal age of diagnosis suggest sex-
specific predisposing factors [35, 36]. A mouse model of estrogen deficiency resulted 
in a SS like disease with increased apoptosis in salivary and lacrimal glands, suggesting a 
role in the development of autoantigens [37]. 
 Immunologic components are involved in the pathogenesis of SS. In blood, 
immunologic activity can be detected ranging from hypergammaglobulinemias, high 
erythrocyte sedimentation rate and C-protein levels, and autoantibodies [38, 39]. 
 Regarding the salivary glands, former studies have shown that minor salivary glands 
become infiltrated with T lymphocytes, although substantial numbers of B cells and plasma 
cells are also present in the inflamed excretory tissue together with (plasmacytoid) 
dendritic cells and macrophages [40-42]. Characteristically, the salivary glands are 
infiltrated around the striated ducts by T- and B lymphocytes [43]. The epithelial cells 
of striated ducts are a likely target of the autoimmune attack. Aberrant apoptosis of 
epithelial cells has been proposed to play a critical role in the pathogenesis of SS. Pro-
inflammatory cytokines and chemokines are driving forces of migration of immune 
cells to salivary and lacrimal glands [44-47]. Elevated levels of these chemokines and 
cytokines are found in the glandular tissue, saliva, tears and serum of pSS patients [44-
47]. The ductal epithelium appears to be an important source of these cytokines and 
chemokines. Thus the ducts are not only target of the autoimmune process but also 
serve important immunological functions, central in the pathogenetic process. Within 
the glandular tissue, these infiltrates can even be organized to ectopic lymphoid tissues 
with segregated T- and B-cell areas, germinal center like structures and high endothelial 
venules [48-50].  Th17 cells are believed to play an important role in the initiation of 
tissue inflammation, the infiltration of other inflammatory cells and the formation of 
ectopic lymphoid tissue. The ectopic lymphoid tissue contains all elements for local, 










The clinical manifestations of SS, such as hyposalivation, reduced tear secretion 
and autoantibody production, have been suggested to be mediated through B cell 
differentiation, activation, cytokine production and altered B cell tolerance [1, 51-
53]. B cell hyperreactivity plays a crucial role in the development and perpetuation 
of pSS disease. Autoantibodies directed against Ro/SSA and La/SSB antigens and/or 
rheumatoid factor are frequently found in pSS patients, together with elevated levels 
of serum immunoglobulins (hyper-gammaglobulinemia) [54]. 
 Although autoantibodies are frequently found in pSS patients, the pathogenetic role 
for these autoantibodies remains unclear [55, 56]. At least part of the autoantibodies 
might be generated in the exocrine tissues from local immune responses. Indeed 
autoantibody forming cells have been found in salivary glands of pSS patients [57]. 
Furthermore, anti-SSA/SSB antibodies are present in saliva and tears [58, 59]. 
Effector CD4+ Th cells are required for humoral immune responses to these protein 
autoantigens. These CD4+ Th cells are essential for the generation of plasma cells, 
as well as for the formation of memory cells in the germinal center like structures in 
the salivary glands [60]. CD4+ Th cells are also critically involved in the inflammatory 
response in the exocrine glands and their cytokines affect directly the ductal epithelial 
cells [40].  
 B cell activating factor (BAFF) is a B cell survival factor required for B cell maturation 
and known to regulate B lymphocyte proliferation and survival. Excess production of 
BAFF in BAFF- transgenic (Tg) mice leads to autoreactive B cell formation [61]. It was 
demonstrated that BAFF Tg mice initially develop an autoimmune condition similar 
to SLE and eventually develop sSS that manifests as sialadenitis and destruction of 
salivary glands when the mice mature [61]. Moreover, BAFF seems to be involved 
in the formation of ectopic germinal centers (GCs) in the salivary glands which may 
be an important step in lymphomagenesis. Similar to pSS, ectopic lymphoid tissue 
is also present in target tissues of several other autoimmune and non-autoimmune 
conditions that are accompanied by B cell disturbances and/or enhanced lymphoma 
risk, for example RA [62], SLE [63], autoimmune thyroiditis [64] and chronic infections 
such as human immunodeficiency virus (HIV) [65] and hepatitis C virus [66]. Plasma 
cells secreting (auto-) antibodies are derived from activated B cells undergoing GC 
reaction [67, 68]. Together with the fact that both Ro/SSA and La/SSB antigens have 
been detected in the salivary glands of SS patients, it is plausible that autoimmune 
plasma cells are produced at the site of inflammation [69, 70]. Furthermore, the pSS 
salivary gland microenvironment provides niches rich in factors, such as CXCL12 and 
IL-6, vital for plasma cell survival [71]. No studies yet exist in which the role of B cells 
and B cell mediated factors are evaluated after depletion of these B cells.
 Chronic inflammation with ectopic lymphoid tissue appears to induce neoplastic 
transformation of lymphocytes from ectopic GCs, leading to MALT lymphoma [72]. 










lesions [73] and are mostly composed by CD20 positive B cells [74]. Taken together, 
these reports illustrate an important interplay between B cells, cytokines, the GC 
microenvironment and salivary gland tissue in the perpetuation and progression of 
SS. However, no reports exist where these factors have been studied simultaneously 
in a human SS disease state before initiation and/or progression, and when clinical 
symptoms reappear after treatment with biologicals.  
 B cell targeted therapy
 Rituximab, a chimeric monoclonal antibody to the CD20 antigen, is a biological 
that has been used with success in the treatment of B cell lymphoma [75]. B cell 
targeting by rituximab has also been beneficial in autoimmune diseases like RA 
[76], SLE [77], multiple sclerosis [78] and myositis [79]. B cells appear to be critical 
in the pathogenesis of pSS too as exemplified by production of autoantibodies and 
cytokines. Therefore, although the direct pathophysiological role of B cells in glandular 
tissue destruction has not been fully elucidated, B cell targeted treatment has been 
proposed as a therapeutic modality in pSS [80]. Several open label and small placebo-
controlled randomized clinical trials with rituximab treatment have been conducted 
demonstrating the potential beneficial clinical effects of B cell targeting in pSS, such 
as improvement in extraglandular manifestations and diminished fatigue [81-84]. The 
beneficial clinical effects of rituximab seem to last for 6-9 months after treatment 
[83]. The direct effects of rituximab on systemic and local immunopathology remain, 
however, to be elucidated. The depletion and subsequent reappearance of B cells in 
conjunction with a return of clinical symptoms provide a unique opportunity to study 
immunologic changes that may precede or accompany the return of disease activity in 
SS. Such data might provide clues to the pathogenesis of SS.
aIm and outlIne of the thesIs
 The main objective of this thesis was to assess the effect of B cell targeting by 
rituximab on systemic and local (i.e. parotid salivary gland tissue) immunopathology in 
pSS. In addition, it was assessed, by comparing the results of a system analysis of salivary 
gland tissue obtained from human and mice with SS, which factors may be involved 
in the pathogenesis of pSS. Finally, an algorithm was developed how to deal with SS 
patients with a mucosa associated tissue B cell lymphoma (MALT). MALT lymphomas 
pose a problem in SS patients as about 7.5% of SS patients develop such a lymphoma 
[7, 13]. Besides in treating SS, rituximab has also been used in the treatment of MALT 
lymphomas. In short:
 pSS mouse studies have hinted to factors (a.o. cytokines and lymphocytes) that 










in human pSS pathogenesis remains obscure as the intersection between pSS mouse 
models and human pSS has not been properly studied. In chapter 2 weighted gene 
co-expression network analysis (WGCNA) is applied to characterize molecular and 
cellular events associated with pSS pathogenesis. Factors involved in the pathogenesis 
of human pSS might resemble factors involved in the pathogenesis of SS-like disease 
in mouse models. Aim of the study described in this chapter was to assess whether 
WGCNA identifies corresponding biological pathways and targets in pSS pathogenesis 
between human with SS and mice with a SS-like disease. Factors studied in the 
subsequent chapters were selected on basis of and/or linked to the results of the study 
described in this chapter.
 In chapter 3 the results of a randomized placebo controlled clinical trial assessing 
the effect of rituximab on the histology of excretory parotid salivary gland tissue in 
patients with pSS are discussed. In this prospective study, 20 patients with pSS had been 
treated with rituximab and 10 with placebo. Parotid gland histology was evaluated at 
baseline and at 12 weeks after rituximab treatment. Emphasis was put on the effect of 
rituximab on the local inflammation and the possible regenerative potential of parotid 
salivary gland tissue.    
 The observations in chapter 3 were on the basis of the study described in chapter 
4, where the effect of rituximab was evaluated on the circulating and parotid tissue 
bound levels of BAFF and a proliferation-inducing ligand (APRIL). These cytokines are 
important regarding B cell survival and activation and have been shown to be elevated 
in pSS patients [85].  
 Cytokines and chemokines are thought to play a critical role in the initiation and 
perpetuation of the chronic inflammatory response in the glandular tissue of patients 
with pSS [86, 87]. Several pro-inflammatory cytokines have shown to be overexpressed 
in saliva and serum of pSS patients [88-90] as well as that B cells are able to produce 
cytokines [91]. The effect of rituximab on a variety of cytokines was therefore 
investigated in chapter 5, with notice on the assumption that the therapeutic effect 
of rituximab on disease activity in pSS patients is mediated by a depletion of cytokine 
producing B cells. 
 Chapters 4 and 5 showed effect of rituximab on serum levels of cytokines and 
chemokines in pSS patients. Cytokines and chemokines play a crucial role in T cell 
activation, but the effect of rituximab on T cells is unclear. T regulatory (Treg) are 
presumed to suppress activation of the immune system and to prevent pathological 










effect of rituximab on T regulatory (Treg) cells in pSS, both locally in inflamed parotid 
gland tissue and systemically in blood. 
 Abnormal B cell stimulation by immune factors, as assessed in the studies described 
in chapters 3 to 6, may eventually result in B cell lymphoproliferation and give rise to 
development of MALT-lymphoma. SS related MALT-lymphoma ranges from indolent 
asymptomatic lymphoma with no pSS disease activity to disseminated lymphoma with 
severe extraglandular pSS manifestations. As no clear guidelines are available for the 
management of pSS patients with a MALT-lymphoma, the progression and treatment of 
a MALT-lymphoma in 35 consecutive pSS patients with such a lymphoma was studied 
and linked to their clinical characteristics, the course of the disease and their response 
to a variety of treatment strategies. In chapter 7 guidelines for the treatment of 
MALT-lymphoma in patients with pSS are given which are based on these data. 
 In chapter 8, the findings of this thesis are summarized and discussed, and 
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 Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disease with complex 
etiopathogenesis. Despite extensive studies to understand the disease process utilizing 
human and mouse models, the intersection between these species remain elusive. 
To address this gap, we utilized a novel systems biology approach to identify disease-
related gene modules and signaling pathways that overlap between humans and mice.
  
Methods 
 Parotid gland tissues were harvested from 24 pSS and 16 non-pSS sicca patients 
and 25 controls. For mouse studies, salivary glands were harvested from C57BL/6.
NOD-Aec1Aec2 mice at various times during development of pSS-like disease. RNA 
was analyzed with Affymetrix HG U133+2.0 arrays for human and MOE430+2.0 
arrays for mouse samples. The images were processed with Affymetrix dChip software. 
Weighted-Gene Co-Expression Network Analysis was used to identify disease related 
and functional pathways. 
Results
 Nineteen co-expression modules were identified in human parotid tissue, 4 of which 
were significantly up-regulated and 3 downregulated in pSS patients compared to non-
pSS sicca patients and controls. Notably, one of the human disease-related modules 
was highly preserved in the mouse model, and was enriched with genes involved in 
immune and inflammatory responses.  Further comparison between these two species 
led to the identification of genes associated with leukocyte recruitment and germinal 
center formation. 
Conclusion
 Our systems biology analysis of genome-wide expression data from salivary gland 
tissue of pSS patients and from a pSS mouse model identified common dysregulated 












 Sjögren’s syndrome (SS) is a chronic, inflammatory autoimmune disease characterized 
by lymphocytic infiltration of the exocrine glands especially salivary and lacrimal glands, 
leading to destruction of their functional components. The disease may exist alone as 
primary SS (pSS) or in conjunction with another autoimmune disorder as secondary 
SS (sSS) [1] . The disease affects 0.5-1.0% of the general population and shows a 
striking 9 : 1 female predominance [2, 3]. Although dry mouth and dry eyes are the 
‘hallmark’ symptoms of pSS, the disease can affect almost any organ of the body and 
can cause substantial morbidity [4] . As yet, symptomatic therapy predominates the 
overall management of affected individuals [5, 6] . 
 The diagnostic criteria, including the American-European Consensus Group (AECG) 
criteria involving either serology or histopathology in conjunction with oral and ocular 
dryness [7] , are often inconsistently applied, are not optimal in differentiating pSS from 
non-pSS sicca patients or addressing extraglandular manifestations. As a result, diagnosis 
of Sjögren’s syndrome often lags disease onset by 6-10 years. Recent attempts to 
address these issues, EULAR Sjögren’s Syndrome Patient Reported Index: ESSPRI), and 
a disease activity index to evaluate systemic complications (EULAR Sjögren’s Syndrome 
Disease Activity Index: ESSDAI) [8, 9]  require further large-scale validation. 
 In addition to the difficulty in disease diagnosis, the underlying pathophysiologic 
mechanisms of Sjögren’s syndrome remain obscure. A common model suggests 
interaction between genetic susceptibility and environmental factors such as viral 
infections for the immune cell activation and protracted inflammatory response 
resulting in glandular dysfunction and systemic autoimmunity [6] . In addition, recent 
studies in human and animal models have highlighted several components of the innate 
and adaptive immune systems as well as nonimmunologic factors [10-13]. However, 
there is a general lack of experimental and research intersections between humans 
and mouse models in terms of biological pathways and key molecular targets. Indeed, 
a wide variety of animal models of Sjögren’s syndrome have been described; each 
capturing certain aspects of the disease [14]. The most widely used mouse model, 
NOD, exhibits CD4+ lymphocyte infiltration, autoantibodies, xerostomia and a female 
dominant phenotype. However, the mice also develop diabetes, which complicates 
the search for Sjögren’s syndrome specific changes of gene expression. Recently, a 
modified NOD mouse model, C57BL/6.NOD-Aec1Aec2 has been described. These 
mice develop the symptoms of Sjögren’s syndrome but not diabetes [15] suggesting 
that they will be a highly valuable model for understanding the pathogenesis pSS. 
 In the present study, we applied weighted gene co-expression network analysis 
(WGCNA) [16] to characterize biological pathways and molecular targets associated 
with pSS pathogenesis in both human parotid tissue and the C57BL/6.NOD-Aec1Aec2 










(pSS) salivary gland tissue compared to salivary gland tissue from a mouse model of 
pSS identified common biological pathways and molecular targets that can pivotally 
contribute to critical molecular alterations in pSS pathogenesis.  
methods
A) Human studies
 The study protocol was approved by the Institutional Review Board of the 
University of California at Los Angeles (UCLA) and the University Medical Center at 
Groningen (UMCG). All patients were recruited from the UMCG Department of Oral 
and Maxillofacial Surgery, were at least 21 years old, and provided written informed 
consent to participate in the study. The study included 24 patients who fulfilled the 
2002 American-European Consensus Group (AECG) criteria for pSS [17], 16 non-
sicca patients with subjective symptoms and objective signs of oral and ocular dryness 
but not fulfilling the AECG criteria for pSS and 25 control patients with no subjective or 
objective evidence of oral or ocular dryness. The patient characteristics are presented 
in Table 1.   
Parotid gland tissue specimens 
 Under local anesthesia, an incisional biopsy of one parotid gland was performed as 
part of the diagnostic workup of the pSS and non-pSS sicca patients following AECG 
criteria, as described [7] , and according to the procedure described by Pijpe et al 
[18] . Tissue was harvested from the dorsal caudal lobe of the parotid gland from the 
control patients during surgery for oral or oropharyngeal squamous cell carcinoma. 
 After harvest, most of the specimen was snap-frozen and delivered to UCLA on 
dry ice and then stored at -80oC for gene expression profiling. A minor part was fixed 
in 4% formalin, embedded in paraffin, sectioned, and stained with hematoxylin and 
eosin for histopathologic evaluation. The evaluation of slides from pSS and non-pSS 
sicca patients was performed independently by two oral pathologists, who determined 
the focus score (50 or more lymphocytes per 4mm2 glandular tissue) and other 
characteristics such as lymphoepithelial lesions, germinal centers, fibrosis, atrophy, etc. 
The specimens from pSS patients showed characteristic features, for example, focus 
score ≥1 and presence of lymphoepithelial lesions, whereas those from non-pSS sicca 
and control subjects did not show any such characteristics. Histopathologic evaluation 
of parotid tissue from controls revealed no carcinoma.  
Gene expression profiling 
 The isolation of total RNA from snap-frozen parotid gland tissues, in sample sizes 










Table 1. Characteristics (mean±SD) of pSS, non-pSS sicca and control subjects.*
Characteristics pSS  non-pSS sicca Controls
  n=24 n=16 n=25
Age (years) 49.0±15.8 52.8±15.4 59.0±12.0
Female : male 21 : 3 13 : 3 12 : 13
Ethnicity 24 Caucasian 16 Caucasian 25 Caucasian
UWS (ml/min) 0.10±0.14 0.12±0.18 NA
SWS (ml/min) 0.31±0.35 0.33±0.40 NA
Schirmer’s test (mm) 9.2±7.6 14.8±11.7 NA
Focal score 3.5±1.2 0.5±1.0 0
SS-A (pos : neg) 23 : 1 2 : 14 0 : 25
SS-B (pos : neg) 19 : 5 0 : 16 0 : 25
*All pSS and non-pSS sicca patients were subjected to a complete AECG diagnostic work-up.
UWS: unstimulated whole saliva; SWS: stimulated whole saliva; NA: not assessed (in controls being head and neck 
cancer patients without parotid involvement, no functional tests were performed as all these patients were already 
scheduled for a neck dissection and functional tests were considered too much a burden to the patients at that time).
system (Ambion, Austin, TX), according to the manufacturer’s protocol. Briefly, each 
frozen tissue specimen was homogenized in 300μl cold cell-disruption buffer and an 
equal volume of 2x denaturing solution was added to it. The total lysate was centrifuged 
for 5 min at 10,000xg to separate out the superficial aqueous phase containing RNA 
and then 1.25 volume of 100% ethanol was added. The mixture was loaded onto a 
spin column followed by washing twice with provided buffer. RNA was eluted at 100oC 
into 50μl of elution buffer. The resultant RNA was subjected to RNase-free DNase 
treatment followed by ethanol precipitation, dissolved into 15μl DNase/RNase-free 
water, and quantified with a Nanodrop spectrophotometer (Nanodrop Technology, 
Wilmington, DE).
 The RiboAmp RNA Amplification system (Molecular Devices, Sunnyvale, CA) was 
used to perform one round of linear amplification of parotid gland tissue mRNAs 
taking 2.5μg total RNA from each specimen as the template. The synthesized cDNA 
was transcribed to cRNA and then biotinylated using the GeneChip Expression 
3´-Amplification reagents (Affymetrix, Santa Clara, CA) for in vitro labeling. Then 15μg 
of labeled cRNA was fragmented into 50- to 200-bp fragments and assessed for 
quality with a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). 
 The fragmented biotin-labeled cRNA from pSS, non-pSS sicca and control subjects 
was hybridized overnight to the Affymetrix HG U133 plus 2.0 arrays. After washing to 
remove the unbound transcripts, the hybridized chips were stained prior to scanning. 
The acquired images were processed with Affymetrix dChip software and imported 
to the statistical program R for data analysis.     











Mouse model of SS-like disease
 C57BL/6.NOD-Aec1Aec2 mice were bred and maintained under specific 
pathogen-free conditions within the mouse facility of the Department of Pathology 
at the University of Florida, Gainesville. The breeding and use of these animals for the 
present studies were approved by the University of Florida Institutional Animal Care 
and Use Committee. The animals were maintained on a 12-hour light-dark schedule 
and provided food and acidified water ad libitum. 
Generation of salivary gland transcriptome data 
 Salivary glands were freshly excised from euthanized mice (n=5 per age group) at 
4, 8, 12, 16, or 20 weeks of age, snap-frozen in liquid nitrogen, and stored at -80°C 
until all glandular samples were obtained. Each salivary gland was comprised of a 
submandibular, sublingual, and parotid gland minus salivary lymph nodes. Total RNA 
was isolated from salivary glands of each mouse using the RNeasy Mini-Kit (Qiagen, 
Valencia, CA), in accordance with the manufacturer’s protocol. Hybridizations were 
carried out with each of the 25 individual RNA samples using Affymetrix GeneChip 
Mouse Genome 430 plus 2.0 Arrays (Affymetrix, Santa Clara, CA), in accordance 
with the manufacturer’s instructions. Each GeneChip contained 45,000 probe sets that 
analyzed the expression level of over 39,000 transcripts and variants from over 34,000 
well-characterized mouse genes. 
C) Statistical procedures
Microarray data preprocessing 
The Affymetrix U133 plus 2.0 microarray data were analyzed with functions and 
packages of the statistical software R 2.12.0 and Bioconductor 2.7. Expression intensity 
values were calculated for the 65 Human microarray CEL files (24 pSS, 16 non-pSS 
sicca and 25 controls) using the mas5 function of the Affy library. Potential array outliers 
were identified by studying their interarray correlation using the SampleNetwork R 
function. After removing potential outliers in a completely unbiased fashion, all 65 
samples remained for downstream analysis. After quantile normalization, the ComBat 
function was used to correct for batch effects [19] . To summarize multiple probe sets 
per gene, we used the default settings of the collapseRows R function [20] . Thus, each 
of the 20718 genes on the array was represented by the probe with the highest mean 
expression value.
 Analogous pre-processing steps were applied to the 25 mouse microarray samples 
corresponding to 5 different time points (weeks 4, 8, 12, 16 and 20, each time point 











Standard Differential Expression Analysis
 To find differentially expressed genes between pairs of groupings (involving pSS, sicca, 
controls), we used 2 R functions in the WGCNA package: standardScreeningBinaryTrait 
and standardScreeningNumericTrait which report p-values, false discovery rates 
(q-values), fold changes and other widely used statistics for selecting differential 
expressed genes. Further, the correlation of each gene with an ordinal measure of 
diagnosis was assessed (0=controls, 1=Sicca, 2=pSS) which allows the identification of 
genes that positively or negatively increase with the disease progression in humans. We 
also correlated each mouse gene with time (week) to find genes that are increasing or 
decreasing as time progresses. These results (p-values, correlations, false discovery rate) 
were used to create Table 2.
WGCNA and preservation analysis 
 The statistical analysis software (WGCNA R package) and R tutorials for constructing 
a weighted gene co-expression network can be found in the literature [16, 21] . The 
WGCNA package first calculates all pair-wise Pearson’s correlation coefficients across 
all samples. In a signed weighted network, the resulting Pearson’s correlation matrix is 
transformed into a adjacency matrix (a(ij) = |0.5+0.5*cor(x(i), x(j))|ß) [22] . The default 
value of the power ß=12 facilitates a soft-thresholding approach that preserves the
continuous nature of the co-expression relationships [16].  As a network dissimilarity 
measure we used 1 - the topological overlap measure as input for average linkage 
hierarchical clustering [23] . We used the dynamic branch cutting method to define 
modules as branches of the hierarchical clustering tree [24] . Unassigned background 
genes, outside of each of the modules, were denoted with the color grey.
 To group the 20718 genes into modules, we used the blockwise Module R function 
in the WGCNA R package. 
Connectivity and module membership measures 
 Module membership (MM), also known as eigengene-based connectivity (kME), is 
a measure of intramodular connectivity [25] . It is defined as MM(i) = cor(x(i), ME), 
where x(i) is the expression profile of i-th gene and ME is the eigengene (first principal 
component) of the given module. We used the MM measure to select module genes 
for a gene ontology enrichment analysis.
Functional enrichment analysis 
 The Ingenuity Pathways Analysis (IPA, Ingenuity® Systems) software was used 
to determine whether sets of genes (e.g. preserved intramodular hub genes) were 












 To evaluate which human modules could also be found in the mouse data, we used 
module preservation statistics implemented in the modulePreservation R function 
[17]. For each module in the reference data (e.g. human data), a permutation test leads 
to the Zsummary statistic in the test data (here the mouse data set). Zsummary>10 
indicates strong evidence of preservation while Zsummary<2 indicates no preservation 
according to the permutation test.
 
results
Identification of gene co-expression modules in parotid glands of pSS patients 
 A signed weighted gene co-expression network was constructed based on the 65 
human parotid gland tissues (24 pSS, 16 non-pSS sicca and 25 controls). The WGCNA 
method clustered the 20718 human genes into 19 distinct gene co-expression 
modules. Since the module detection is unbiased and does not make use of gene 
ontology information, each of the modules was initially labeled with a unique color as 
an identifier (Figure 1). To define a representative module expression profile (referred 
to as the module eigengene), we summarized the (standardized) gene expression 
profiles of the module eigengene (= first principal component). The module eigengene 
can be considered a weighted average of the module gene expression profiles. To 
identify disease related modules, we correlate each module eigengene with disease 
status.
 Strikingly, 7 out of 19 modules showed significant differential expression between pSS 
and control samples, which reflects the fact that thousands of genes are differentially 
expressed between the two groups. In particular, we found a highly significant positive 
correlation between disease and the Magenta (comprised of 576 genes) module 
eigengene (r = 0.67, p < 2E-7), the Brown (2502 genes) module eigengene (r = 0.6, 
Figure 1. Detection of modules based on weighted gene-coexpression network analysis (WGCNA) of parotid gland 
biopsy tissue from pSS patients compared to non-pSS sicca and controls. Hierarchical cluster tree used for module 
detection. Modules correspond to branches of the tree and are assigned color categories as indicated by the color bands 










p < 6E-6), the Light-Cyan (349 genes) module eigengene (r = 0.42, p < 0.002), and 
the Grey60 (based on 216 genes) module eigengene (r = 0.47, p <8E-4). Since a 
positive correlation indicates that the corresponding module genes are over-expressed 
in the diseased individuals, the Magenta, Brown, Light-Cyan and Grey60 modules are 
comprised of genes over-expressed in pSS samples compared to both non-pSS sicca 
and controls (Figure 2). 
Figure 2. Identification of pSS disease-related gene modules revealed by WGCNA. The barplots show the mean 
value of the module eigengene (Y-axis) versus human disease progression status (X-axis) where 0 denotes healthy 
controls, 1 denotes non-pSS sicca patients, and 2 denotes pSS patients. The Kruskal Wallis test p-values above the plots 
show that the module eigengenes of all four modules, Magenta (contained 576 genes), Brown (2502 genes), Grey60 
(216 genes), and Light-Cyan (349 genes), are significantly over-expressed in pSS patients compared to both non-pSS 
sicca patients and controls.
 On the other hand, we found a highly significant negative correlation between 
disease status and the Turquoise (based on 3981 genes) module eigengene (r = 
-0.52, p < E-4), the Grey (based on 3011 genes) module eigengene (r = -0.41, p < 
0.003), and the Salmon (based on 446 genes) module eigengene (r = -0.28, p <0.005). 










under-expressed in pSS samples compared to both non-pSS sicca and controls (Figure 
3). All of these p-values remain highly significant even after carrying out the most 
stringent multiple comparison adjustment (Bonferroni correction) for the number 
of modules. This co-expression module-based analysis has a major advantage over a 
standard differential gene expression analyses since it only relates 19 modules to pSS 
disease status alleviating the multiple comparison problem inherent in the raw data. 
Figure 3. pSS disease-related co-expression modules that are down regulated in pSS patients. The barplots are analo-
gous to those described in Figure 2. The module eigengenes of two modules, Turquoise (contained 3981 genes) and 
Grey (3011 genes), are significantly under-expressed in pSS patients compared to both non-pSS sicca patients and 
controls. Note that the Salmon module (446 genes) differs from the other two modules with respect to the non-pSS
sicca patients, where the module eigengene is under-expressed compared to controls.
Preservation of human magenta module in a mouse SS model 
 We applied the modulePreservation R function to assess whether modules defined 










model data sets. We selected the C57BL/6.NOD-Aec1Aec2 mice for the comparative 
gene expression analysis because it is a spontaneous disease model, probably the best-
defined mouse model to date with respect to its disease profile, and has a comparative 
control with the same genetic background that mimics virtually all molecular and 
clinical aspects defined in humans. Importantly for this study, extensive transcriptomic 
profiling data of salivary glands defining development of SS is available.  The module 
preservation statistics allow one to quantify which aspects of within-module topology
are preserved between a reference network (human parotid glands) and a test 
network (mouse salivary glands). We used two composite preservation statistics 
(Zsummary and medianRank) to assess overall module preservation. We evaluated 
the preservation of the human modules in the entire mouse data set (i.e. all weeks 
together). Strikingly, both statistics revealed that the human Magenta module is the 
most highly preserved module in the mouse data (e.g. Zsummary = 11, p < E-18).  
 Furthermore, the Magenta module eigengene in the mouse data shows increasing 
expression across times, i.e. the Magenta genes are significantly (p=.034) over-expressed 
in weeks 16 and 20. These results indicates that the mouse model is appropriate 
when it comes to an aspect of the human disease embodied in the magenta module.
GO and pathway enrichment analysis 
 To study the ontology of genes in the 7 human pSS related co-expression modules, 
we used IPA (Ingenuity Pathway Analysis®) software. Here, we highlight results for the 
two most significant modules, Magenta and Turquoise.
 For the Magenta module, the top-3 overrepresented subcategories within ‘Gene 
Ontology – Biological Process’ were immune response (115 genes out of 423 Magenta 
module genes in both human and mouse dataset, p = 1.58E-52, Bonferroni corrected 
p = 3.39E-49), defense response (p = 2.69E-27, Bonferroni corrected p = 5.76E-24) 
and inflammatory response (46 genes in both human and mouse dataset, p = 1.96E-17, 
Bonferroni corrected p = 4.20E-14). Additional enriched categories for the Magenta 
module include antigen processing and presentation (p=2.95E-17), positive regulation 
of response to stimulus (p=4.30E-17), Cell adhesion molecules (CAMs) (p=1.34E-13), 
humoral immune response (p=2.38E-13), response to wounding (p=5.68E-13), 
lymphocyte activation (p=2.93E-11), and cell activation (p=9.03E-11).
 Strikingly, 4 of the Magenta genes are implicated the IL-4 signaling pathway (p = 
0.025). Figure 4 shows an Ingenuity Pathway Analysis network plot where genes colored 
in grey are part of the Magenta module. Genes identified include those that encode 
for TLRs and their signal transduction molecule MyD88, molecules that present antigen 
to NK cells (e.g., members of CD1), molecules involved in immune cell recruitment 
and adherence (e.g., CCL21, CXCL10, CXCL12, CCR7 and SLAM7), and molecules 
responsible for formation of germinal centers in secondary lymphocyte organs (e.g., 










of particularly interest as they indicate recruitment of specific leukocyte subsets, in 
particular, macrophages, dendritic cells, T and B lymphocytes, and NK cells. We have 
independently validated these six genes using qPCR.
Figure 4. Ingenuity Pathway Analysis® network plot. Genes shaded in grey were part of the magenta module and are 
significantly altered in the parotid gland of pSS patients.
For the Turquoise module where the genes were under-expressed in pSS, the top-
3 overrepresented subcategories within ‘Gene Ontology – Biological Process’ were 
Oxidation reduction (p = 7.89E-11, Bonferroni corrected p = 3.74E-7), Generation 
of precursor metabolites and energy (p = 4.72E-09, Bonferroni corrected p = 2.24E-
5) and Cofactor metabolic process (p = 1.45E-6, Bonferroni corrected p = 0.0069). 
The category ‘KEGG pathway’ yielded the following top-3 categories: oxidative 
phosphorylation (p = 9.12E-7, Bonferroni corrected p = 1.77E-4), Alzheimer’s disease 
(p = 5.66E-6, Bonferroni corrected p = 0.0011) and Huntington’s disease (p = 3.69E-5, 










Table 2 reports genes with concordant progression patterns in human and mouse 
disease. Positively related genes were selected by requiring i) a correlation>0.5 with 
human progression status (defined as 0 for controls, 1 for sicca, and 2 for pSS), ii) a 
correlation >0.5 with mouse progression status (weeks). Similarly, we selected the 
negatively correlated genes using a correlation threshold of minus 0.5. Corresponding 
p-values are reported in the Table 2.  The module membership column (MM.magenta) 
shows that most of these genes have concordant pattern with the magenta module 
eigengene illustrating again that this module contains genes that are involved in both 
human and mouse disease pathology.
Table 2. Genes with concordant progression patterns in human and mouse disease.
Progression       GeneSymbol        corHuman p.Human          corMouse          p.Mouse         MM.magenta
       +         ADA 0.57 5.5e-07   0.62  9.2e-04  0.70
       +        AIF1      0.51  1.6e-05       0.57  3.1e-03           0.67
       +        C1QB      0.54  3.2e-06       0.65  4.6e-04           0.71
       +       CASP3     0.59  1.8e-07       0.52  8.2e-03           0.59
       +        CYBB      0.63  1.6e-08  0.56  3.4e-03           0.82
       +      ENTPD1      0.51  1.2e-05  0.62  8.5e-04           0.66
       +        GZMA      0.63  1.7e-08  0.70  1.0e-04           0.72
       +        GZMK      0.61  5.8e-08  0.55  4.1e-03           0.63
       +    HLA-DQB1  0.53  6.0e-06  0.65  5.0e-04     0.48
       +   HLA-DRB1 0.53  5.9e-06  0.74  2.6e-05           0.89
       +      IFIT1      0.59  2.6e-07  0.59  1.9e-03           0.43
       +      ITGAX      0.51  1.2e-05  0.63  6.8e-04           0.68
       +        LY86      0.58  4.4e-07  0.53  6.4e-03           0.78
       +     PLEKHA2    0.63  1.5e-08  0.52  7.1e-03      0.87
       +       STAT1     0.67  7.2e-10  0.64  5.2e-04      0.60
       +        TLR7      0.63  1.6e-08  0.63  6.6e-04  0.61
       -     ALDH3A2     -0.50  1.8e-05  -0.63 8.0e-04        -0.64
       -     ANGPTL4    -0.50  1.9e-05  -0.58 2.6e-03        -0.40
       -      ATP1B1     -0.56  1.0e-06  -0.58  2.5e-03        -0.62
       -       CPT1A     -0.54  4.0e-06   -0.76  8.7e-06        -0.55
       -       FAF1     -0.54  4.1e-06  -0.55  4.5e-03        -0.58
       -       NEO1     -0.52  9.6e-06  -0.53  6.9e-03        -0.47
       -       PALMD     -0.50  2.2e-05  -0.64  6.1e-04        -0.65
       -      PDHA1     -0.58  3.9e-07  -0.63  8.0e-04        -0.71
       -    PPFIBP2     -0.56  1.2e-06  -0.57  3.2e-03        -0.48
corHuman denotes the correlation of the gene with human progression status(defined as 0 for controls, 1 for sicca, 
and 2 for pSS). corMouse denotes the correlation of the gene with mouse progression status (week). p.Human and 
p.Mouse report the correlation test p-values in human and mouse data, respectively.  MM.magenta reports the module 











 We have utilized a systems approach to identify the molecular and cellular events 
underlying the pathogenic process in parotid glands of pSS patients, and compared the 
altered expressed genes and key signaling pathways with those in the salivary glands of 
mice that mimic the features of pSS. With a robust statistical and bioinformatics tool, 
WGCNA, coupled with GO and IPA, we have clustered hundreds of co-expressed 
genes into 19 gene modules. Since the module definition does not make use of GO 
information, the modules are initially named by a color.
 Our analyses highlighted 7 co-expressed modules that were enriched with genes 
that could discriminate pSS patients from unaffected individuals using parotid gland 
tissue, a prime target in SS pathogenesis. Interestingly, 4 of the 7 modules, namely 
Magenta, Brown, Light-Cyan and Grey60, were positively correlated with the disease 
status, suggesting that the genes contained in these modules are overexpressed in pSS. 
On the other hand, Turquoise, Gray and Salmon modules were negatively correlated 
with the disease status, suggesting that the genes in these modules are under-expressed 
in pSS. 
 We acknowledge that clinical samples are not gender-matched between the 
Sjögren’s and non-Sjögren’s subjects which can be a potential source of bias. We have 
found that gender has a negligible effect on gene expression levels in the controls. 
None of the genes were gender related at an FDR threshold of .05. Of the 5461 
genes that were differentially expressed between pSS cases and controls at a false 
discovery threshold of .05, only 140 genes showed differential expression (p<.05) 
between males and females of the control samples. Further, we find a) that the vast 
majority of module genes are on autosomes and b) there is no evidence that gender 
affects their expression level in the control group.
 When comparing human and mouse data, we found that the Magenta module 
was the most highly conserved module between these two species. Not surprisingly, 
this module was enriched with genes involved in immunity and inflammation, the two 
cardinal events in pSS pathogenesis. To our knowledge, we are the first to map out 
important intersects between human and mouse pertaining to key molecules and 
associated pathways in pSS. The knowledge gained from this work will enhance future 
target-based therapies for this devastating disorder. Our novel co-expression module 
based comparison of human and mouse models can be used to judge whether a given 
mouse model mirrors the human disease at the transcriptional level. Future studies 
could explore whether other mouse models allow for the preservation of additional 
human disease related modules.
 Characterizing the molecular and cellular events during the progression of pSS from 
a healthy or even a non-pSS state remains an important challenge. Because of the lack of 










progress to pSS. The gain in knowledge of these events can suggest which non-pSS 
individuals are at risk for developing pSS. In addition, the knowledge base could be 
used to intervene in the progression of disease by target-based therapies. Surprisingly, 
such specific regimens are not in place at present, still relying on a few trials with B 
cell-targeted and TNF-directed therapies evolved from testing on other autoimmune 
diseases [6, 10, 26-29]. Our systems-level analyses of high throughput gene expression 
data can demystify the critical molecular alterations in pSS pathogenesis.  
 WGCNA is a tool of systems biology analysis and has proven to be instrumental 
in identifying biological pathways and key gene constituents in a number of diseases 
[16, 21, 25, 30, 31]. Our module-based analysis not only alleviated the multiple testing 
problems inherent in microarray data analysis but also identifies biologically plausible, 
pSS-related modules that are highly significantly enriched with relevant GO categories. 
 The GO analyses have revealed striking correlations, both positive and negative, 
between gene modules and disease status. The most positively correlated Magenta 
module was significantly enriched with genes involved in antigen processing and 
presentation, and immune and inflammatory responses. Antigen processing and 
presentation are two important events in innate immunity in relation to pSS and our 
findings support these two phenomena [28] . Interestingly, a few Magenta genes were 
found to be part of the IL-4 signaling pathway, which interconnected with the TNF 
pathway that has been implicated in pSS disease progression. The negatively correlated 
Turquoise module is enriched with genes under-expressed in pSS, including those 
involved in oxidation reduction, generation of precursor metabolites and energy, and 
cofactor metabolic process. pSS patients are known to have reduced energy levels, 
while chronic fatigue syndrome is a common extraglandular manifestation [32] . Our 
data seem in line with this clinical presentation of the disease.   
 A unique feature of the present study is the direct comparison of the human gene 
expression data with that of the SS-susceptible C57BL/6.NOD-Aec1Aec2 mouse 
model. Since only the human disease related Magenta module was highly significantly 
preserved in the mouse data, we focused on the Magenta module to identify disease 
relevant pathways and target genes common to both species. A majority of the 
identified genes were part of the immune response, whereas a minor fraction was part 
of the inflammatory response. Further comparison between overexpressed genes in 
human and increasingly expressed genes during the disease time course in mouse 
led to the identification of CD1, CCR7, CXCL10 (or IP10) CXCL12 (or stromal cell-
derived factor-1), SLAM7 and LTA. They are of particularly interest as they indicate 
recruitment of specific leukocyte subsets, in particular, macrophages, dendritic cells, T 
and B lymphocytes, and NK cells, or involved in germinal center formation [33] . These 
observations provide a compelling concept that our systems approach can identify 
targets and pathways overlapped in human and mouse, supporting the concept that 










development and manifestations of clinical disease. We have independently validated 
these six genes using qPCR.                 
 In conclusion, our systems approach has generated intriguing data towards 
identification of conserved biologic pathways and key molecules related to pSS 
pathogenesis, especially in parotid glands that have the potential of being therapeutic 
targets in this debilitating disease. The novel findings pertaining to a human-mouse 
intersection network will help elucidate critical pathways and molecular alterations 
dysregulated in pSS pathogenesis and the ability to utilize appropriate rodent models 
that best mimic human pathogenesis. This intersection should also permit identification 
of those genes and pathways that ought to be the major focus of studies in mouse 
models.  In addition, the current results clearly point to the fact that our investigations 
show proof of concept that by comparing and contrasting human and rodent salivary 
gland WGCNA data it is possible to generate resources for future experimental as 
well as computational studies in evaluating the progression of pSS as revealed by 
human tissue analysis and then be experimentally interrogated by the most suitable 
mouse models as revealed by comparative WGCNA analysis.          
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 To assess the effect of rituximab (anti-CD20; RTX) therapy on parotid gland 
immunopathology in patients who have primary Sjögren’s syndrome (pSS).
Methods
 In a double-blinded, placebo-controlled trial sequential parotid biopsies were taken 
in 20 RTX and 10 placebo treated pSS patients before and 12 weeks after RTX or 
placebo treatment. The relative amount (stained for CD45) and B/T-cell ratio (stained 
for CD3, CD20, CD79a) of the lymphocytic infiltrate as well as the relative quantity of 
germinal centers and lymphoepithelial lesions were assessed. At the same time interval 
the histological findings were correlated to secretion of stimulated parotid saliva. 
Results
 In all RTX treated patients a major reduction of the lymphocytic infiltrate and of 
the B/T-cell ratio was observed, while no reduction in infiltrate and B/T-cell ratio was 
observed in placebo-treated patients. The relative number of lymphoepithelial lesions 
and germinal centers was significantly reduced in RTX-treated, but not in placebo-
treated patients. In RTX-treated patients there was no significant change in stimulated 
parotid salivary flow compared to baseline, while parotid flow had significantly 
decreased in the placebo treated patients.
Conclusion
 RTX treatment leads to major reduction loss of lymphocytic infiltration, germinal 
centers, lympho epithelial lesions and relative B cell component. Together with this 
reduction, a redifferentiation of lymphoepithelial lesions into regular striated ducts 
was observed, reflecting major decrease of histologically verified disease activity. This 












 Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized 
by lymphocytic infiltration and destruction of exocrine glands, in particular lacrimal and 
salivary glands. The main clinical features of pSS are progressive dryness of the eyes 
(keratoconjunctivitis sicca) and mouth (xerostomia), concomitant with presence of a 
variety of systemic complications [1]. 
 In the salivary glands the infiltrates are primarily located around striated ducts. 
These infiltrates are largely composed of T- and B-lymphocytes, macrophages and 
(plasmacytoid) dendritic cells [2, 3]. They can be organized as ectopic lymphoid 
tissue with segregated T- and B-cell areas and development of germinal center (GC) 
like structures [4]. Another histopathological characteristic is the development of 
lymphoepithelial lesions (LEL), formerly called “epimyoepithelial islands”, triggered by 
intraepithelial lymphocytes [5]. LEL develop from basal cell hyperplasia of striated ducts 
with aberrant differentiation into a multi-layered and reticulated epithelium, devoid of 
luminal oxyphilic cells. This represents severe impairment of the physiological function 
of the ductal epithelium, especially of sodium reabsorption [5]. LELs develop intensely 
in the parotid gland and are sparse or absent in minor salivary glands [6]. Eventually, as 
the disease progresses, the acini are involved as well, leading to progressive lipomatous 
parenchymal atrophy [7, 8].
 Immunohistologic studies of the lymphocytic infiltrate in the labial salivary gland 
(LSG) have revealed a predominance of T lymphocytes over B lymphocytes [9, 10]. 
However, recent data indicate that this might be the case for mild lesions, whereas in 
severe lesions B cells predominate [11]. 
 Insights into the functions of B cells have indicated that B lymphocytes play a central 
role in the pathogenesis of pSS [12]. B cells become activated and undergo, presumably 
in the GC-like structures, antigen-driven changes such as Ig heavy chain class switching 
and affinity maturation. These antigen-driven changes are thought to ultimately lead to 
the local generation of memory B and antibody-producing plasma cells [13].
Increased activation of B lymphocytes in pSS is apparent in increased levels of serum 
immunoglobulins, including rheumatoid factor and autoantibodies directed to SSA 
and SSB antigens, accompanied by disturbances in the relative proportion of B cell 
subsets and the aforementioned formation of ectopic lymphoid tissue with GC-like 
structures in glandular tissue [3, 14, 15]. Furthermore, 5 to 10% of patients with pSS 
may eventually progress to develop malignant B cell lymphoma in the salivary glands, in 
particular the parotid glands [16, 17]. The role of B cells in the pathogenesis of pSS is 
further strengthened by the observed beneficial objective and subjective clinical effects 
of blood B cell depletion by rituximab (RTX), a chimeric monoclonal antibody that 










The LSG biopsy is used frequently as a diagnostic tool for the diagnosis of pSS [22]. 
However, for scientific purpose, i.e. drug monitoring, parotid biopsies are superior to 
LSG [22]. Furthermore an incisional biopsy of the parotid gland may cause less long 
term morbidity compared to LSG biopsy [6]. A further important advantage of parotid 
biopsy relies on the fact that the same parotid gland can be repeatedly biopsied in 
time and is, therefore, not only a valuable diagnostic asset but also fundamental in 
monitoring disease treatment at a glandular level in the same salivary gland as assessed 
before [6, 23]. 
 In an open-label phase II study it was previously shown, in sequential parotid 
biopsies of 5 pSS patients, that RTX treatment might lead to regeneration of secretory 
tissue at a glandular level in responding patients [24]. This study showed a reduced 
lymphocytic infiltration with partial or complete loss of GC-like structures and major 
redifferentiation of LEL to regular striated ducts. These histopathological changes were 
associated with increased parotid saliva flow in patients responding to RTX treatment 
at a glandular level [24]. However, this study was limited due to the small number of 
patients and lack of a placebo group. The present study reports on the effect of RTX 
treatment in pSS patients based on sequential parotid biopsies obtained in a placebo–




 Thirty patients with pSS were treated in a randomized double-blinded placebo-
controlled trial on days 1 and 15 with either 1,000 mg RTX i.v. (Roche, Woerden, 
the Netherlands) (n= 20) or placebo i.v. (n= 10) at the University Medical Center 
Groningen, the Netherlands, as described before [20]. All patients fulfilled the 
European-US criteria for pSS [25]. To minimise side effects (infusion reactions, serum 
sickness), all patients, including the placebo treated patients, were pre-medicated with 
methylprednisolone (100 mg/i.v.), acetaminophen (1000 mg/p.o.) and clemastine (2 
mg/ i.v.), and received 60 mg oral prednisone on days 1 and 2, 30 mg on days 3 and 4, 
and 15 mg on day 5 after each infusion. A detailed account of the patients included in 
this trial has been described before [20].
 Serum samples were collected from all pSS patients at baseline, and at 5, 12, 36 
and 48 weeks after end of RTX or placebo treatment. An incisional biopsy was taken 
under local anesthesia from the same parotid gland before and 12 weeks after therapy 
[6]. A time period of 12 weeks was chosen because at that time a total depletion 
of B cells was observed in serum [21]. All patients provided informed consent in 












 Parotid gland tissue biopsies were fixed in 4% neutral buffered formalin, embedded 
in paraffin, cut at a thickness of 3 μm, and stained with hematoxylin and eosin. The 
focus score (defined as the number of mononuclear cell infiltrates containing at least 
50 inflammatory cells per 4 mm2 glandular section) and number of GC-like structures 
per mm2 parotid gland tissue section was assessed. In addition, all striated ducts were 
evaluated, and of each duct the presence of lymphoepithelial lesions was assessed [24]. 
Biopsies were independently scored by 2 investigators (R.P. and S.I.) in a blinded setting. 
In case of discrepancy a definite scoring was established in a consensus meeting.
Immunohistochemical analysis
 An anti-CD45 staining, that identifies all leukocytes, was utilized for assessment of 
the extent of lymphocytic infiltrate in the parotid gland. 
 Immunostaining was utilized for the analysis of lymphocytic infiltrate and was 
performed as follows. Parotid glands were fixed in formaldehyde (4%), embedded 
in paraffin and sectioned. Sections were stained after deparaffinisation, pre-
treatment with Ultra CC1 (Ventana Medical Systems, Inc, USA), antigen retrieval 
and endogenous peroxidase blocking using the Benchmark machine. Sections were 
immunohistochemically stained with anti-CD45 (dilution 1:25, Dako, Heverlee, 
Belgium, clone 2B11+PD7/26), anti-CD79a (dilution 1:100, Dako, Heverlee, Belgium, 
clone JCB117), anti-CD20 (dilution 1:200, Dako, Heverlee, Belgium, clone L-26) and 
anti-CD3 (dilution 1:20, Monosan, Uden, the Netherlands, clone PS-1) antibodies. The 
sections were then treated with peroxidase-labelled secondary antibody and visualized 
with the chromogen DAB (3,3’ Diaminobenzidine) solution. The relative amount of 
CD45-positive lymphocytic infiltrates was assessed in relation to the total amount of 
tissue parenchyma by morphometry with use of ImageJ software (v1.46). Furthermore, 
in representative areas of lymphocytic infiltrates the number of B cells (CD20) and T 
cells (CD3) was estimated among 1000 lymphocytes per infiltrate and consecutively 
calculated as B/T-cell ratio. To evaluate a possible down-regulation of CD20 antigen on 
persisting B cells due to anti-CD20 therapy, quantification of B cells was performed not 
only with CD79a but also with antibodies to CD20. 
 A double immunohistochemical labeling technique for cytokeratin 14 (CK14;Serotec, 
Düsseldorf, Germany; expressed by basal cells of striated ducts and myoepithelial cells 
in the acini) and Ki67 (Dianova, Hamburg, Germany) was performed as described 
previously [26] in order to improve exact localization of cellular proliferation in different 
types of epithelial cells. 
Parotid gland function
 Stimulated parotid saliva was collected in a standardized way at baseline and at 12 











 The Wilcoxon matched pairs test was used for intra-individual comparison of pre- 
and post-treatment values. Data are presented as the mean or median. A value of 
P<0.05 was considered statistically significant.
 
results
 From the 30 patients, six patients had to be excluded from histopathological analysis, 
either due to serum sickness (n=1, RTX-group) or the full use of the parotid biopsy 
sample at baseline for diagnostic purposes (n=4, RTX-group; n=1, placebo group). 
Thus, evaluation could be performed of parotid glands taken from 15 RTX treated 
patients and 9 placebo treated patients. 
Lymphocytic infiltrate in parotid glands 
 While focus scores remained at the same level in both treatment groups (figure 1a), 
the far more accurate measurement of the amount of lymphocytic infiltrate, using anti 
CD45 staining, clearly demonstrates a significant decrease (P= 0.015, figure 1b) at 12 
weeks after RTX treatment. In the placebo group no change in lymphocytic infiltrate 
was observed between baseline and 12 week post-treatment values (P= 0.426, figure 
1b). 
 The amount of B cells based on staining for CD79a and CD20 did not differ between 
both groups. A subsequent analysis of the B/T-cell ratio showed that at baseline 58% 
of the cells in the infiltrates in the parotid glands of pSS patients were B cells and 42% 
T cells. Twelve weeks after RTX treatment the B/T-cell ratio was reversed (36% B cells 
versus 64% T cells), thus showing a significant decrease in the relative percentage of B 
cells in the infiltrates (P=0.0089, figure 2). By calculating the amount of B and T cells 
from the lymphocytic infiltrate, it was observed that there was an absolute decrease 
in the amount of B cells (from 11.1x105 μm2 to 3.4x105 μm2) as well as in the amount 
of  T cells (from 8.2x105 μm2 to 5.9x105 μm2) at 12 weeks after rituximab treatment 
compared to baseline. 
 Analysis of the B/T-cell ratio in the placebo group showed that 66% of B cells and 
33% of T cells were present in the infiltrates of parotid glands at baseline. Percentages 
of B and T cells remained unaffected at 12 weeks after treatment (62% versus 38%, 
respectively). This notion was confirmed by calculation of the total amount of B cells 
(from 27.2x105 μm2 to 31.2x105 μm2) and T cells (from 13.6x105 μm2 to 15.3x105 










Figure 1A: Focus score 
Figure 1B: Relative area of infiltrates
Figure 1. Effect of placebo (n=9) and RTX (n=15) treatment on lymphocytic infiltrate in parotid glands of pSS patients. 
*indicates significant difference compared with baseline values (P<0.05). Horizontal lines indicate median values.
A. Focus score in parotid gland tissue.










Figure 2A: Parotid biopsy specimen before RTX treatment.
Figure 2B: Parotid biopsy specimen 12 weeks after RTX treatment.
A. Immunohistochemistry for CD79a B cells (panel 1, brown), CD3 T-cells (panel 2, brown) and CK14-Ki67 
localization (panel 3, brown) before RTX treatment in parotid gland tissue. Dense lymphocytic infiltration was mostly 
located around the striated duct (SD) and consisted of CD3 cells and CD79a positive B cells. In panel 3, a striated 
duct is transformed into fully-developed lymphoepithelial lesion (LEL) with numerous intraepithelial lymphocytes 
(arrows). 
B. Immunohistochemistry for CD79a B cells (panel 1, brown), CD3 T cells (panel 2, brown) and CK14-ki67 
localization (panel 3, brown) 12 weeks after RTX in parotid gland tissue. When compared to the specimen showed in 
figure 3a, a profound reduction in periductal lymphocytic infiltration, especially of B-lymphocytes, is clearly visible. 











Figure 3A: Lymphoepithelial lesions
Figure 3B: GC-like structures
Figure 3.  Amount of LELs and GC-like structures in parotid glands of placebo (n=9) or RTX treated (n=15) patients. 
*indicates significant (P<0.05) difference compared with baseline values. Horizontal lines indicate the median values.
A. Number of LEL in parotid biopsies. 










Lymphoepithelial lesions and germinal centers
 In the RTX treated group a significant decrease in amount of LEL was observed 
after 12 weeks of treatment (P= 0.025; figures 2, 3a). Twelve out of 15 cases were even 
completely devoid of LEL and showed exclusively histomorphological regular striated 
ducts, after RTX treatment. In the placebo group no change in amount of LEL was 
observed after 12 weeks (P= 0.155; figure 3a).   
 GC-like structures were present in 68% of parotid glands at baseline. The RTX 
treatment group showed a significant decrease in total amount of GC-like structures 
(per surface unit) (P= 0.049; figure 3b) after RTX treatment. Twelve out of 15 cases 
were completely devoid of GC-like structures 12 weeks after treatment. In the placebo 
group no significant difference was observed in the total amount of GC-like structures 
(P= 0.525; figure 3b) between baseline levels, and 12 weeks after treatment.
 CK14-Ki-67 double staining showed sparse staining for Ki-67 in ductal basal cells 
indicative of low proliferation before and after RTX treatment (figure 2b). Furthermore, 
proliferation of acinar cells in the parotid glands in both treatment groups was 
comparable before and after treatment (rituximab from 2.2% to 2.1% and placebo 
2.1% to 2.2%).  
Parotid gland function 
 In the RTX treated group no significant difference was observed in stimulated 
parotid salivary flow at 12 weeks in comparison to baseline (figure 4). In marked 
contrast, however, in placebo treated patients stimulated parotid salivary flow had 
significantly decreased 42% at 12 weeks after placebo (P=0.039).
Figure 4: Parotid salivary flow 
Figure 4. Effect of placebo (n=9) and RTX (n=15) treatment on parotid salivary secretion in pSS patients. *indicates 











 The results of the current placebo controlled study showed that RTX treatment 
is able to significantly reduce overall lymphocytic infiltrate with major loss of B cell 
component and GC-like structures. In addition, a major reduction of LELs as a sign 
of structural regeneration of the glands was observed. Therefore, it was concluded 
that, targeting B cells in pSS leads to a major decrease in histologically verified local 
inflammation state, demonstrating the crucial role of B cells in this autoimmune disease. 
Although RTX treatment results in the almost complete absence of B cells in the 
serum of patients with pSS, this is not mirrored by a complete absence of B cells 
in parotid salivary gland tissue indicating that RTX does not fully depletes B cells in 
salivary (parotid) glands of pSS patients. 
 The lack of total depletion of B cells in the salivary glands could be responsible for 
the relapse of pSS disease activity. These results are in line with other studies in pSS [27] 
and RA [28-30] showing persistence of B cells in the local tissue after RTX treatment. 
Devauchelle-Pensec et al. reported a total depletion in B cells in LSG samples of 
pSS patients after RTX treatment [31]. The reason for the discrepancy between the 
latter results and the findings in the current study is unclear. Possible explanations may 
include the difference in sample size or the notion that GC-like structures are more 
frequently present in parotid glands compared to LSGs [32]. These GC-like structures 
can act as a niche with restricted access to RTX, leading to the persistence of B cells 
after treatment [33, 34]. 
 
 The exact mechanism regarding possible regeneration of ductal epithelium from LEL 
is not known. LELs in pSS develop from enhanced proliferation of basal cells of striated 
ducts with an aberrant metaplastic lymphoepithelial differentiation, triggered by the 
epitheliotropic autoimmune inflammation [5]. Studies from the intestinal epithelium 
indicate that cytokines are key regulators of epithelial homeostasis (reviewed by 
Koch and Nusrat, 2012) [35]. For example, IFN-γ and TNF-α are central mediators of 
disruption of the epithelial barrier function of the intestine. Also, the integrity of the 
ductal and acinar epithelium of salivary gland tissue is affected by these cytokines by 
disorganization of the tight junctions [36]. 
 It can be assumed that pro-inflammatory cytokines, such as IL-6, IFN-α and TNF-α 
trigger the basal cells to proliferation and differentiation. Furthermore, it was recently 
demonstrated that pro-inflammatory cytokines, such as IL-6, IFN-α and TNF-α, 
decrease after RTX treatment [37]. This decrease in pro-inflammatory cytokines could 
explain the regeneration of ductal epithelium from LEL.  
 According to the immunohistologic improvement, some clinical improvement in 
parotid flow after RTX treatment was expected. In contrast to the findings in 3 out 










increased after RTX treatment in the current study but remained at the baseline level. 
Importantly, however, parotid flow in placebo treated subjects reduced during the 
same observation period. This reduction of parotid flow in the placebo treated patients 
is in line with the findings on the natural progression of salivary gland dysfunction in 
pSS patients [38]. Increased apoptotic loss and gradual dedifferentiation of acinar cells 
contribute to gradual parenchymal atrophy in pSS [7, 39-41]. After RTX treatment 
the observed low proliferative capacity of the salivary acinar parenchyma is obviously 
not able to compensate for the inflammation-induced parenchymal cell loss in most 
patients. This might explain the observed lack of improvement in parotid salivary flow 
in the current study, despite of profoundly reduced lymphocytic infiltrate. 
 In conclusion, RTX treatment leads to major reduction of lymphocytic infiltration 
and relative B cell component with major loss of GC-like structures and with 
redifferentiation of LELs into regular striated ducts, reflecting major reduction of 
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 To assess the effects of rituximab (RTX) treatment in primary Sjögren’s syndrome 
(pSS) patients on B cell activating factor (BAFF) and proliferation-inducing ligand 
(APRIL).
Methods
 In a randomised double-blinded placebo-controlled trial, pSS patients were treated 
on days 1 and 15 with B cell depleting therapy with RTX (n=20) or placebo (n=10). 
Serial blood samples were collected from the pSS patients at various time intervals (0, 
5, 12, 36 and 48 weeks) following RTX/placebo treatment and from 10 age- and sex-
matched healthy controls (HCs). Parotid gland biopsies were taken from pSS patients 
at baseline and at 12 weeks after RTX/placebo treatment, to analyse presence of BAFF 
in glandular tissue before and after treatment. Numbers of B cells were examined in 
peripheral blood from pSS patients and HCs by four-color flow cytometry. Serum 
levels of BAFF and APRIL were measured by enzyme-linked immunosorbent assay. 
Results
 Complete depletion of circulating B cells was observed in patients treated with 
RTX. Partial reconstitution of B cells started after 12 weeks following RTX treatment. 
At baseline, BAFF and APRIL serum levels were significantly increased in pSS-patients 
compared to HCs (P<0.05). Following RTX treatment, BAFF levels increased up to 
12 weeks after RTX treatment (3-4 fold, P<0.05), where after BAFF levels gradually 
returned to baseline values. In contrast to BAFF, no changes in serum levels of APRIL 
were observed after RTX treatment. 
Conclusion
 RTX treatment of pSS patients results in a significant increase of serum levels of BAFF, 











 Primary Sjögren’s syndrome (pSS) is characterized by mononuclear infiltrates, mainly 
composed of B- and T-lymphocytes, in exocrine glands. In particular, lacrimal and salivary 
glands are affected leading to destruction of these glands, which results in dryness of 
mouth (xerostomia) and eyes (keratoconjunctivitis sicca) [1]. 
 Involvement of B-lymphocytes in pSS is apparent considering the presence of 
autoantibodies, including rheumatoid factor and antibodies directed against SS-A/Ro 
and SS-B/La antigens, and hypergammaglobulinemia [1, 2]. B cell involvement is further 
demonstrated by the presence of B cell infiltrates with germinal center-like structures 
in affected tissues and aberrant distribution of B cell subsets in the peripheral blood [3, 
4]. B cell involvement is also illustrated by the notion that 5-10% of patients with pSS 
develop MALT lymphoma [5]. 
 In line with an important role for B cells in pSS, B cell depletion using rituximab 
(RTX), a chimeric monoclonal antibody that targets the pan-B-lymphocyte antigen 
CD20, appears to be effective in the treatment of patients with early diagnosed 
pSS [6-8]. Clinical effects persisted for 24-36 weeks, a time period during which B 
cells in the peripheral blood were reduced. Reduction in glandular inflammation and 
redifferentiation of duct lesions to regular striated ducts together with an increase 
in parotid flow was demonstrated at 12 weeks after rituximab treatment [6, 9, 10]. 
Together these data suggest that B cells are involved in inducing lesions in glandular 
tissue in pSS. 
 B cell activating factor (BAFF) and proliferation-inducing ligand (APRIL), both members 
of the tumor necrosis factor (TNF)-ligand family, are important cytokines involved in 
B cell survival and activation [11]. These cytokines are thought to play significant roles 
in the pathogenesis of various autoimmune diseases including pSS [12, 13]. Binding of 
BAFF to the BAFF receptor (BAFF-R) induces survival signals for B cells [14]. As such, 
signalling of the BAFF-R positively regulates B cell homeostasis. BAFF can also bind to 
another receptor; the transmembrane activator and calcium-modulator and cyclophilin 
ligand interactor (TACI), to which also APRIL can bind. Interaction of BAFF or APRIL to 
TACI leads to B cell activation resulting in T cell independent isotype switching and in 
production of immunoglobulins [15, 16]. Finally, in particular APRIL contributes to the 
maintenance/ survival of long-lived plasma cells by interaction with the receptor B cell 
maturation antigen (BCMA) on plasma cells [17, 18]. Studies in BAFF transgenic mice 
demonstrated that excessive BAFF production results in autoimmunity, caused by a 
less stringent selection of immature/transitional B cells and survival of low/intermediate 
affinity self-reactive B cells [19-21]. Importantly, these BAFF-transgenic mice develop 
severe autoimmune symptoms that are similar to systemic lupus erythematosus (SLE) 










BAFF and APRIL levels in serum and saliva are elevated in patients with pSS compared 
to healthy controls [22]. The origin of these cytokines is not completely understood. A 
recent study conducted by Yoshimoto et al., revealed that circulating monocytes from 
pSS patients produced higher amounts of BAFF than normal monocytes, even in the 
absence of stimulation [23]. In salivary glands of pSS patients, both ductal and infiltrating 
cells appear to produce BAFF, which might be induced by virus, TLR signalling, or by 
type I Interferon (IFN) [24, 25]. Furthermore, levels of both APRIL and BAFF correlate 
with serum IgG levels in pSS-patients and BAFF levels are higher in patients with 
anti-SSA and anti-SSB antibodies [13, 26, 27], denoting their possible role in disease 
progression. Together these observations demonstrate that BAFF and APRIL could be 
important players in the pathogenesis of pSS. 
 BAFF levels rise after RTX treatment of patients with rheumatoid arthritis and SLE 
[28, 29]. Limited data are currently available on BAFF levels in pSS patients treated 
with RTX. Lavie et al. have demonstrated a rise in BAFF levels after RTX treatment 
in two pSS patients with one time point after RTX treatment [30]. Effects on APRIL 
levels in pSS after RTX treatment are lacking. With regard to the strong impact of BAFF 
and APRIL on B cell survival and activation, it is therefore of importance to study in 
detail the effects of RTX-induced B cell depletion on serum BAFF and APRIL levels 
in patients with pSS. For this reason we assessed here in a double-blind, randomised, 
placebo-controlled trial the effects of RTX treatment in pSS patients on serum BAFF 
and APRIL levels up to 48 weeks after RTX treatment. In addition we analyzed whether 
BAFF is still produced in the affected glandular tissue, despite the RTX treatment.
 
materIals and methods
Patients and controls 
 Thirty patients with pSS had been treated in a randomised double-blinded placebo-
controlled trial on days 1 and 15 with either 1,000 mg RTX (Roche, Woerden, The 
Netherlands) (n= 20) or placebo (n= 10) at the University Medical Center Groningen, 
The Netherlands [6]. All patients fulfilled the European-US criteria for pSS [31]. 
To minimize side effects (infusion reactions, serum sickness), all patients were pre-
medicated with methylprednisolone (100 mg/i.v.) and received 60 mg oral prednisone 
on days 1 and 2, 30 mg on days 3 and 4, and 15 mg on day 5 after each infusion with 
rituximab. A detailed account of the patients included in this trial has been described 
before [6]. From the 30 patients, two patients were excluded from analysis, either due 
to serum sickness (n=1, RTX-group) or insufficient serum sample at baseline (n=1, 
placebo group). In addition to the pSS patients, 10 age- and sex-matched healthy 
controls (HCs) were included in the current study (1 male and 9 females; mean age 










in accordance with the ethics committee of the University Medical Center Groningen 
(METC approval: 05.229).
B cell analysis
 Estimation of B cell numbers was performed on fresh blood samples from HCs and 
from pSS patients at various time points (baseline, 5, 12, 36 and 48 weeks after RTX/
placebo treatment) with use of FACS-Calibur flow cytometer as previously described 
[32].
Quantification of soluble BAFF, APRIL and IgG 
 Serum samples were collected from all pSS patients at various time points (at 
baseline, and at 5, 12, 36 and 48 weeks after rituximab treatment) and from 10 age- 
and sex-matched HCs. Concentrations of BAFF and APRIL in serum were measured by 
enzyme-linked immunosorbent assay (ELISA) using commercial kits from R&D systems 
(Minneapolis, USA) and Bender Med Systems (San Diego, USA), respectively, following 
the manufacturer’s instructions. The minimal detectable concentration of BAFF-ELISA 
was 3.38 pg/mL and for APRIL-ELISA was 400 pg/mL. Levels of IgG were measured by 
laser nephelometry.
Immunohistochemical staining of BAFF in parotid gland tissue
 Serial parotid biopsies were collected before and 12 weeks after the first infusion 
of RTX/placebo as previously described [10, 33]. To analyse whether BAFF was still 
produced after RTX treatment, we examined biopsies of 10 patients (5 rituximab, 
5 placebo) for BAFF expression. Cryostat sections (5 µm) were fixed with acetone 
and incubated with 10 µg/mL rat anti-human BAFF (Buffy 2) (Abcam, Cambridge, 
UK). Sections were subsequently washed with phosphate buffered saline (PBS) and 
incubated with biotin labeled goat anti rat Ig (1:50; BD Bioscience, San Diego, USA) 
supplied with 1% normal human serum. After rinsing, horseradish peroxidase labeled 
avidin (1:50; BD Bioscience) and 3,3′-diaminobenzidine substrate (Sigma Chemical Co., 
St. Louis, Missouri, USA) were used for visualization. Sections were counterstained 
using hematoxylin (Sigma Chemical Co., St. Louis, Missouri, USA). After dehydration 
with alcohol, slides were mounted in DePeX mounting medium (VWR International, 
Amsterdam, the Netherlands). Immunostained slides were evaluated by light microscopy.
Statistical analysis
A linear mixed effect analysis test (SPSS version 18.0) was used to analyze the difference 
of BAFF/APRIL serum levels between treatment groups. Analysis was performed 
using time and treatment as variables. The paired t-test was used for intra-individual 
comparison of values at different time points. Spearman Rank Correlation Coefficient 










levels. A log transformation prior to statistical analysis was performed, if data were not 
normally distributed. Data are presented as the mean or median and range. A value of 
p<0.05 was considered statistically significant. 
 
results
RTX treatment results in complete depletion of B cells in peripheral blood
 As previously described in detail elsewhere, peripheral blood B-lymphocytes 
were completely depleted in patients treated with RTX [32]. Partial reappearance of 
B-lymphocytes started 12 weeks after treatment. In patients treated with placebo a 
drop in B-lymphocyte levels was only visible at 5 weeks, most likely due to the effect 
of corticosteroids given to all pSS patients to prevent adverse events.
Figure 1: BAFF and APRIL levels
Figure 1. BAFF and APRIL levels in HCs and pSS patients at baseline. *indicates significant differences between HCs 
and pSS subjects (P<0.05). The horizontal lines indicate the median values.
A. BAFF levels
B. APRIL levels
BAFF levels increase after RTX treatment
 At baseline, serum BAFF levels were significantly higher (1.3 fold) in pSS patients 
(median 1277 pg/mL [range 906.9-3802 pg/mL]) compared to HCs (median 982.6 
pg/mL [range 599.9-1564 pg/mL]); P<0.01; figure 1a). These findings are in line with 
observations by others [22]. In RTX treated patients a 3-4 fold increase in BAFF levels 
(P<0.001) was observed up to 12 weeks after treatment followed by a gradual return 
towards baseline levels (figure 2a). When B cell numbers declined as a consequence 
of RTX treatment, BAFF levels rose significantly, and when B cells reappeared, BAFF 
levels decreased again towards their baseline values [6]. Indeed, correlation analysis 










Figure 2: BAFF and APRIL levels in pSS patients before and after treatment
Figure 2. Effect of placebo and RTX treatment on BAFF and APRIL levels in pSS patients. *indicates significant 
differences compared with baseline values (P<0.05). The horizontal lines indicate the median values.
A. BAFF levels
B. APRIL levels
in serum (P<0.0001). In contrast to RTX treated patients, in placebo treated patients 
only a slight, but significant increase in BAFF levels, was detected at 5 weeks after 
treatment (P<0.001), but not at other timepoints. At this time point B cell numbers 
were slightly decreased. A linear mixed effect analysis confirmed a significant treatment 











APRIL levels are unaffected after RTX treatment
 At baseline, not only BAFF levels, but also APRIL levels were significantly higher (7-
8 fold) in serum of pSS patients (median 15098 pg/mL [range 1891-228591 pg/mL]) 
compared to HCs (median 1965 pg/mL [range 889-4567 pg/mL]; P<0.05; figure 1b), 
as has been described previously [26]. In marked contrast with BAFF, no changes over 
time were observed in serum APRIL levels in RTX or placebo treated subjects during 
follow up (figure 2b). There was a remarkable variation in APRIL levels at baseline. 
This was clearly a characteristic of the individual patients since patients with high 
baseline values of APRIL remained high during the entire time period studied. One 
of the pSS patients had very high APRIL levels (8-fold) at baseline (figure 2b). After 
RTX treatment APRIL levels in this patient remained persistently high. There was no 
significant difference in APRIL levels between the placebo and RTX group over the 
time period studied (P=0.054, linear mixed effect analysis), even not when the patient 
with the very high APRIL levels (in the RTX group) was omitted from the analysis.
 
Figure 3A: immunohistochemistry for CD79a B cells (1), CD3 T cells (2) and BAFF (Buffy-2) localization (3) in 
pSS patients at baseline.
Figure 3B: immunohistochemistry for CD79a B cells (1), CD3 T -cells (2) and BAFF (Buffy-2) localization (3) in 
pSS patients 12 weeks after RTX treatment.
A. Immunohistochemistry for CD79a B cells (3A-1, brown), CD3 T cells (3A-2, brown) and BAFF (Buffy-2) 
localization (3A-3, brown) before RTX in parotid gland tissue. Lymphocytic infiltration was mostly located around 
the striated duct (SD) and consisted of CD3 T cells and CD79a positive B cells. BAFF is predominantly localized in 
the lymphocytic infiltrate (arrows). 
B. Immunohistochemistry for CD79a B cells (3B-1, brown), CD3 T cells (3B-2, brown) and BAFF (Buffy-2) 
localization (3B-3, brown) after RTX in parotid gland tissue. A reduction in lymphocytic infiltration around the 










Figure 4: Serum IgG levels
Figure 4. Serum IgG levels of placebo/ RTX treated patients. *indicates significant (P<0.05) differences compared 
with baseline values. The horizontal lines indicate the median values. 
BAFF is expressed in parotid glands after RTX treatment
 Immunohistochemistry of parotid gland samples showed the presence of 
lymphocytic infiltrates in all patients at baseline. The lymphocytic infiltrates were 
predominantly located around the striated ducts and consisted predominantly of T 
cells (CD3+) and B cells (CD79a+) (figure 3A1-2). At 12 weeks after treatment the 
lymphocytic infiltrates were clearly smaller in size in the RTX treated group, but not in 
the placebo treated group (figure 3B1-2). Staining for BAFF showed the presence of 
this cytokine, both in tissue sections obtained at baseline and those at 12 weeks after 
RTX or placebo treatment. In all tissue sections BAFF was located predominantly in 
the lymphocytic infiltrates surrounding the ducts. Despite the reduction in size of the 
lymphocytic infiltrates no clear changes in BAFF staining were observed after RTX 
treatment (figure 3A3, B3).
Decreased serum levels of IgG after RTX treatment
 BAFF (and APRIL) are also involved in B cell activation and higher BAFF levels 
could therefore result in higher IgG serum concentrations observed in pSS patients 
[6, 34]. As expected, at baseline, patients with pSS had higher IgG levels compared to 
healthy controls. However, in contrast to Mariette et al. [34], there was no positive 
correlation between baseline levels of BAFF and IgG (R=-0.3547, P=0.0695). After 
RTX treatment, levels of IgG decreased significantly for a prolonged period of time 
(figure 4). Meanwhile, levels of BAFF increased significantly, compared to baseline 
values (figure 2a). In placebo patients IgG levels were only decreased, at 5 weeks after 
treatment, at a timepoint that BAFF levels were also significant increased. This was most 











 Although intervention treatment options for pSS are currently very limited, B cell 
depletion with RTX appears to be an effective modality [6, 10]. Treatment with RTX 
results in an effective depletion of B cells in the peripheral blood and thus interferes 
with B cell homeostasis. Since BAFF and APRIL are two critical cytokines for the control 
of B cell homeostasis, we studied the effects of RTX treatment on the serum levels 
of these cytokines in pSS patients. We observed in a placebo controlled trial that the 
already higher baseline levels of serum BAFF in pSS patients further increase after RTX 
treatment, when B cells were absent. BAFF levels declined, when B cells reappeared. In 
marked contrast, APRIL levels, which partly target the same receptors as BAFF, were 
largely unaffected, and remained high after RTX treatment. 
 A likely explanation for the increase in BAFF levels after RTX treatment is that 
depletion of B cells also results in removal of BAFF-R which is highly expressed on 
mature B cells. Expression of BAFF-R is low on newly formed, immature, B cells and is 
upregulated when these cells become mature B cells [35]. Absence of mature B cells 
results in absence of available BAFF-R leading to an increase in free, unbound BAFF 
in serum. Indeed, in line with this notion, decline in serum BAFF levels coincides with 
the reappearance of B cells in blood after RTX treatment [32]. In addition to this 
mechanism, Lavie et al. [30] also observed that after RTX treatment mRNA levels 
encoding for BAFF in peripheral blood mononuclear cells are higher than before 
treatment. Apparently, in addition to an increase in BAFF due to absence of receptors, 
there is also a positive transcriptional regulation of BAFF production. However, no 
evidence exists for a direct influence of B cells on BAFF-mRNA levels in monocytes 
[30]. It is therefore possible that an indirect mechanism is responsible for upregulation 
of BAFF mRNA levels in monocytes. An important factor for the stimulation of BAFF 
production is type I IFN [36] , but serum levels of these cytokines decrease rather than 
increase after RTX treatment. It thus remains to be shown how BAFF-mRNA levels are 
upregulated after RTX treatment. 
 APRIL levels are rather stable after B cell depletion with RTX. The two major 
receptors for APRIL, TACI and BCMA, are largely restricted to activated B cells and to 
plasma cells, respectively [37, 38]. Since numbers of activated B cells are relatively low, 
and plasma cells are largely unaffected by RTX treatment, it is therefore not surprising 
that depletion of peripheral B cells, dominated by mature B cells that do not express 
appreciable levels of TACI and/or BCMA, does not result in a change in serum APRIL 
levels. 
 The observed increase of serum BAFF levels after RTX treatment may result in 










activation. B cell receptor (BCR) signaling and BAFF-R signaling synergize in B cell 
survival, which is mediated by activation of NF-kB [39]. BCR signaling activates the 
classical NF-kB pathway, that results in the production of p100 substrate, required for 
BAFF-R signaling via the alternative NF-kB pathway [40]. Evidence from studies with 
transgenic mice indicates that BAFF levels regulate the stringency of the selection 
of naïve B cells [21, 41, 42]. Anergic B cells compete poorly with non-anergic B cells 
when BAFF levels are limited and excess of BAFF rescues autoreactive cells that are 
anergized after the early transitional B cell stage, but not at the early B cell stage 
[41]. One possible explanation is that autoreactive transitional B cells downregulate 
their BCR, which results in less availability of substrate (p100), required for BAFF-R 
signaling. As a consequence these cells require higher BAFF levels for their survival and 
differentiation to mature B cells [20]. In contrast, long-lived memory B cells, that arise 
after an antigen driven autoimmune response, appear to be completely independent 
from BAFF (and APRIL) [18, 20]. The notion that BAFF levels regulate the selection of 
naïve B cells is based on studies with (genetically-engineered) mice (reviewed in Liu 
and Davidson [43]), and studies in human are entirely lacking. Nevertheless, higher 
BAFF levels are speculated to play a role in the pathogenesis of various autoimmune 
diseases, including pSS [26, 44]. Whether the elevated serum BAFF levels observed 
after RTX treatment also impair the stringency of the selection of naïve B cells in 
pSS patients, and therewith promote autoreactivity, is not known. The majority of re-
emerging B cells after RTX treatment are transitional type B cells [32] and it remains 
to be seen that this B cell fraction comprises more autoreactive cells compared to 
placebo treated patients. In conclusion, we cannot completely rule out the possibility 
that the elevated BAFF levels contribute to the new formation of autoreactive cells 
from the bone marrow, but, probably BAFF does not affect the survival of long-lived 
autoreactive memory cells. 
 Another effect of the rise in BAFF levels after RTX treatment might be that higher 
BAFF levels could result in hyperactivation of B cells. Hyperactivation of B cells can 
be reflected by elevated IgG levels. Others have shown in patients with pSS, RA or 
SLE that the levels of IgG correlate well with the levels of BAFF. We could, however, 
not confirm this observation when we looked at baseline serum BAFF and IgG levels. 
Differences in patient populations and treatment regimes might well explain this 
discrepancy. Furthermore, after RTX treatment the levels of BAFF rise, whereas IgG 
levels decline simultaneously. A decrease in IgG levels has also been observed in SLE 
patients treated with RTX [45]. Thus, clearly after RTX there is no positive correlation 
between BAFF levels and IgG levels, and there is no evidence that after RTX therapy 
the higher BAFF levels results in hyperactivation of B cells, persisting in lymphoid organs 
and tissues. On the other hand, after RTX treatment, IgG levels correlated well with 










depletion therapy could result in an insufficient replacement of long-lived plasma cells. 
Taken the half-life of IgG into account, fewer plasma cells could result in lower IgG 
levels. That even severe B cell depletion results in only a slight reduction of IgG in 
serum might be explained by the fact that most IgG plasma cells are probably long-
lived. This is also reflected by our finding that Ig producing cell clones present before 
therapy, persist up to a year after RTX therapy [46]. 
 Survival of long-lived plasma cells is supported by APRIL by its interaction with BCMA 
[18], in conjunction with IL-6 and CXCL12/Sdf-1 [47]. These latter two cytokines are 
found in close proximity to the plasma cells and form special niches in the salivary 
glands of pSS patients [48]. The high APRIL levels, before and after RTX treatment, may 
further support the survival of IgG producing plasma cells in the salivary glands of pSS 
patients. BAFF can also bind to BCMA on the plasma cells. BAFF is produced locally 
in salivary gland tissue by epithelial cells, T cells and B cells [36, 49, 50]. Ittah et al. [25] 
showed that the expression of BAFF by salivary gland epithelial cells increases after 
stimulation with type I IFN or by interaction with viral RNA. This increased expression 
of BAFF may lead to local activation of autoreactive mature B cells leading to chronic 
auto-immune inflammation [24, 25]. In our study, we demonstrated the presence of 
BAFF in parotid gland tissue even after RTX treatment. It can be speculated that this 
local BAFF is also involved in the survival of local plasma cells after RTX-treatment. 
 High BAFF levels have been implicated in the pathogenesis and disease activity of 
pSS [26]. In this study we have shown that BAFF levels further increase after RTX 
treatment. These elevated BAFF levels likely contribute to repopulation of the naïve 
B cell pool. Indeed, Pers et al. [51] demonstrated that higher BAFF levels before RTX 
treatment lead to a shorter period of B cell depletion. This has implications for the 
development of treatment modalities. It can be speculated that adding anti-BAFF to 
RTX-treatment may lead to a prolonged reduction of (auto reactive) B cells. Therefore, 
combining B cell depletion therapy with RTX and anti-BAFF therapy might result in 
a prolongation of B cell depletion. The additional beneficial effect might be that there 
is less de novo generation of autoreactive cells after depletion by RTX. Since B cell 
reappearance correlates well with clinical relapse [6] such a treatment modality might 
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The mechanism by which B cell depletion by rituximab (RTX) exerts its beneficial 
clinical effect in primary Sjögren syndrome (pSS) needs further elucidation. As cytokines 
play a critical role in the initiation and perpetuation of the chronic inflammatory 
response in pSS, we explored whether the beneficial effect of RTX on disease activity 
is mediated by a change in (pro-inflammatory) cytokine levels. 
Methods
Thirty pSS patients were treated on days 1 and 15 with either RTX (1,000 mg, n= 
20) or placebo (n= 10). Blood samples were collected at baseline and at 5, 12, 36 and 
48 weeks after treatment. In addition, blood samples were collected from age and sex 
matched healthy controls (HC, n=10). B cells were examined by four-color cytometry. 
A multiplex-bead array cytokine assay was used for simultaneous measurement of 25 
cytokines and chemokines.
Results
Depletion of B cells was observed in the RTX group at 5 weeks after treatment, 
partial reconstitution of B cells started after 12 weeks. At baseline, when compared to 
HC, all, but IL-8, IFN- γ and RANTES, cytokine levels were increased in patients with 
pSS. With regard to RTX or placebo treatment, linear mixed effect analysis showed a 
significant decrease in a subset of, mainly pro-inflammatory, cytokines (GM-CSF, IL-1Ra, 
IL-6, IL-10, IFN-α, TNF-α) and chemokines (MIP-1β (CCL4), MIG (CXCL9)) in RTX 
treated patients. Levels of these cytokines and chemokines were significantly decreased, 
compared to baseline levels, at 5-12 weeks after RTX treatment (p<0.05). After this 
initial decline, levels had reached baseline levels by 36 weeks after RTX treatment.
Conclusion
This study demonstrated that depletion of B cells resulted in a concomitant 
decrease in serum levels of a subset of mainly pro-inflammatory cytokines. Our findings 
suggest that the beneficial effect of RTX in pSS patients is mediated by depletion of 
pro-inflammatory cytokine producing B cells. This insight may contribute to better 
understanding of the role of B cells in the pathogenesis of pSS and development of 











Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized 
by chronic inflammation and destruction of exocrine glands, primarily the salivary 
and lacrimal glands [1-3]. The main clinical features are progressive dryness of mouth 
(xerostomia) and eyes (keratoconjunctivitis sicca). General symptoms of pSS include 
fatigue, weight loss and fever [1]. Extraglandular manifestations may occur at the level 
of skin, joints, muscles, peripheral and central nervous system, kidneys and lungs [4-
7]. These clinical manifestations lead to a diminished health related quality of life in 
patients with pSS [8]. 
In the salivary glands, the infiltrates are primarily located around the ducts and are 
largely composed of T and B lymphocytes, macrophages and (plasmacytoid) dendritic 
cells [9, 10]. These infiltrates can even be organized to ectopic lymphoid tissues with 
segregated T and B cell areas, germinal center like structures and high endothelial 
venules [11]. 
Cytokines and chemokines play a critical role in the initiation and perpetuation of 
the chronic inflammatory response in glandular tissue of patients with pSS [12, 13]. A 
wide variety of both pro- and anti-inflammatory cytokines and chemokines is involved 
in the inflammatory process, leading to infiltrates and ultimately the destruction of the 
glands. Important cytokines in this process include interleukin (IL)-6 and tumor necrosis 
factor (TNF)-α. These cytokines are not only actively synthesized in the salivary glands, 
but are also overexpressed in saliva and serum of pSS patients [14-16]. Their presence 
in saliva indicates that they are directly involved in the local inflammatory process [17, 
18]. Besides driving inflammation, cytokines can also assert a direct effect on salivary 
gland function. This is illustrated by the notion that chronic exposure of parotid gland 
epithelial cells to the pro-inflammatory cytokines TNF-α and interferon (IFN)-γ led to a 
disruption of tight junction integrity followed by an increase in paracellular permeability 
of the epithelium [19]. Increased permeability affects the composition of the secreted 
saliva. 
B cells play a critical role in the pathogenesis of pSS and appear to be hyperactivated 
[1, 20]. Increased activation of B cells in pSS is reflected by the increased levels of 
serum immunoglobulins (hyper-gammaglobulinemia) amongst which autoantibodies 
directed against Ro/SSA and La/SSB antigens [20]. The disease is characterized by its 
type I interferon (IFN) signature, leading to high levels of B cell activating factor (BAFF) 
in pSS [21]. The high levels of cytokines IL-6 and BAFF may be responsible for B cell 
hyperreactivity in pSS [22]. The importance of B cells in pSS is further exemplified by 
the beneficial effect on the clinical symptoms upon administration of rituximab (RTX), 
a chimeric monoclonal antibody to CD20, leading to peripheral B cell depletion [23-
26]. The mechanism by which RTX exerts its beneficial clinical effect remains to be 










important other immunological functions, such as cytokine production and antigen 
presentation [27]. Studies indicate that B cells can produce a variety of cytokines 
including granulocyte-macrophage colony stimulating factor (GM-CSF), IL-6, IL-10, 
IFN-γ and TNF-α [28-30]. 
In the work presented here we explored the possibility that the effect of RTX on 
disease activity in pSS patients is mediated by depletion of cytokine producing B cells. 
If B cells are indeed a (major) source of cytokine production this might be reflected 
by decreased cytokine levels in peripheral blood of pSS patients [31]. This insight may 
contribute to a better understanding of the role of B cells in the pathogenesis of pSS 




Thirty patients with pSS were treated in a randomised double-blinded placebo-
controlled trial on days 1 and 15 with intravenous (IV) injections of either 1000 mg 
RTX (n= 20) or placebo (n= 10) in the University Medical Center Groningen, The 
Netherlands. To minimize side effects (infusion reactions, serum sickness), all patients 
were treated with methylprednisolone (100 mg IV), acetaminophen (1000 mg orally) 
and clemastine (2 mg IV) and received 60 mg oral prednisone on days 1 and 2, 30 
mg on days 3 and 4, and 15 mg on day 5 after each infusion. All patients fulfilled the 
European-US criteria for pSS, as well as the recently published ACR criteria [2, 3]. A 
detailed account of the patients included in this trial has been described before [23]. 
From these 30 clinical trial patients, 28 patients (1 male, 27 females; mean age 43 
years (range 20-69 years)) were included in the present study. One patient (RTX 
group) was excluded due to the development of serum sickness like disease and 
another patient (placebo group) because of insufficient sample at baseline. In addition, 
10 age- and sex-matched healthy controls (HC) were included in the current study (1 
male and 9 females; mean age 46 years (range 29–60 years)). All patients and controls 
provided informed consent in accordance with the ethics committee of the University 
Medical Center Groningen (METC approval: 05.229).
Blood samples
Blood samples were collected at baseline and at 5, 12, 36 and 48 weeks following 
RTX or placebo treatment. In addition, blood samples were collected from healthy 
controls.  Serum was collected, aliquoted and stored at -20ºC until analysis. 
B cell analysis










using the FACSCalibur flow cytometer and TruCOUNT tubes (Becton Dickinson, 
Breda, The Netherlands) as previously described [32].
Multiplex cytokine assay
A multiplex-25 bead array cytokine assay (Invitrogen, Breda, The Netherlands) was 
used enabling simultaneous measurement for the following cytokines and chemokines: 
GM-CSF, IL-1β, IL-1 receptor  antagonist (IL-1Ra), IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, 
IL-10, IL-12p40/p70, IL-13, IL-15, IL-17, IFN-α, IFN-γ, TNF-α, monocyte chemotactic 
protein (MCP-1/CCL2), macrophage inflammatory protein (MIP-1α/CCL3), MIP-1β 
(CCL4), regulated upon activation normal T cell expressed and secreted (RANTES/
CCL5), Eotaxin (CCL11), monokine induced by gamma-interferon (MIG/CXCL9) 
and interferon-gamma inducing protein (IP-10/CXCL10). Standard curves for each 
cytokine were generated using the reference cytokine and chemokine concentrations 
supplied in the kit. 
The assay was used in a 96-well plate provided in the kit. All incubation steps were 
performed at room temperature and in the dark due to the light sensitivity of the bead 
mix according to manufacturer instructions. In short, the 96-well plate was prewetted 
with 200 µl of working washing solution; this solution was aspirated using a vacuum 
manifold. The beads were pipetted into each well and wells were washed two times 
with washing buffer and were subsequently vacuum filtered. Incubation buffer (50 µl) 
and 1:4 diluted serum samples or standards (50 µl) were pipetted into the well and 
incubated for 2 hours with the beads. Thereafter, wells were washed using the vacuum 
manifold and detector antibody conjugated to biotin (diluted 1:10 with biotin diluent) 
was added. After incubation for 1 hour, beads were washed followed by an incubation 
of 30 minutes with streptavidin conjugated to R-phycoerythrin (streptavidin-RPE, 
diluted 1:10). After washing to remove unbound streptavidin-RPE, beads were analyzed 
in the Luminex 100 instrument. Raw data (mean fluorescent intensity) from all kits 
were analyzed by MasterPlex Quantitation Software (MiraiBio, Inc., Alameda, CA, USA) 
to obtain concentration values.
Statistical analysis
The nonparametric Mann-Whitney U test was used for comparison of cytokine/
chemokine values between HC and patients with pSS at baseline. In patients with 
pSS, a linear mixed effect analysis test (SPSS version 18.0) was used to analyze which 
cytokines/chemokines were affected by RTX treatment in comparison to placebo 
treatment during the study period. The linear mixed effect analysis test was performed 
using time and treatment as explanatory variables and the log transformed cytokine/
chemokine values as response. The Wilcoxon matched pairs test was used for intra-
individual comparison of pre- and post-treatment values. Data are presented as the 











B cells started to reappear 12 weeks after RTX treatment
At baseline, B cell numbers were comparable between RTX treated and placebo 
treated patients. At 5 weeks, a complete depletion of peripheral blood B cells was 
observed in the RTX treated group. B cells started to reappear from 12 weeks 
after RTX treatment. In the placebo treated group, a moderate decrease in B cells 
was observed at 5 weeks post-treatment only, most likely due to the prednisone 
administration, given to prevent adverse reactions [32]. 
In patients with pSS most serum cytokine levels were elevated compared to HC
As we show in table 1, baseline serum levels for nearly all cytokines/chemokines 
analyzed (cytokines: GM-CSF, IL-1β, IL-1Rα, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-10, IL-
12p40/p70, IL-13, IL-15, IL-17, IFN-α, TNF-α; chemokines: MCP-1 (CCL2), MIP-1α 
(CCL3), MIP-1β (CCL4), Eotaxin (CCL11), MIG (CXCL9) and IP-10 (CXCL10)) 
were significantly higher in patients with pSS compared to HC (Mann-Whitney U 
test,  P<0.05). Only levels of IL-8, IFN-γ and RANTES (CCL5) did not differ between 
patients with pSS and HC (Mann-Whitney U test, P>0.05). 
Mainly pro-inflammatory cytokines and chemokines decreased after RTX treatment 
After RTX treatment in patients with pSS, levels of various cytokines and chemokines 
were decreased. A linear mixed effect analysis showed a significant treatment effect 
between RTX treated and placebo treated patients for serum levels of the following 
cytokines: GM-CSF, IL-1Ra, IL-6, IL-10, IFN-α and TNF-α, and the chemokines: MIP-1β 
(CCL4) and MIG (CXCL9) (P<0.05).
In the RTX group, levels of these cytokines and chemokines were significantly 
decreased, compared to baseline levels, at 5-12 weeks after RTX treatment (Wilcoxon 
matched pairs test, P<0.01) (figure 1A-H). After this initial decline, all followed a gradual 
return towards baseline levels 36-48 weeks after treatment. Other cytokines (IL-1β, IL-
2, IL-2R, IL-4, IL-5, IL-7, IL-12p40/p70, IL-13, IL-15 and IL-17) and chemokines (MCP-1 
(CCL2), MIP-1α (CCL3), Eotaxin (CCL11) and IP-10 (CXCL10)) did not differ in their 
expression levels between the two treatment groups during the studied time period.
In the placebo group, hardly any effects were observed on cytokine/chemokine 
serum levels. A gradual increase in IL-6 levels was noted in placebo treated patients 
during the 48 weeks study period. This increase resulted in significantly higher levels of 
IL-6, 48 weeks after placebo treatment, in comparison to baseline (Wilcoxon matched 
pairs test, P<0.05, figure 1C). Also, in the placebo group MIP-1β (CCL4) serum levels 
appeared to be higher 36 weeks after treatment compared to baseline (Wilcoxon 










Table 1. Serum cytokine and chemokine levels (median (range) values in pg/ml) of 10 healthy controls (HC) and 28 
patients with pSS at baseline measured by multiplex-25 bead array cytokine assay
  HC pSS patients P-value
Cytokines   
 GM-CSF 11.7 (7.2 - 43.0) 315.4 (19.7 - 2517) 0.0001
 IL-1β 10.0 (1.9 - 161.1) 411.1 (9.4 - 3103) <0.0001
 IL1-Ra 426.0 (292.7 - 21727) 78864 (742.2 - 1.4 x 106) <0.0001
 IL-2 4.0 (1.2 - 56.5) 154.7 (3.8 - 2152) <0.0001
 IL-2R 114.9 (64.1 - 1265) 3097 (43.4 - 48048)   0.0001
 IL-4 31.6 (25.7 - 73.9) 546.5 (32.2 - 11336) <0.0001
 IL-5 2.5 (1.1 - 3.2) 14.5 (2.0 - 458.7)  0.0002
 IL-6 4.1 (1.4 - 28.6) 30.2 (2.6 - 332.4)  0.0002
 IL-7 17.6 (6.4 -  58.2) 176.7 (8.3 - 1428)  0.0008
 IL-8 15.9 (8.7 - 54.9) 25.1 (7.2 - 281.3)  0.1477
 IL-10 2.4 (1.4 - 9.6) 225.6 (5.1 - 927.2) <0.0001
 IL-12p40/p70 214.7 (90.7 - 449.7) 1393 (214.8 - 6665) <0.0001
 IL-13 4.9 (1.3 - 95.8) 98.5 (1.8 - 1933)  0.0004
 IL-15 18.5 (10.3 - 723.2) 2080 (23.6 - 12284) <0.0001
 IL-17 13.0 (7.1 - 40.6) 469.0 (13.5 - 5455) <0.0001
 IFN-α 29.9 (17.9 - 290.7) 495.6 (69.8 - 3051) <0.0001
 IFN-γ 143.1 (91.8 - 238.5) 152.0 (83.7 - 259.7)   0.85950
 TNF-α 3.5 (2.2 - 7.3) 41.05 (4.6 - 1107) <0.0001
Chemokines   
 MCP-1 (CCL2) 636.4 (291.5 - 1209) 1950 (373.7 - 17388) <0.0001
 MIP-1α (CCL3) 83.3 (49.9 -1012) 1520 (92.6 - 7008) <0.0001
 MIP-1β (CCL4) 84.9 (32.8 - 807.3) 1082 (130.7 - 7304) <0.0001
 RANTES (CCL5) 3808 (2652 - 44920 3870 (2791 - 4680) 0.3940
 Eotaxin (CCL11) 196.8 (74.4 - 264.0) 412.9 (110.8 - 911.0) 0.0011
 MIG (CXCL9) 45.1 (18.6 - 217.8) 1552 (68.6 - 29815) <0.0001










Figure 1: Cytokine and chemokine levels
Figure 1. Cytokine and chemokine serum levels of healthy controls (HC) and effect of RTX treatment in pSS 
patients. The horizontal lines indicate the median values in pg/ml. *indicates significant differences compared with 
baseline values (P<0.05). Only cytokines and chemokines that showed a significant treatment effect of RTX treatment 
compared to placebo treatment are shown. (A) GM-CSF; (B) IL-1Ra; (C) IL-6; (D) IL-10; (E) IFN-α; (F) TNF-α; (G) 











In this study we demonstrated that depletion of B cells resulted in a concomitant 
decrease in serum levels of a selected number of cytokines (GM-CSF, IL-1Ra, IL-6, IL-
10, IFN-α and TNF-α) and chemokines (CCL4 and CXCL9). Most of these cytokines 
and chemokines belong to the group of pro-inflammatory cytokines. These decreased 
serum levels of cytokines and chemokines may help explain, at least in part, the positive 
effects on disease activity after RTX treatment [23, 24, 26].
It is known that local synthesis and secretion of cytokines and chemokines in 
glandular tissues play a critical role in the inflammatory process of pSS [13, 16]. Many 
cytokines and chemokines are expressed at higher levels in the salivary and lacrimal 
glands, indicating that most arms of the immune system are intensely involved in the 
immunopathogenesis. These cytokines and chemokines are subsequently released in 
the secretions (saliva and tears) and in serum. In this study we showed that at baseline 
nearly all cytokines and chemokines analyzed are elevated in serum of patients with 
pSS, compared to healthy controls. Our observations are in agreement with other 
studies collectively showing the broad increase of cytokines and chemokines in these 
patients [14, 15, 33-35]. 
RTX treatment results in a rapid depletion of CD20 expressing B cells. This is 
reflected by the virtually complete absence of B cells in peripheral blood 5 weeks 
after treatment. However, not all B cells are depleted, some cells persist in secondary 
lymphoid organs and in the affected salivary glands of patients with pSS [36, 37]. In 
addition, fully matured plasma cells do not express CD20 and are not targeted by RTX. 
We have already shown, by analysis of variable immunoglobulin (Ig) heavy chain genes, 
that certain clones of long-lived B cells/plasma cells persist in the salivary glands after 
RTX treatment [36]. Indeed, serum IgG levels (including autoantibodies) decreased 
only moderately after one course of RTX treatment in patients with systemic lupus 
erythematosus (SLE) [38] or pSS [23]. One study in RA showed that IgG levels were 
not affected at all after RTX treatment [39]. 
Besides immunoglobulin production, B cells are also responsible for the production 
of a number of cytokines [28-30]. In line with this notion, we observed in the current 
study that serum levels of only certain cytokines and chemokines are decreased after 
RTX treatment, but not after placebo treatment, in pSS patients. 
Patients with pSS have a pathologic overproduction of type I IFN (IFN-α, IFN-β) [40, 
41] and have a type I IFN signature [21]. The IFN-α inducing capacity of serum of pSS 
patients is positively associated with labial salivary gland focus scores [40]. Indeed we 
observed increased levels of IFN-α in our patients at baseline, which decrease after 
RTX treatment. Plasmacytoid dendritic cells (pDCs) are specialized in the production 
of type I IFN [41]. Furthermore, it is shown that B cells enhance IFN-α production 










GM-CSF might play a role in the activation of pDCs [43]. Ghirelli et al. demonstrated 
that GM-CSF can activate pre-pDCs in a Toll-like receptor (TLR) independent manner 
[43]. B cells are able to produce GM-CSF, therefore, depletion of B cells not only 
explains the lower GM-CSF levels after RTX treatment, but may also contribute to 
lower IFN-α levels [30]. Interestingly, IFN-α was shown to induce production of IL1-
Ra and MIG (CXCL9) in patients with SLE [44, 45]. We speculate that lower levels of 
IFN-α subsequently results in a decrease of IL1-Ra and MIG (CXCL9) in serum of RTX 
treated patients with pSS. 
Besides production of GM-CSF, B cells produce a number of other cytokines 
including the pro-inflammatory cytokines IL-6 and TNF-α and the anti-inflammatory 
cytokine IL-10 [28, 29]. The depletion of B cells by RTX treatment in pSS patients 
may therefore directly result in decreased levels of these cytokines. The decreased 
IL-6 serum levels that we observed after RTX treatment are in line with findings in 
RTX treated rheumatoid arthritis (RA) patients [46]. Together with TNF-α, IL-6 is one 
of the most prominent pro-inflammatory cytokines with a wide variety of effects. 
At the B cell level, IL-6 stimulates B cell proliferation and differentiation to plasma 
cells, amongst others via IL-21, which contribute to the B cell hyperreactivity and 
hypergammaglobulinemia seen in patients with pSS [22]. IL-6 is also involved in pSS 
pathogenesis of the salivary glands, illustrated by the fact that plasma levels of IL-6 
correlates with the degree of lymphocytic infiltrate in the glandular tissue [47]. Barr et 
al [31] showed with experimental autoimmune encephalomyelitis (EAE) in mice that B 
cell depletion resulted in amelioration of disease, which was mediated by elimination of 
IL-6 producing B cells. Similarly in patients with multiple sclerosis, the elevated levels of 
IL-6 secretion by B cells were normalized after RTX treatment. The authors therefore 
suggested that the reduced disease severity, observed in patients treated with RTX, 
was the result of elimination of IL-6 producing B cells. Importantly, in patients with pSS, 
elevated circulating IL-6 levels are also associated with extraglandular manifestations 
[47]. Furthermore, IL-6 plays an important role in immunopathology by the generation 
of Th17 pro-inflammatory lymphocytes [48]. Th17 lymphocytes seem to be involved 
in the formation of ectopic lymphoid follicles in the salivary glands [49]. These ectopic 
lymphoid follicles have been suggested to exacerbate disease course and propagate 
chronic autoimmune inflammation [50]. 
In addition to a decrease in some pro-inflammatory cytokines, also a decrease in 
IL-10 levels was observed after RTX treatment of patients with pSS. A similar decrease 
of IL-10 levels has been observed in RA patients treated with RTX [46]. This might be 
directly due to eradication of IL-10 producing B-cells. IL-10 is predominantly an anti-
inflammatory cytokine and suppresses, amongst others, antigen-presentation capacity 
of antigen presenting cells. However, in the presence of pro-inflammatory inducing 
factors, such as IFN-α, IL-10 can display a paradoxical pro-inflammatory effect [51]. This 










diseases, such as SLE [52, 53]. Administration of an IL-10 antagonist in SLE patients 
showed improvement of clinical manifestations [54]. Furthermore, in pSS, IL-10 has 
also been related to salivary gland disease activity and extraglandular manifestations, 
such as cutaneous vasculitis [33]. Finally, in a transgenic murine model for pSS, IL-
10 induced both destruction of glandular tissues through apoptosis and lymphocytic 
infiltration [55]. As mentioned above, after RTX treatment, however,  levels of IFN-α 
decrease, and IL-10 may acquire a more beneficial, anti-inflammatory function, resulting 
in improvement of disease parameters.
In conclusion, we have shown that RTX treatment in patients with pSS resulted in a 
significant decrease in the production of a number of cytokines and chemokines. We 
suggest that this decrease is explained, at least in part, by a direct removal of (pro-
inflammatory) cytokine producing B cells. This may subsequently lead to a decline in 
levels of other cytokines and chemokines. The decreased levels of cytokines, such as 
IL-6, may contribute to the improvement of disease progression and various clinical 
and histopathological parameters as found after RTX treatment of patients with pSS 
[23, 24]. The results from our study may have implications for the development of 
new treatment modalities, which are eagerly awaited [56]. Based upon our findings 
we anticipate that more specific treatment approaches, e.g. blockade of IL-6, might be 
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B cell depletion therapy with anti-human CD20 (rituximab; RTX) has been shown to 
be an effective treatment strategy for patients with primary Sjögren’s syndrome (pSS) 
[1;2]. However, the mechanisms through which RTX exerts its effects have not been 
fully elucidated. Besides the immediate effect caused by destruction of autoreactive B 
cells, RTX-therapy may also influence the frequency and function of regulatory T cells 
(Tregs). Previous studies have shown that RTX-treatment restored the impaired Tregs 
of patients with systemic lupus erythematosus (SLE) or idiopathic thrombocytopenic 
purpura (ITP) [3-5]. Therefore, augmentation of Tregs mediated effects on peripheral 
self-tolerance after RTX-therapy may be an additional pathway by which such a therapy 
is effective in patients with autoimmune diseases.
In the work described here we analyzed the frequency of Tregs in parotid gland 
biopsies before and 12 weeks after RTX (20 patients) and placebo (10 patients) 
treatment . A detailed account of the patients included in this trial has been described 
before [2]. In addition the proportion and function of Tregs cells in freshly isolated 
PBMCs from 5 pSS-patients, at baseline and at 24 weeks after RTX-infusion, and from 
5 age- and sex-matched healthy controls was assessed. 
The frequency of Tregs in parotid gland was assessed by double staining with CD3 
and FOXP3. The proportion of Tregs was assessed by flow cytometry using CD4, CD25 
and FoxP3 markers, whereas suppressive function of sorted Tregs was determined by 
co-culture assay. 
No difference in the amount of Tregs in the parotid gland was observed after 
placebo (p= 0.6523) or RTX (p=0.4212) treatment compared to baseline (figure 1 
and 2). Furthermore, we showed that RTX-treatment of pSS-patients did not alter the 
frequency (figure 3) and function (figure 4) of Tregs cells. This different outcome of 
RTX-therapy in pSS-patients, compared to patients with SLE and ITP, is not completely 
clear. A likely explanation for this difference might be due to the fact that baseline 
levels of Tregs-function in pSS-patients are not impaired (figure 4), in contrast to Tregs 
in patients with SLE and ITP. We suggested that these (normal) levels of Tregs numbers 
and function may not allow further upregulation in frequency and function of Tregs 
in pSS-patients after RTX-treatment. The finding that RTX-therapy affects Tregs in 
patients with SLE and ITP argues that B cells directly contribute in the abrogation of 
Tregs function. It has been speculated by Vigna-Perez el al. [4] that depletion of B cells 
in SLE-patients would induce a decrease in activated T cells expressing glucocorticoid-
induced TNF-receptor ligand (GITRL), a ligand that is able to impair the frequency and 
function of Tregs [6;7]. Therefore, it is feasible that a decrease in GITRL+ cells after 
RTX-treatment favour an increase in number/function of Tregs in SLE- and ITP-patients. 
However, data regarding the impact of B cell depletion on GITRL+ cells in relation to 
Tregs properties in pSS-patients are lacking. Obviously, further sophisticated studies 
in pSS are needed to address this speculation. On the other hand, RTX-therapy in 










Tregs generation [9]. The decrease in IL-10, therefore, may prevent the expansion of 
Tregs in pSS-patients. In general, it seemed that the observed positive effects of RTX-
treatment in pSS-patients did not act through the Tregs arm.
In summary, we show that Tregs frequency in parotid tissue are unaffected and 
that both the relative frequency and the suppressive function of Tregs from pSS-
patients at baseline are not impaired, and remained unaffected during B cell depletion 
following RTX-treatment. Thus, the effectiveness of RTX-treatment in pSS-patients is 
not associated with enhancement of Tregs numbers and/or function.
Figure 1A: Parotid biopsy specimen before RTX treatment
Figure 1B: Parotid biopsy specimen 12 weeks after RTX treatment
A. Immunohistochemistry for CD79a B-cells (1A-1, brown) and CD3 T-cells (1A-2, brown)  before RTX in parotid 
gland tissue. Lymphocytic infiltration was mostly located around the striated duct (SD) and consisted of CD3 T-cells 
and CD79a positive B-cells. CD3-FOXP3 is predominantly localized in the lymphocytic infiltrate (arrows). 
B. Immunohistochemistry for CD79a B-cells (1B-1, brown) and CD3 T-cells (1B-2, brown) localization (3B-3, 
brown) after RTX in parotid gland tissue. A reduction in lymphocytic infiltration around the striated duct (SD) was 










Figure 2:  Tregs in parotid glands before and after treatment
Figure 2.  Amount of Tregs in parotid glands of placebo (n=9) or RTX treated (n=15) patients. An incision biopsy was 
taken under local anesthesia from the same parotid gland before and 12 weeks after placebo (n=10) or RTX (n=20) 
therapy. No difference in Tregs frequency was observed in placebo (p= 0.6523) or RTX  (p=0.4212) treatment group 
when compared to baseline. 
Figure 3: Frequency of circulating Tregs in pSS-patients before and after RTX-treatment, compared with HCs.
Figure 3. (A) Representative example of FACS-plots and gating of CD25High and FoxP3+CD25High cells among 
CD4+T-cells in a pSS-patient (middle and right panels) and an age- and sex-matched HC (left panels). Values in each 
gate represent the percentage of positive cells. (B) Percentage of CD25High – and (C) FoxP3+CD25High cells among 
CD4+T-cells, and (D) percentage of FoxP3-expression within the CD25HighCD4+T-cells in peripheral blood of 
pSS-patients (before and after RTX-treatment) and sex- and age-matched HCs. Bars represent median percentage. 
In this study, PBMCs from 5 pSS-patients (at baseline and at 24 weeks post RTX-treatment) and 5 age- and sex-
matched healthy controls (HC) were isolated immediately from freshly drawn blood by density-gradient centrifugation 
on Lymphoprep. Cells recovered from the gradient interface were washed and immediately incubated with appropriate 
concentrations of FITC-anti-CD3, PerCP-anti-CD4, and PE-anti-CD25, for 30 minutes at 4 oC in the dark. Cells 
were fixed/permeabilized followed by the addition of APC-conjugated rat anti-human-FoxP3. After incubation for 30 
minutes at 4 oC, the cell suspension was washed and immediately analyzed on FACS-Calibur (Becton & Dickinson). 
For all flow cytometry analyses, data were collected for 105 cells. Lymphocytes were gated by forward and side scatter, 
and plotted using the Win-List software package (Verity Software House Inc, ME, USA). Positively and negatively 










Figure 4: Functional characterization of Tregs in pSS-patients, before and after B cell depletion, compared to HCs.
Figure 4. PBMCs from 5 pSS-patients (at baseline and at 24 weeks post RTX-treatment) and 5 age- and sex-matched 
healthy controls (HC) were isolated immediately from freshly drawn blood and incubated for 45 minutes at 4 oC 
with appropriate concentrations of APC-anti-CD4, PE-anti-CD25, and a cocktail of anti-CD8, anti-CD56, and anti-
γδTCR, all FITC labeled. Cells were washed and sorted on a FACS-MoFlow (Becton & Dickinson) according to 
their forward and side scatter properties. Subsequently, FITC-positive cells were excluded, and the CD4+T-cell fraction 
was sorted into a CD4+CD25- population as responder T-cells (T
Resp
) and a CD4+CD25High population as regulatory 
T-cells (Tregs). The purity of the sorted T
Resp




 (1x104 cells per well) and Tregs (1x104 cells per well) were cultured in triplicate, separately or in co-
culture (ratio 1:1), in round-bottom 96-well plates in 200µL of complete RPMI1640 medium. Cells were incubated 
in the absence or presence of soluble anti-CD3 and anti-CD28 for 6 days at 37°C in 5% CO
2
. For the last 18 hours of 
culture 1 µCi/well (3H)-thymidine was added, and (3H)-thymidine incorporation was counted and expressed as counts 
per minute. The percentage suppression of proliferation was calculated as follows: 
% Suppression= 1- (mean cpm of co-culture / mean cpm of responder cells alone) x 100%
Percentage suppression of Tregs proliferation by autologous Tregs from HCs (n=5), and pSS-patients (n=5) before and 
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 To retrospectively analyze the clinical course of patients with mucosa-associated 
lymphoid tissue (MALT)-type lymphoma of the parotid gland and associated Sjögren’s 
syndrome (SS).
Methods
 All consecutive patients with SS and MALT lymphoma (MALT-SS) diagnosed in the 
University Medical Center Groningen, The Netherlands, between January 1997 and 
January 2009 were analyzed. Clinical course and treatment outcome of SS and MALT 
lymphoma were evaluated. 
Results
 From a total of 329 SS patients, 35 MALT-SS patients were identified, with a median 
follow-up of 76 months (range 16-153 months). MALT lymphoma was localized in the 
parotid gland in all cases. Treatment consisted of “watchful waiting” (n=10), surgery 
(n=3), radiotherapy (n=1), surgery combined with radiotherapy (n=2), rituximab 
only (n=13), or rituximab combined with chemotherapy (n=6). Complete response 
was observed in 14 patients, partial response in one patient and stable disease in 20 
patients. 
 In six of 7 patients with initially high SS disease activity (M-protein, cryoglobulins, 
IgM-Rf > 100 KIU/l, severe extraglandular manifestations) their MALT lymphoma 
progressed and/or SS disease activity increased after a median follow-up of 39 months 
(range 4-98 months), necessitating retreatment. Only one MALT patient with low SS 
disease activity showed lymphoma progression when left untreated.
Conclusion
 An initially high SS disease activity likely constitutes an adverse prognostic factor for 
progression of lymphoma and/ or SS. Such patients may require treatment for both 
MALT lymphoma and SS. In SS patients with localized asymptomatic MALT lymphoma 












 Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by chronic 
inflammation of the salivary and lacrimal glands. SS is frequently accompanied by 
systemic symptoms. Four-to-seven percent [1;2] of patients with SS develop malignant 
B cell lymphoma, 48-75% of which are of the mucosa-associated lymphoid tissue 
(MALT)-type. These B cell lymphomas are most frequently located in the parotid 
gland [3-5]. A recent study showed a 6.6-fold increase of non-Hodgkin lymphoma 
(NHL) in SS patients as compared to controls [6]. MALT lymphoma of the parotid 
gland was almost exclusively associated with SS, as there was a 1000-fold increase in 
the relative risk of having SS in case of a MALT lymphoma presenting in the parotid 
gland [6]. In SS patients parotid gland enlargement is frequently present but varies in 
time. The change from variable to persistent enlargement of glands is an important 
clinical sign, indicating the possible development of MALT lymphoma. Furthermore, the 
emergence of lymphoma in SS may be heralded by extraglandular manifestations of 
SS (e.g., palpable purpura, vasculitis, renal involvement, peripheral neuropathy). None 
of these features are specific for MALT lymphoma in SS, but any of them should raise 
suspicion, particularly if accompanied by features such as monoclonal gammopathy, 
reduced levels of complement C4, CD4+ T lymphocytopenia, a sharp decrease in IgG 
levels or cryoglobulinemia [2;7-10]. 
 Assessment of SS patients who may have developed a MALT lymphoma is not 
always easy, but an incisional biopsy of the parotid gland can safely be performed under 
local anesthesia [11].
 MALT lymphoma in general is an indolent disease, with a reported 5-year overall 
survival between 86% and 95%, without significant difference in clinical course between 
localized and disseminated disease [12;13]. Recurrences may involve extra-nodal or 
nodal sites. Progression to aggressive lymphoma is rare, occurring in less than 10% of 
cases [14]. 
 MALT lymphoma in patients with SS is often localized at one or more salivary glands 
[usually the parotid gland[s]], but can also occur in other extranodal sites, such as the 
orbital adnexa [15] and stomach [16]. Dissemination of MALT-SS may be observed 
in local draining lymph nodes or, sometimes, distant nodes, and, occasionally, other 
mucosal sites and bone marrow [17]. Prognosis does not seem to be influenced by 
dissemination to other MALT organs, although involvement of lymph nodes might be 
an adverse prognostic factor [13;17].
 The relative infrequency and heterogeneity of MALT lymphomas, with their 
different biology, clinical presentation and behaviour, makes it difficult to define optimal 
treatment of these patients in general. Antibiotics are widely used as initial treatment 










lymphoma associated with Helicobacter Pylori [18-21]. In other MALT lymphomas with 
symptomatic local disease, local treatment (surgery or radiotherapy) results in excellent 
disease control [22]. However, in SS patients conventional radiotherapy of the salivary 
glands (25 to 39 Gy) may lead to significant further xerostomia [23;24]. An alternative 
approach might be low-dose 2x2 Gy involved field radiotherapy. This therapy is very 
effective in follicular lymphoma [25] and data in MALT lymphoma seems promising 
[26;27]. For symptomatic disseminated disease, chemotherapy has commonly been 
used, with 75% complete remission rate and 5 years event-free survival and overall 
survival rates of 50% and 75% respectively [12;13;28-30]. More recently, Rituximab, 
a chimeric murine/human anti-CD20 monoclonal antibody that is highly efficacious 
in patients with B cell lymphoma, alone or in combination with chemotherapy [31-
34], has also been used effectively in patients with MALT lymphoma, with or without 
associated SS [35-40]. 
 At present, no clear guidelines exist for the management of patients with MALT-SS. 
In this retrospective study we report our experience in 35 consecutive patients with 




 Our hospital, the University Medical Center Groningen, is a referral institute for SS 
in the Netherlands. Patients are referred to either the department of Rheumatology or 
Oral Medicine. Subsequently, all patients with suspicion of SS are routinely evaluated in 
both departments. In case of MALT lymphoma, patients are also seen by a hematologist. 
A retrospective analysis was performed of all consecutive patients diagnosed with 
SS and MALT lymphoma in our hospital, between January 1997 and January 2009. 
Included were patients with a diagnosis of extranodal marginal zone (MALT) lymphoma 
according to the WHO classification [41]  and a concomitant diagnosis of SS according 
to the American-European consensus criteria [42]. All MALT-SS patients were seen at 
6-month intervals for routine follow-up. Follow up ended on February 1, 2010 (median 
follow-up 76 months, minimal follow-up of 12 months). 
Diagnosis of SS and MALT lymphoma
 A full routine diagnostic work-up for SS was carried out in all patients at their first 
visit as described before [38]. In short, this work-up included: subjective complaints 
of ocular and oral dryness, eye tests (Rose bengal staining and Schirmer tear test), 
measuring unstimulated whole salivary flow, parotid sialography, and serology (anti-
SSA/B-antibodies). In all patients an incision biopsy of the parotid gland was part of 
the SS work-up and performed under local anesthesia [11;43]. All patients in our 










American-European SS association, Hepatitis C and HIV infections were  excluded 
accordingly [42].
 All biopsies were reviewed by a hematopathologist (PK). In all 35 cases 
immunohistochemistry was performed for at least CD3, CD5, CD20, CD79a, CD10, 
BCL6 and cytoplasmic immunoglobulins [kappa, lambda, IgM, IgG and IgA]. In 21/35 
cases DNA analysis of clonality was performed using PCR for FR1, FR2 and FR3 of the 
immunoglobulin heavy chain gene complex, as described by Van Dongen et al.[44] and 
Sandberg et al.[45] All FR PCR reactions were performed in fourfold at two dilutions. 
All 21 cases revealed a dominant and reproducible monoclonal population of B cells 
in one or more framework PCR reactions. To distinguish between reactive benign 
lymphoproliferation and MALT lymphoma, the classification of Quintana et al. [46] was 
used. All lymphomas were classified according to the WHO classification published in 
2008 [41]. 
Staging of MALT lymphoma and disease activity score of SS
 Patients were staged according to a standard lymphoma protocol including CT or 
MRI-scans of head/neck, thorax and abdomen, and a bone marrow biopsy [47]. For SS 
associated MALT lymphomas located in the salivary gland, we used a relatively simple 
staging system based on the Ann Arbor classification [47] and the modification for 
primary gastric lymphoma by Musshoff [48] as follows:
 (1) Localized disease: lymphoma located in one or more salivary glands [unilateral 
  or bilateral], without enlargement of lymph nodes;
 (2) Locally disseminated disease: lymphoma localized in one or more salivary 
  glands [unilateral or bilateral] with one or more enlarged regional lymph nodes 
  [> 1 cm];
 (3) Disseminated disease: localization of lymphoma in one or more salivary glands
  [unilateral or bilateral] with one or more enlarged distant lymph nodes 
  (> 1 cm), and/or bone marrow, spleen, liver, or other extranodal site than the  
  salivary gland, or localization of lymphoma in multiple extranodal sites.
 SS disease activity was evaluated based on the following variables: the presence 
of extraglandular manifestations (e.g. arthritis, fatigue, vasculitis, glomerulonephritis), 
subjective sicca symptoms (using a 100-mm visual analogue scale (VAS)), salivary gland 
function and serological parameters (levels of total IgG and IgM rheumatoid factor 
(IgM-Rf), C4, cryoglobulins, M-protein). Based on these parameters a global impression 
of disease activity (low, moderate, high) was determined by the physicians (R.P., J.P., H.B., 











Treatment and treatment evaluation
 The choice of treatment modality was decided by a team of experts (rheumatologist, 
oral surgeon, pathologist, haematologist) based on clinical, serological and radiographic 
data. In general the following treatment regimens were used:  watchful waiting, surgery, 
radiotherapy, surgery combined with radiotherapy or cyclophosphamide-prednisone. 
Rituximab was available from 2002 onwards and added to the treatment regimens. 
Rituximab monotherapy was given as 4 weekly infusions of 375 mg/m2 [38]; Rituximab 
with cyclophosphamide and prednisone (R-CP) was given as 6-8 intravenous infusions 
of 375 mg/m2 of rituximab and 750 mg/m2 cyclophosphamide. One infusion was 
given every 3-4 weeks, in combination with 100 mg prednisone p.o. for 5 days. After 
initial rituximab or R-CP treatment no maintenance immunotherapy was given. 
 Time between diagnosis of SS and presentation of lymphoma, response to treatment, 
and clinical course during follow-up were retrieved from the medical records. Tumor 
responses were classified as complete response (CR), partial response (PR), stable 
disease (SD), or recurring/progressive disease (PD), according to the standardized 
response criteria for malignant lymphomas [49;50]. In brief, CR required the absence 
of palpable swelling of salivary glands and return of all nodes to less than 1 cm on 
CT/MRI, and normalization of bone marrow, spleen, liver or other extranodal sites, 
if initially involved. In patients with localized disease CR was considered when no 
evidence of disease was present after diagnostic surgical excision with or without 
subsequent radiotherapy or after R-CP objectified by MRI. Seven patients treated with 
rituximab monotherapy took part in a prospective clinical trial in which a repeated 
parotid gland biopsy was performed after treatment as defined by protocol [38]. In 
these patients, a repeated biopsy of the involved parotid gland had to show complete 
disappearance of the lymphoma infiltrate for classifying these patients to have reached 
CR. PR required regression of initial tumor mass by ≥ 50% without development of 
new lesions. SD was defined as < 50% regression or < 50% increase of the known 
sites of disease. PD recurrence required ≥ 50% increase of any previously identified 
abnormal lesions or any new lesion (including recurrence in case of previous CR), 
irrespective of simultaneous responses at other sites. 
 Since there are no validated disease activity response criteria for SS yet [51;52], 
deterioration of SS was arbitrarily defined as the occurrence of one or more of the 
following: an increase in levels of IgG, an increase in levels of IgM-Rf, decrease in salivary 
gland function, increase in subjective oral or ocular symptoms, and/or the development 
of extraglandular manifestations [arthritis, vasculitis; pulmonary, hepatic or renal SS 
involvement]. Improvement of SS required one or more of the following: a decrease in 
levels of IgG and/or IgM-Rf, improvement of salivary gland function [53], improvement 
of subjective symptoms, and/or the disappearance of extraglandular manifestations. 










to the above mentioned criteria. The criteria mentioned above are in agreement with 
the outcome criteria in SS for clinical trials as proposed by Pillemer et al.[54] and the 
later developed, not yet validated, disease activity scales  [51;52]. 
results
Patient characteristics
 From a total of 329 SS patients diagnosed in our hospital between January 1997 and 
January 2009, 35 (11%) MALT-SS patients were identified. Two SS patients developed 
extraglandular lymphoproliferative malignancies without parotid gland involvement; 
one patient had an inguinal extra-ossal plasmacytoma, the other a rectal MALT 
lymphoma. For the purpose of this study, these patients were both excluded from 
analysis. Characteristics of MALT lymphoma and SS of the 35 patients included in this 
study are listed in tables 1 and 2.
Table 1. Clinical characteristics of the 35 patients with MALT-SS 
   No. of patients Percentage (%)
  Characteristic
  
  Gender   
                male 3 9
                female 32 91
  
  Staging MALT*   
                Localized disease 26 74
                Locally disseminated 5 14
                Disseminated disease 4 11
  
  SS disease activity*  
                low activity 28 80
                high  7 20
   
*See methods for MALT-SS staging and SS disease activity definitions
 In 11 out of 35 (31%) patients MALT lymphoma was detected by chance in a parotid 
biopsy during routine diagnostic work-up of SS. Eighteen (51%) MALT lymphomas 
were detected in patients presenting with active SS and suspicion of MALT lymphoma 
development based on persistent glandular swelling, confirmed after parotid biopsy. Six 
(17%) patients presented with a parotid gland tumor initially, in whom a diagnosis of 
MALT lymphoma in association with SS was made following the parotid biopsy. 
Median age at MALT lymphoma diagnosis was 55 years (range 26-84). MALT lymphoma 
was localized in the parotid gland in all cases (n=35). The majority of patients had 
localized disease (26 out of 35 (74%)) Five patients (14%) had locally disseminated 










Table 2. SS characteristics of the MALT-SS patients
Abbreviatons:  UPN: unique patient number; *patient with high SS disease activity; see Patients and Methods; #Age 
at time of diagnosis of MALT-SS; F: female; M: male; SS: Sjögren’s syndrome; PGS: parotid gland swelling; M-protein: 
monoclonal protein present; IgG: immunoglobulin G (normal 8.5-15 g/liter); IgM-Rf: IgM rheumatoid factor 
(normal <11 kIU/l)
lacrimal gland involvement in two patients, and involvement of the stomach in one 
patient). Seven patients had high SS disease activity initially, as exemplified by monoclonal 
gammopathy / cryoglobulins, increased IgM-Rf and one or more severe extraglandular 










Treatment and response of MALT lymphoma
 Ten patients (28%) received no initial treatment because the lymphoma was 
asymptomatic. These patients were closely monitored (“watchful waiting”) (tables 3 
and 4). In 5 patients a diagnostic superficial parotidectomy was performed because of 
persistent symptomatic unilateral parotid gland swelling, which resulted in complete 
excision of the lymphoma in 3. Three patients received radiotherapy including the 2 
patients with incomplete excision of the lymphoma.  Thirteen patients (37%) were 
treated with rituximab only, seven of those patients participated in a phase II study with 
rituximab and have been described in a previous report. [38] Six patients (17%) were 
treated with R-CP. 
Table 3. Treatment and outcome of the 35 MALT-SS patients
Abbreviations:  L, localized disease;  LD, locally disseminated disease;  DD, disseminated disease;  
 CR, complete remission; PR, partial response; SD, stable disease ; RCP: 
 rituximab-cyclophosphamide-prednisone combination (see patients and methods)
Lymphoma response in the 25 patients treated with surgery, radiotherapy, rituximab 
or R-CP was as follows: CR in 14 patients (56%), PR in one patient (4%) and SD in 10 











































































































































































































































Table 5. Adverse factors before and after initial treatment of the MALT-SS patients
Abbreviatons:  UPN: unique patient number; *patient with high SS disease activity; see Patients and Methods; PGS: 





















































































































































































Figure 1:  Progression-free survival of MALT-lymphoma.
Figure 1. Progression-free survival of MALT lymphoma according to initial SS disease activity; Red, 28 MALT-
SS patients with low initial SS disease activity; Black, 7 MALT-SS patients with high initial SS disease activity The 
difference in disease-free-survival of patients with initial low versus high SS disease activity was significant (p< 0.05) 
*One patient with high initial SS disease activity was retreated with cyclophosphamide because of SS disease activity 
without signs of MALT-lymphoma (table 6)
 A reduction in extraglandular manifestations (arthritis, vasculitis, pulmonary, hepatic 
or renal SS involvement) was seen in all systemic treated patients (rituximab or R-CP). 
Improvement in serologic parameters (increase C4, no presence of cryoglobulins and 
M-protein) was observed in the majority of patients (9 out of 13) treated with rituximab. 
Three of the four patients that did not show improvement in serologic parameters after 
rituximab treatment had high SS disease activity initially. All six patients treated with 
R-CP showed normalization of these serologic parameters after treatment (table 5).
Long-term outcome and  follow-up
 After a median follow-up of 76 months (range16-153) after initial MALT-SS diagnosis, 
progression or recurrence of MALT lymphoma was observed in 10 out of 35 patients 
at a median time of 45 months after diagnosis (range 4-98 months, table 6). Five of 
the 10 patients with progression or recurrence of lymphoma had high SS disease 
activity initially (table 3). The difference in disease-free-survival of patients with initial 
low versus high SS disease activity was significant (p< 0.05, figure 1). 
 In the “watchful waiting” group, two of the 10 patients showed MALT-lymphoma 
progression after 34 and 81 months. One of these patients also had high SS disease 
activity at the initial MALT diagnosis. All other patients in the “watchful waiting” group 










Figure 2: Management of MALT-SS
Figure 2. Clinical algorithm leading to MALT-SS diagnosis and treatment. A: patients in whom MALT-SS is diag-
nosed by chance at routine diagnostic biopsy for SS diagnosis; B: patients with known SS and strong clinical suspicion 
of lymphoma; C: patients with unknown parotid gland swelling; MALT/SS: patients with MALT lymphoma and 
associated Sjögren’s syndrome (SS); FNA: fine needle aspiration; *extraglandular disease: polyarthritis/myositis, glo-
merulonephritis, nervous system involvement, cryoglobulinemic vasculitis, other severe organ involvement, serological 
abnormalities: cryoglobulinaemia, C4 < 0.10 g/l; **R-CP: six intravenous infusions of 375 mg/m2 of rituximab and 










Increased extraglandular SS activity without progression of MALT lymphoma 
necessitating immunosuppressive retreatment was observed in 1 patient treated with 
rituximab at 27 months after MALT diagnosis (table 6). 
Transformation to high-grade lymphoma was not observed. Thirty-four patients are 
alive at a median follow-up of 76 months (range 16-153 months), one patient died of 
pneumonia unrelated to MALT lymphoma.
dIscussIon
 In this retrospective study we analyzed the clinical course of patients with SS and 
associated MALT lymphoma. SS patients with MALT lymphoma of the parotid gland 
usually had localized disease. High SS disease activity at presentation, i.e. multiple 
extraglandular SS manifestations, low C4, presence of cryoglobulins and/ or M-protein, 
was associated with clinical progression or recurrence of MALT lymphoma and/or 
deterioration of SS during follow-up necessitating (re)treatment. Although the median 
follow-up of 6 years is still relatively short, transformation to high-grade lymphoma was 
not observed and no patient died from lymphoma. 
 MALT lymphoma in patients with SS is part of a spectrum ranging from indolent 
asymptomatic lymphoma and low SS disease activity to locally disseminated or 
disseminated lymphoma and severe extraglandular SS manifestations. According to 
the latest diagnostic consensus criteria, pre-existent lymphoma is considered to be an 
exclusion criterion of SS, because lymphoma of the parotid gland itself can cause mouth 
dryness and parotid gland swelling [42]. In our opinion, however, MALT lymphoma of 
the salivary gland should not be considered as an exclusion criterion for the diagnosis 
of SS. As also shown in the study by Ekström et al [6], the great majority of these 
lymphomas are associated with SS or other autoimmune diseases [17;55]. According to 
that study, vasculitis, peripheral nerve involvement, glomerulonephritis, fever, anaemia, 
and lymphopenia are observed significantly more often in MALT-SS patients than in the 
general SS population [5]. In our study the majority of patients (71%) had no severe 
extraglandular manifestations. This discrepancy might be explained by the inclusion of 
11 patients in whom a MALT-lymphoma was detected during diagnostic work-up for 
SS, which included a parotid biopsy in our institution instead of a labial biopsy.  
 The parotid biopsy is preferred because of its association with less morbidity and 
comparable diagnostic potential to that of a labial biopsy in the diagnosis of SS [43]. 
Other studies have found an incidence of 3.4 to 7% of MALT-lymphoma within their 
SS cohort [1;2;5]. Since the parotid is the gland most commonly involved in MALT-
lymphoma, the routine use of the parotid biopsy for the diagnosis of SS likely explains a 
slightly higher incidence of MALT-lymphoma in our SS cohort (11%) [56]  as well as the 











The high survival rate in our cohort (97%, one patient died of pneumonia unrelated to 
MALT-lymphoma) is in accordance with literature of MALT-lymphoma not associated 
with SS  [13;14]. Progression/relapse was seen in 29% of our patients, this finding is also 
in accordance with the 30% progression/relapse rate reported for MALT lymphoma 
not associated with SS [57]. 
 The staging system for MALT-SS used in this study [see Patients and Methods] 
may provide better prognostic information at diagnosis than the traditional Ann Arbor 
staging. Although MALT-lymphoma in SS can localize in other mucosal sites, it usually 
localizes in the main target of the autoimmune disease, i.e the parotid gland, [16;56] It 
is debatable whether it is necessary to perform full staging in patients with MALT-SS, 
including CT-scans of thorax and abdomen and bone marrow biopsy. Bone marrow 
involvement is rare in the patients described, and probably does not influence prognosis 
nor treatment [12].  
 In some patients with locally disseminated or disseminated disease, it may be difficult 
to decide whether symptoms should be attributed to lymphoma activity or to SS activity. 
For example, B symptoms such as weight loss, might be attributed to lymphoma activity, 
but they could also be part of SS disease activity. In these patients, both lymphoma 
and SS disease activity need to be addressed: not only the clinical characteristics of 
the lymphoma, but also the severity of SS manifestations might determine the choice 
of treatment. We are aware of the fact that the use of an international standardised 
activity score is needed for evaluating SS disease activity. However, in the time frame 
this cohort was diagnosed, no standardised activity score was available [51;52]. By that 
time the disease activity was assessed by a team of experts according to our own 
standardized methods (Methods section).
 As observed in this analysis, “watchful waiting” seems a suitable option in patients 
with asymptomatic MALT lymphoma in the absence of high SS disease activity, since 
most patients remained asymptomatic for a long period of time (figure 1). In patients 
with symptomatic MALT lymphoma, such as a persistent disabling parotid gland 
swelling, but with low SS disease activity, local treatment with low-dose involved field 
radiotherapy to spare remaining salivary function (2x2 or 1x4 Gy) might be sufficient. 
However, experience with low-dose involved field radiotherapy in extra-nodal MALT-
lymphoma is limited.
 Our study also suggests that in SS-MALT patients with initial high SS disease activity 
rituximab monotherapy might not be sufficient because these patients required 
retreatment due to recurrence of MALT-lymphoma and/or development of SS disease 
activity. Also, normalization of serological parameters was not seen (low C4 levels and 
presence of cryoglobulins and/or M-protein). In these patients treatment might have 
to include more intensive immunosuppressive therapy, for instance a combination of 
rituximab with cyclophosphamide and prednisone (R-CP). This combination therapy is 










Current guidelines for management and treatment of patients with MALT-SS in our 
center are based on the treatment experience stated in this article (figure 2):
 i. Asymptomatic MALT and low SS disease activity: watchful waiting
 ii. Symptomatic local MALT,  no- or low SS disease activity: radiotherapy; 
 iii. High SS disease activity and asymptomatic MALT: rituximab only (phase II
  trial) or immunochemotherapy: Rituximab-Cyclophosphamide-Prednisone   
  (R-CP) 
 iv. Symptomatic MALT and high SS disease activity: R-CP
Although our study indicates that most treated patients fare well, recurrences may 
occur. Whether these patients might benefit from maintenance B-cell depletion therapy, 
as has been shown in indolent B-cell lymphoma and autoimmune diseases like RA and 











1. Sutcliffe N, Inanc M, Speight P, et al. Predictors of 
lymphoma development in primary Sjögren’s syndrome. 
Semin Arthritis Rheum 1998; 28:80-7.
2. Theander E, Henriksson G, Ljungberg O, et al. 
Lymphoma and other malignancies in primary Sjögren’s 
syndrome: A cohort study on cancer incidence and 
lymphoma predictors. Ann Rheum Dis. 2006; 65: 796-803
3. Kassan SS, Thomas TL, Moutsopoulos HM, et al. 
Increased risk of lymphoma in sicca syndrome. Ann Intern 
Med 1978; 89: 888-92.
4. Tzioufas AG, Boumba DS, Skopouli FN, et al. 
Mixed monoclonal cryoglobulinemia and monoclonal 
rheumatoid factor cross-reactive idiotypes as predictive 
factors for the development of lymphoma in primary 
Sjögren’s syndrome. Arthritis Rheum 1996; 39: 767-72.
5. Voulgarelis M, Dafni UG, Isenberg DA, et al. Malignant 
lymphoma in primary Sjögren’s syndrome: a multicenter, 
retrospective, clinical study by the European Concerted 
Action on Sjögren’s Syndrome. Arthritis Rheum 1999; 42: 
1765-72.
6. Ekstrom Smedby K, Vajdic CM, Falster M, et al. 
Autoimmune disorders and risk of non-Hodgkin 
lymphoma subtypes: a pooled analysis within the 
InterLymph Consortium. Blood 2008; 111: 4029-38.
7. Fox RI. Sjögren’s syndrome. Lancet 2005; 366: 321-31.
 
8. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-
term risk of mortality and lymphoproliferative disease 
and predictive classification of primary Sjögren’s 
syndrome. Arthritis Rheum 2002; 46 :741-7.
9. Ramos-Casals M, Brito-Zeron P, Yague J, et al. 
Hypocomplementaemia as an immunological marker 
of morbidity and mortality in patients with primary 
Sjögren’s syndrome. Rheumatology 2005; 44: 89-94.
10. Theander E, Manthorpe R, Jacobsson LT. Mortality 
and causes of death in primary Sjögren’s syndrome: 
a prospective cohort study. Arthritis Rheum 2004; 50: 
1262-9.
11. Kraaijenhagen HA. Letter: Technique for parotid 
biopsy. J Oral Surg 1975; 33:328.
12. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-
associated lymphoid tissue lymphoma is a disseminated 
disease in one third of 158 patients analyzed. Blood 2000; 
95: 802-6.
13. Zucca E, Conconi A, Pedrinis E, et al. Nongastric 
marginal zone B-cell lymphoma of mucosa-associated 
lymphoid tissue. Blood 2003; 101: 2489-95.
14. Thieblemont C, Bastion Y, Berger F, et al. Mucosa-
associated lymphoid tissue gastrointestinal and 
nongastrointestinal lymphoma behavior: analysis of 108 
patients. J Clin Oncol 1997; 15: 1624-30.
15. Coupland SE, Krause L, Delecluse HJ, et al. 
Lymphoproliferative lesions of the ocular adnexa. Analysis 
of 112 cases. Ophthalmology 1998; 105: 1430-41.
16. Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas 
in patients with Sjögren’s syndrome are marginal zone 
B-cell neoplasms, arise in diverse extranodal and nodal 
sites, and are not associated with viruses. Blood 1997; 90 
:766-75.
17. Ambrosetti A, Zanotti R, Pattaro C, et al. Most cases 
of primary salivary mucosa-associated lymphoid tissue 
lymphoma are associated either with Sjögren’s syndrome 
or hepatitis C virus infection. Br J Haematol 2004; 126: 
43-9.
18. Du MQ, Isaccson PG. Gastric MALT lymphoma: 
from aetiology to treatment. Lancet Oncol 2002; 3: 97-104.
19. Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence 
for an association between Chlamydia psittaci and ocular 
adnexal lymphomas. J Natl Cancer Inst 2004; 96: 586-94.
20. Lecuit M, Abachin E, Martin A, et al. 
Immunoproliferative small intestinal disease associated 
with Campylobacter jejuni. N Engl J Med 2004; 350: 
239-48.
21. Roggero E, Zucca E, Mainetti C, et al. Eradication 
of Borrelia burgdorferi infection in primary marginal 
zone B-cell lymphoma of the skin. Hum Pathol 2000; 31: 
263-8.
22. Thieblemont C. Clinical presentation and 
management of marginal zone lymphomas. Hematology 
2005; 307-13.
23. Tsang RW, Gospodarowicz MK, Pintilie M, et al. 
Localized mucosa-associated lymphoid tissue lymphoma 
treated with radiation therapy has excellent clinical 
outcome. J Clin Oncol 2003; 21: 4157-64.
24. Vissink A, Jansma J, Spijkervet FK, et al. Oral sequelae 











25. Haas RL, Poortmans P, de Jong D, et al. High response 
rates and lasting remissions after low-dose involved field 
radiotherapy in indolent lymphomas. J Clin Oncol 2003; 
21: 2474-80.
26. Luthy SK, Ng AK, Silver B,  et al. Response to low-
dose involved-field radiotherapy in patients with non-
Hodgkin’s lymphoma. Ann Oncol 2008; 19: 2043-7.
27. Pijpe J, Van Imhoff GW, Vissink A, et al. Changes 
in salivary gland immunohistology and function after 
rituximab mono-therapy in a patient with Sjögren’s 
syndrome and associated MALT-lymphoma. Ann Rheum 
Dis 2005; 64: 958-60.
28. Hammel P, Haioun C, Chaumette MT, et al. Efficacy of 
single-agent chemotherapy in low-grade B-cell mucosa-
associated lymphoid tissue lymphoma with prominent 
gastric expression. J Clin Oncol 1995; 13: 2524-9.
29. Thieblemont C, de la Fouchardiere A, Coiffier 
B. Nongastric mucosa-associated lymphoid tissue 
lymphomas. Clin Lymphoma 2003; 3: 212-24.
30. Zinzani PL, Magagnoli M, Galieni P, et al. 
Nongastrointestinal low-grade mucosa-associated 
lymphoid tissue lymphoma: analysis of 75 patients. J Clin 
Oncol 1999; 17: 1254.
31. Coiffier B, Lepage E, Briere J, et al. CHOP 
chemotherapy plus rituximab compared with CHOP 
alone in elderly patients with diffuse large-B-cell 
lymphoma. N Engl J Med 2002; 346: 235-42.
32. Maloney DG, Grillo-Lopez AJ, White CA, et al. 
IDEC-C2B8 [Rituximab] anti-CD20 monoclonal 
antibody therapy in patients with relapsed low-grade 
non-Hodgkin’s lymphoma. Blood 1997; 90: 2188-95.
33. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy 
plus rituximab compared with CVP as first-line 
treatment for advanced follicular lymphoma. Blood 2005; 
105: 1417-23.
34. Valencak J, Weihsengruber F, Rappersberger K, et al. 
Rituximab monotherapy for primary cutaneous B-cell 
lymphoma: response and follow-up in 16 patients. Ann 
Oncol 2009; 20: 326-30.
35. Conconi A, Martinelli G, Thieblemont C, et al. 
Clinical activity of rituximab in extranodal marginal 
zone B-cell lymphoma of MALT type. Blood 2003; 102: 
2741-5.
36. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical 
activity of rituximab in gastric marginal zone non-
Hodgkin’s lymphoma resistant to or not eligible for 
anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23: 
1979-83.
37. Nuckel H, Meller D, Steuhl KP, et al. Anti-CD20 
monoclonal antibody therapy in relapsed MALT 
lymphoma of the conjunctiva. Eur J Haematol 2004; 73: 
258-62.
38. Pijpe J, Van Imhoff GW, Spijkervet FK, et al. 
Rituximab treatment in patients with primary Sjögren’s 
syndrome: An open-label phase II study. Arthritis Rheum 
2005; 52: 2740-50.
39. Raderer M, Jager G, Brugger S, et al. Rituximab for 
treatment of advanced extranodal marginal zone B cell 
lymphoma of the mucosa-associated lymphoid tissue 
lymphoma. Oncology 2003; 65: 306-10.
40. Meijer J, Meiners P, Vissink A, et al. Effective rituximab 
treatment in primary Sjögren’s syndrome: A randomised, 
double-blind, placebo-controlled trial. Arthritis Rheum 
2010 Apr; 62: 960-8
41. Swerdlow SH CEHNeal. WHO Classification of 
Tumours of Haematopoietic and Lymphoid Tissues [ed 
4th]. Lyon, France: IARC Press. 2008.
42. Vitali C, Bombardieri S, Jonsson R, et al. Classification 
criteria for Sjögren’s syndrome: a revised version of the 
European criteria proposed by the American-European 
Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
43. Pijpe J, Kalk WW, Van der Wal JE, et al. Parotid gland 
biopsy compared with labial biopsy in the diagnosis of 
patients with primary Sjögren’s syndrome. Rheumatology 
2007; 46: 335-41.
44. van Dongen JJ, Langerak AW, Bruggemann M, et 
al. Design and standardization of PCR primers and 
protocols for detection of clonal immunoglobulin 
and T-cell receptor gene recombinations in suspect 
lymphoproliferations: report of the BIOMED-2 
Concerted Action BMH4-CT98-3936. Leukemia 2003; 
17: 2257-317.
45. Sandberg Y, Gastel-Mol EJ, Verhaaf B, et al. 
BIOMED-2 multiplex immunoglobulin/T-cell receptor 
polymerase chain reaction protocols can reliably replace 
Southern blot analysis in routine clonality diagnostics. J 










46. Quintana PG, Kapadia SB, Bahler DW, et 
al. Salivary gland lymphoid infiltrates associated 
with lymphoepithelial lesions: a clinicopathologic, 
immunophenotypic, and genotypic study. Hum Pathol 
1997; 28: 850-61.
47. Lister TA, Crowther D, Sutcliffe SB, et al. Report 
of a committee convened to discuss the evaluation and 
staging of patients with Hodgkin’s disease: Cotswolds 
meeting. J Clin Oncol 1989; 7 :1630-6.
48. Musshoff K. [Clinical staging classification of non-
Hodgkin’s lymphomas [author’s transl]]. Strahlentherapie 
1977; 153: 218-21.
49. Cheson BD, Horning SJ, Coiffier B, et al. Report 
of an international workshop to standardize response 
criteria for non-Hodgkin’s lymphomas. NCI Sponsored 
International Working Group. J Clin Oncol 1999; 17: 
1244-53.
50. Cheson BD, Pfistner B, Juweid ME, et al. Revised 
response criteria for malignant lymphoma. J Clin Oncol 
2007; 25: 579-86.
51. Seror R, Ravaud P, Bowman S, et al. EULAR 
Sjögren’s Syndrome Disease Activity Index [ESSDAI]: 
Development of a consensus systemic disease activity 
index in primary Sjögren’s syndrome. Ann Rheum Dis. 
2010; 69: 1103-9
52. Bowman SJ, Sutcliffe N, Isenberg DA, et al. Sjögren’s 
Systemic Clinical Activity Index [SCAI]--a systemic 
disease activity measure for use in clinical trials in primary 
Sjögren’s syndrome. Rheumatology 2007; 46: 1845-51.
53. Pijpe J, Kalk WW, Bootsma H, et al. Progression of 
salivary gland dysfunction in patients with Sjögren’s 
syndrome. Ann Rheum Dis 2007; 66: 107-12.
54. Pillemer SR, Smith J, Fox PC, et al. Outcome 
measures for Sjögren’s syndrome. J Rheumatol 2005; 32: 
143-9.
55. Cavalli F, Isaacson PG, Gascoyne RD, et al. MALT 
Lymphomas. Hematology 2001; 241-58.
56. Batsakis JG. Primary lymphomas of the major salivary 
glands. Ann Otol Rhinol Laryngol 1986; 95: 107-8.
57. Arcaini L, Burcheri S, Rossi A, et al. Nongastric 
marginal-zone B-cell MALT lymphoma: prognostic 
value of disease dissemination. Oncologist 2006; 11: 
285-91.
58. Chambers SA, Isenberg D. Anti-B cell therapy 
[rituximab] in the treatment of autoimmune diseases. 
Lupus 2005; 14: 210-4.
59. Czuczman MS, Grillo-Lopez AJ, White CA, et al. 
Treatment of patients with low-grade B-cell lymphoma 
with the combination of chimeric anti-CD20 
monoclonal antibody and CHOP chemotherapy. J Clin 










































 Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by 
lymphocytic infiltrates in the exocrine glands, affecting predominantly the salivary 
and lacrimal glands. Patients mainly suffer from dry mouth (xerostomia) and dry 
eyes (keratoconjunctivitis sicca). Multiple manifestations such as fatigue, arthralgia and 
myalgia are frequently present and together with the dryness related complaints lead 
to a diminished quality of life in patients with SS. Two forms of SS exist, namely, primary 
SS (pSS), when the salivary and lacrimal glands are involved in the disease process, and 
secondary SS (sSS), when the patients also suffer from another autoimmune disease 
such as rheumatoid arthritis and systemic lupus erythematosus. SS can be accompanied 
by a lymphoid malignancy. Studies have determined the risk of developing mucosa 
associated lymphoid tissue (MALT) lymphoma to be between six [1] and 20 [2] times 
greater than within the general population. Approximately 7.5% of patients develop 
MALT lymphoma, particularly in the primary presentation of the syndrome [3, 4]. 
 No acknowledged treatment for pSS exists, but B cell depletion by rituximab, a 
monoclonal directed against CD20 on B cells, has shown promising clinical beneficial 
results in several trials. In these trials most attention was given to clinical parameters, 
disease activity and quality of life. Less focus was given to the immunopathology 
in pSS during B cell depletion treatment. Information gathered on the local and 
systemic effects before and after B cell depletion therapy can provide insight into the 
immunopathogenic mechanism of pSS. In the research described in this thesis, the focus 
has been put on systemic immunopathological effects of B cell targeted anti-CD20 
monoclonal antibody therapy (rituximab) in pSS, in particular the effects of rituximab 
treatment on the cytokine and chemokine profile, and on the local inflammation and 
regenerative potential of the epithelial component of secretory tissue of parotid glands. 
Furthermore, guidelines for the management of MALT lymphoma were developed in 
which rituximab treatment also plays a role.
 There is evidence that genes and their protein products are organized into functional 
modules according to cellular processes and pathways. Systems biology analysis, 
based on microarray data, is increasingly used to provide relative measurements of 
mRNA levels for thousands of genes in a biological sample. In chapter 2 a systems 
biology analysis of expression data from human salivary gland tissue (parotid gland) 
and mouse salivary gland tissue is described. This analysis demonstrated 4 significant 
upregulated and 3 downregulated co-expression modules in parotid glands from 
human pSS patients compared to control parotid glands. From these 7 co-expression 
modules, one human disease related module was highly preserved in the SS mouse 
model suggesting a shared pathway. This module was enriched with genes involved in 










lymphocyte recruitment and molecules involved in germinal center (GC) formation. 
Cell type abundance assessments of the parotid gland of pSS patients compared to 
controls showed a predominance of B cells over other immune cells such as T cells 
and dendritic cells. These observations support the notion that B cells and B cell 
related factors, such as GCs and certain cytokines/chemokines (a.o., BAFF, IFN-α and 
IL-6) play an important role in human pSS pathogenesis and prompted us to study 
the immunoregulatory aspect, with focus on B cells and B cell related factors, in the 
subsequent chapters. 
 Based on the significance of the immune factors, and the notion that B cells 
predominate in the parotid glands (chapter 2), it was plausible to study the local 
effects of rituximab on the local inflammation and regenerative potential of salivary 
tissue after B cell targeted therapy in parotid glands. Therefore, in chapter 3 a double 
blind, randomized, placebo controlled trial with rituximab in patients with pSS is 
described in which the local inflammation and regenerative potential of the parotid 
gland was assessed. Thirty pSS patients had been included in this trial of which 20 
patients received rituximab and 10 received placebo treatment. In all rituximab treated 
patients a major reduction of the lymphocytic infiltrate and of the B/T-cell ratio was 
observed, while no reduction in infiltrate and B/T-cell ratio was observed in placebo-
treated patients. The relative number of lymphoepithelial lesions and GC-like structures 
was significantly reduced in rituximab treated, but not in placebo-treated patients. In 
the rituximab treated patients there was no significant change in stimulated parotid 
salivary flow compared to baseline, while parotid flow had significantly decreased 
in the placebo treated patients. Thus rituximab treatment leads to major reduction 
of lymphocytic infiltration, GC-like structures, lymphoepithelial lesions and relative B 
cell component. Together with this reduction, a major loss of GC-like structures and 
redifferentiation of lymphoepithelial lesions into regular striated ducts was observed, 
reflecting major reduction of histologically verified disease activity. This reduction of 
inflammation in the parotid gland is reflected by a preservation of the parotid salivary 
flow.
 
 Clinical effects of rituximab monotherapy have been shown to last for 6-9 months. 
This notion, together with the results of chapters 2 and 3, suggests that there are 
additional factors enabling the survival and reappearance of (autoreactive) B cells. B 
cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are known B 
cell survival factors. Adding together, these observations led us to determine the effect 
of B cell depletion by rituximab treatment on BAFF and APRIL levels in serum and 
localization in parotid gland tissue (chapter 4). Blood samples were collected from 
the 30 pSS patients (20 rituximab and 10 placebo; see also chapter 3), at various 










of localization of BAFF, parotid gland biopsies of 5 rituximab and 5 placebo treated 
patients were immunohistologically stained before and after treatment. The results 
showed increased levels of BAFF and APRIL in blood of pSS patients at baseline when 
compared to healthy controls. Notably, rituximab treatment resulted in a period of 
nearly depleted peripheral B cells and a profound increase in BAFF levels. The APRIL 
levels did not change after treatment. Localization assessment of BAFF in parotid glands 
of rituximab treated patients revealed staining of BAFF in the lymphocytic infiltrate 
surrounding the ducts. Despite the reduction in size of these infiltrates, BAFF staining 
was still clearly present. From this study it was concluded that rituximab treatment 
leads to a significant increase of BAFF. This increase, together with the local presence of 
BAFF, might explain survival of (auto-reactive) B cells and reoccurrence of SS disease 
activity.
 
 The results of the study described in chapter 2 pointed towards the critical role 
of cytokines and chemokines in the pathogenesis of pSS. In chapter 4 we have 
shown that B cell depletion results in a rise in BAFF levels which could lead to a BAFF 
modulated repopulation of B cells in the blood and salivary glands of rituximab treated 
patients. Whether the (elevated) levels of other (pro-inflammatory) cytokine levels 
are affected by rituximab treatment was addressed in chapter 5. Blood samples at 
various time points from treated pSS patients (20 rituximab, 10 placebo) and blood 
from 10 healthy controls were analyzed for a large panel pro-inflammatory and other 
cytokines. The results of this study showed elevated levels for nearly all cytokines in 
pSS patients compared to healthy controls at baseline, reflecting the immune activity 
of this autoimmune disease. More importantly, when compared to placebo, a decrease 
in a subset of mainly pro-inflammatory cytokines (GM-CSF, IL-1Ra, IL-6, IL-10, IFN-α, 
TNF-α) and chemokines (MIP-1β (CCL4), MIG (CXCL9)) was observed in rituximab 
treated patients. After this initial decline, levels reached baseline values by 36 weeks 
after rituximab treatment. This study demonstrated that depletion of B cells resulted 
in a concomitant decrease in serum levels of a subset of mainly pro-inflammatory 
cytokines. These results suggest that the beneficial effect of rituximab treatment in 
pSS patients is mediated, at least in part, by depletion of pro-inflammatory cytokine 
producing B cells.  
 
 Besides the immediate effect caused by depletion of (autoreactive) B cells, rituximab 
treatment may also influence the frequency and function of regulatory T cells (Tregs). 
Tregs are a subset of T cells that play an essential role in immune homeostasis by 
suppression of the proliferation and function of, amongst others, effector T cells (Teffs). 
In chapter 6 a study is described in which the effect of rituximab treatment on the 
frequency and function of Tregs was assessed. From the 30 patients of the clinical trial, 










blood from 10 healthy controls was analyzed. Finally, from 5 patients treated with 
rituximab the function of Tregs was assessed by co-culture assay at baseline and 24 
weeks after rituximab infusion. The results of this study showed no significant difference 
between Tregs of healthy controls and pSS patients as well as that rituximab treatment 
did not change the frequency of Tregs. Functional analysis of Tregs revealed no change 
in function before and after rituximab treatment. Thus, the effectiveness of rituximab 
treatment in pSS patients is not associated with enhancement of peripheral Tregs 
numbers and/or function. 
A variety of immune factors (a.o., GCs, IL-6, BAFF), as assessed in the previous chapters, 
is thought to play a role in the lymphoproliferation that may progress into MALT-
lymphoma. In chapter 7 a retrospective study is described on basis of which results 
guidelines for the management of MALT-lymphoma patients with associated SS were 
developed. A total of 329 SS patients was evaluated amongst which 35 MALT-pSS 
patients were identified with a median follow-up of 76 months. In all cases, the MALT-
lymphoma was localized in the parotid gland. Treatment consisted of “watchful waiting”, 
surgery, radiotherapy, surgery combined with radiotherapy, rituximab only or rituximab 
combined with chemotherapy. It was shown that MALT-lymphoma progressed in 6 out 
of 7 patients with initial high pSS disease activity and in only 1 out of 28 patients with 
initial low pSS disease activity. From this study it was concluded that an initially high 
pSS disease activity likely constitutes an adverse prognostic factor for progression of 
lymphoma. Furthermore, in pSS patients with localized asymptomatic MALT lymphoma 
and low pSS disease activity, a “watchful waiting” strategy seems justified. Guidelines for 
the treatment of pSS derived MALT-lymphoma are given.
     
general dIscussIon
 Several factors, including genetic predisposition and environmental triggers, have 
been posed to be involved in the development of SS. Although the exact primary event 
in the etiology of SS remains elusive, the studies described in this thesis demonstrate a 
critical role of B cells and B cell related immune factors in the pathogenesis of pSS. 
B cells in the lymphocytic infiltrate of the salivary glands
 The hallmark in the development of pSS is the formation of lymphocytic infiltrates 
in exocrine glands. The parotid gland tissue used in the studies described in this thesis 
provide the unique opportunity for repeated biopies of the same gland to study the 
effect in the same target organ before and after targeted therapy. In chapter 3 it is 
shown that immunostaining results of parotid gland tissue of pSS patients supported 










in parotid gland tissue by demonstrating a predominance of B cells over T cells at 
baseline. 
 The predominance of B cells in the lymphocytic infiltrate in parotid gland tissue 
is in contrary to the T cell predominance in human minor labial glands. In the latter 
glands, T cells account for approximately 80% of the total infiltrate, with the remaining 
20% composed of B cells and plasma cells [5]. It has been suggested that during 
the progression of SS the initial predominance of T cells is gradually reduced by an 
accumulation of B cells and plasma cells [6, 7]. The initial discrepancy in B cell numbers 
between minor salivary and parotid glands in pSS, might be caused by the more 
favorable niche for B cell development in the parotid gland in which gland type GC-like 
structures are commonly observed.   
Immune factors involved in B cell development and survival
 In GC-like structures, which are ectopic lymphoid microstructures, mature B cells 
rapidly proliferate, differentiate, mutate (through somatic hypermutation) and class 
switch their antibodies during an immune response. B cells become activated and 
undergo, presumably in the GC-like structures, antigen-driven changes such as Ig heavy 
chain class switching and affinity maturation. These antigen-driven changes are thought 
to ultimately lead to the generation of memory B and antibody-producing plasma 
cells [8]. It has been suggested that GC-like structures affect disease expression in pSS, 
exemplified by studies showing that presence of GC-like structures coincides with 
elevated titres of rheumatoid factor, autoantibodies, increased IgG levels and larger 
lymphocytic infiltrates [9, 10]. 
 The effect of GC-like structures is mediated by the higher lymphocytic organization 
leading to increased disruption of glandular tissue [11]. GC-like structure formation can 
increase the effectiveness of communication between lymphocytes, thereby aiding in 
lymphocyte function [10]. Furthermore, in a retrospective study it has been proposed 
that the presence of GC-like structures in labial salivary glands of pSS patients might 
be used as a highly predictive and easy to obtain marker for lymphoma development 
[12]. 
 B cell development is dependent on survival factors such as B cell activating factor 
(BAFF) and a proliferation induced ligand (APRIL) which were shown to be elevated 
in serum of pSS patients (chapter 4). After rituximab treatment serum BAFF level 
increased profoundly and immunostaining showed presence of BAFF in parotid gland 
tissue (chapter 4). In particular, survival of B cells in parotid gland tissue after rituximab 
therapy might be modulated by BAFF through its effects on their lifespan [13]. As a 
result, BAFF can act as a survival signal for B cells and may diminish the efficacy of 
rituximab treatment [13, 14]. Therefore, adding an anti-BAFF treatment to a treatment 











Autoreactive B cell selection and activation after rituximab treatment
 The incomplete resolving of GC-like structures and, more importantly, the observed 
increase of serum BAFF levels after rituximab treatment may result in undesired side 
effects on selection and survival of autoreactive B cells and on B cell activation. B cell 
receptor and BAFF-receptor (BAFF-R) signaling synergize in B cell survival, which is 
mediated by activation of NF-kB [16]. B cell receptor signaling activates the classical 
NF-kB pathway that results in the production of p100 substrate, required for BAFF-R 
signaling via the alternative NF-kB pathway [17]. Evidence from studies with transgenic 
mice indicates that BAFF levels regulate the stringency of the selection of naive B cells 
[13, 18, 19]. Current models suggest that naive B cells expressing a transgenic surface 
Ig that binds DNA or protein autoantigens first attempt to alter the B cell receptor 
by further variable gene rearrangement using “receptor editing” [20, 21]. If receptor 
editing is unsuccessful, then the offending B cell may be eliminated by clonal deletion 
[22] or it may enter maturity, although with reduced or altered function so that it no 
longer reacts to the self-antigens, which is referred to as clonal anergy [23, 24]. 
 The half-life of anergic B cells, when compared to non-anergic B cells, is substantially 
decreased when BAFF levels are reduced [18]. Excess of BAFF rescues autoreactive 
cells that are anergized after the early transitional B cell stage, but not at the early B cell 
stage [18]. One possible explanation, for the poor survival response when BAFF levels 
are limited, is that autoreactive transitional B cells down regulate their B cell receptors, 
which results in less availability of substrate (p100), required for BAFF-R signaling. As a 
consequence these cells require higher BAFF levels for their survival and differentiation 
to mature B cells [25]. In contrast, long-lived memory B cells that arise after an antigen 
driven autoimmune response, appear to be completely independent from BAFF (and 
APRIL) [25, 26]. It might therefore be that the increased peripheral expression and 
local presence of BAFF could lead to survival of the (auto-) reactive B cell in the 
GC-like structures. The majority of re-emerging B cells after rituximab treatment are 
transitional type B cells [27] and it remains to be seen that this B cell fraction comprises 
more autoreactive cells compared to placebo treated patients.
 The notion that BAFF levels regulate the selection of naïve B cells is based on studies 
with (genetically-engineered) mice (reviewed in Liu and Davidson [28]). Studies in 
human are lacking. Whether the elevated serum BAFF levels observed after rituximab 
treatment also impair the stringency of the selection of naive and/or memory B cells 
in pSS patients, and therewith promote autoreactivity, is not known. In conclusion, 
the possibility that the persistence of GC-like structures and elevated BAFF levels 
contribute to the new formation of autoreactive cells from the bone marrow and 
lymphoproliferation cannot be completely ruled out, but, probably BAFF alone does 










Role of IL-6 in development and survival of B cells
 At the B cell level, IL-6 stimulates B cell proliferation and differentiation to plasma 
cells, amongst others via IL-21, which contribute to the B cell hyperreactivity and 
hypergammaglobulinemia seen in patients with pSS [29]. More importantly, IL-6 
stimulates GC-like structure formation, amongst others, by CXCL13 and IL-6 induced 
production of IL-21 [30-32].
 In pSS patients, it was shown that IL-6 serum cytokine levels are increased at baseline 
and decrease after rituximab treatment (chapter 5). The decrease of IL-6 after 
rituximab treatment is in conjunction with a decrease in GC-like structures (chapter 3), 
which suggests a linked pathway. Furthermore, IL-6 has been shown to play an important 
role in immunopathology by the generation of Th17 pro-inflammatory lymphocytes 
[33], which lymphocytes seem to be involved in the formation of GC-like structures 
in the salivary glands [34]. Thus, reduced levels of IL-6, after rituximab treatment, may 
result in fewer Th17 cells. In rheumatoid arthritis, a reduction in the Th17 response in 
the synovial tissues of patients has been observed after rituximab therapy too [35]. 
The observed decrease of IL-6 (chapter 5), after rituximab treatment, could explain 
the reduction in GC-like structures (chapter 3) in salivary gland tissue. Reduced IL-6 
levels seen after rituximab treatment may also cause less B cell activation of remaining 
local B cells. Furthermore, since this cytokine is also is an important survival factor 
for plasma cells, rituximab could also affect, indirectly via IL-6, the number of plasma 
cells in the body and the IgG levels seen in serum. Indeed, in vitro experiments have 
shown that there is a strong correlation between concentration of IL-6 and IgA or IgG 
secretion by plasma cells [36]. 
Etiology and immunoregulatory pathway
 Although the findings reported in this thesis share light on the immune factors 
involved in the pathogenesis of pSS, the exact etiology remains obscure. A viral trigger 
has been implicated in the initial development of SS. It is known that most viruses can 
induce production of type I interferons. Interferons (IFNs) are a family of cytokines 
derived from different cell types in response to many stimuli including bacteria, viruses, 
foreign cells, macromolecules, and other chemical compounds. The majority of INFs 
constitute of the 13 IFN-α subtypes [37, 38].
 A pathologic overproduction of type I IFN has been observed in autoimmune diseases, 
such as systemic lupus erythematosus, type 1 diabetes mellitus and dermatomyositis 
[39]. Serum IFN-α levels are found to correlate with activities and severity of both 
diseases as well as some clinical manifestations such as fever and skin rashes in patients 
with systemic lupus erythematosus [40, 41]. Recently, overproduction of type I IFN has 
been noted in pSS patients too [39, 42]. IFN production was observed in both in sera 











 Type I IFN, which can be produced by, amongst others, plasmacytoid dendritic cells 
and epithelial cells, has strong antiviral effects but can also enhance proliferation of 
autoreactive B cells and the autoantibody production [43, 44]. Type I IFN can also 
increase the expression and exposure of autoantigens to autoreactive B cells and 
T cells [45, 46], the underlying mechanism is yet unknown. More interestingly, BAFF 
expression is largely increased by stimulation with type 1 or 2 IFN [47].
 BAFF is an IFN-induced gene and studies have shown that BAFF-expression is 
through a type I IFN-dependent mechanism [48]. Previous studies have shown that 
TNF blockers are not effective in the treatment of pSS. It was shown that treatment of 
pSS patients with TNF blocker etanercept led to a significant increase in plasma IFN-α 
[49]. The increase of IFN-α leads to an increase in BAFF. This indicates BAFF as a more 
relevant therapeutic target for the disease [49]. 
 It can be speculated that viral infection, in genetic and hormonal predisposed 
individuals, results in activation and overproduction of the type I IFN system in the 
salivary glands (chapter 2) which may be involved in the development of pSS. Virus-
specific T Iymphocytes may lead to (over-)production of type II IFN-γ (chapter 5). 
IFN type I and II would drive the inflammation leading to the formation of neoepitopes 
and breakdown of self tolerance, achieved in part by the oxidative damage of certain 
ribonucleoprotein particles, such as proteins Ro and La, as observed in systemic lupus 
erythematosus [50], Activated B cells would become autoreactive memory B cells in 
GC-like structures (chapter 3), under stimulation of BAFF (chapter 4). and stimulate 
the production of proinflammatory cytokines, such as IL-6 and TNF-α (chapter 5). 
These pro-inflammatory cytokines lead to the perpetuation of GC-like structures, 
inhibition of Tregs (chapter 6) [51] and continuous tissue inflammation. Continuous 
tissue inflammation results in tissue destruction, decreased glandular function, 
extraglandular manifestations and increased risk of MALT-lymphoma development 
(chapter 7). Indeed we have demonstrated that a decrease of B cells could lead to a 
decrease in IFN type I/II (chapter 5) and may account, in part, for the beneficial effects 
of rituximab treatment. 
Future perspectives
 In this thesis it is shown that monotherapy of rituximab, although beneficial in 
improving extraglandular manifestations, might not be sufficient to improve parotid 
glandular function and maintain clinical beneficial effects longer than 36 weeks in pSS 
patients. It is also shown that local B cells and plasma cells [52] survive after rituximab 
treatment in pSS, probably because of a survival niche mediated by BAFF, and that 
rituximab treatment leads to a profound elevation of peripheral BAFF levels. These 
observations may have implications for future treatment regiments in pSS. 
 It can be speculated that anti-BAFF or anti-IL-6 therapy, e.g., belumimab and 










complementary therapy aside B cell depletion with rituximab. Indeed clinical trials 
with anti BAFF and anti IL-6, although not combined with rituximab, have already 
proven successful in rheumatoid arthritis [53] and systemic lupus erythematosus [54, 
55].  Effects of these treatment regiments are currently unknown in pSS and clinical 
trials are eagerly awaited [56]. Currently, at our department, anti BAFF and anti IL-
6 trials are designed to assess the effect on clinical and immunohistopathology in 
pSS. Furthermore, combining the targeting of BAFF with rituximab treatment could 
enhance and prolong the effect of rituximab in pSS. 
 In addition to the crucial role of B cells exemplified in this thesis, T cells play a 
fundamental part in the pathogenesis too. For example, effector CD4+ T helper 
(Th) cells are required for humoral immune responses to the ubiquitously expressed 
ribonucleoproteins, the proteins the autoantibodies against Ro/SSA and La/SSB are 
directed to. These CD4+ Th cells are essential for the generation of plasma cells and the 
formation of memory cells in the GC-like structures in the salivary glands [57]. CD4+ 
Th cells are also critically involved in the inflammatory response in exocrine glands and 
their cytokines affect directly ductal epithelial cells [58]. Most of the activated CD4+ 
T cells in salivary glands of pSS express cytokines such as IFNγ and TNFα, which are 
classically considered to be prototypic for Th1 cells [59]. In addition to Th1 cells, also 
Th17 cells have been shown to be involved in the pathogenesis of pSS [57]. 
 Activation of CD4+ T cells requires recognition of the T cell receptor of peptide 
bound to MHC class II molecules and co-stimulation by binding of the co-stimulatory 
molecules CD80/CD86 to CD28 expressed on the surface of the T cells [60, 61]. 
Dendritic cells are critically involved in the full activation of naïve CD4+ T cells. These 
cells not only present antigen to the T cells, but also deliver the required co-stimulatory 
signals [62]. In order to receive appropriate help from effector CD4+ T cells, B cells 
also present antigen to the T cells and express the co-stimulatory molecules CD80/86, 
in order to become either a memory or plasma cell [63]. Interestingly, ductal epithelial 
cells in salivary glands of pSS patients also appear to act as antigen presenting cells [64]. 
Probably under the influence of pro-inflammatory cytokines, these epithelial cells not 
only express MHC class II molecules, but, importantly, also express the co-stimulatory 
molecules CD80/86 [64]. The role of this form of antigen presentation to T cells in 
pathogenesis of pSS remains to be elucidated. The biological disease modifying anti-
inflammatory rheumatic drug abatacept inhibits co-stimulation of T cells by binding 
with high affinity to the molecules CD80 and CD86, herewith blocking their binding 
to CD28 on the surface of T cells [65]. It is expected that in absence of appropriate 
co-stimulation by CD28 both arms of the adaptive immune responses will be inhibited. 
This inhibition may lead a.o. to reduced inflammation (by Th1 cells), decrease in ectopic 
lymphoid tissue formation (by Th17 cells), decreased memory B cell formation (by 
follicular helper T cells) and plasma cell formation (by Th1 and Th2 cells). Ultimately 










currently used for the treatment of rheumatoid arthritis and it appears to be safe and 
effective [66]. First results of the open label trial with abatacept at our department 
reveal that abatacept treatment is well tolerated, safe and effective with respect to 
disease activity, laboratory parameters and general fatigue in patients with pSS. 
Treatment of SS has been just symptomatic for a long time. The increasing availability of 
targeted treatment modalities has created possibilities for intervention in pathogenic 
pathways involved in the disease. This availability has also provided insight into the 
pathogenesis of pSS. Unlike most other diseases accompanied by lymphocytic infiltration, 
the salivary glands are accessible to biopsy, before and after treatment. Therefore, pSS 
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In hoofdstuk 1 wordt kort de geschiedenis van het syndroom van Sjögren (SS) 
beschreven en de opbouw van het proefschrift uiteengezet. SS is een systemische 
auto-immuunziekte die wordt gekenmerkt door lymfocytaire-infiltraten in de exocriene 
klieren, in het bijzonder in de speeksel- en traanklieren. De lymfocytaire infiltraten 
bestaan voornamelijk uit B- en T-cellen en leiden uiteindelijk tot destructie van deze 
klieren. Twee vormen van SS kunnen worden onderscheiden, namelijk het primaire SS 
(pSS), wanneer alleen de speeksel- en traanklieren zijn betrokken bij het ziekteproces, 
en het secundaire SS (sSS), wanneer de patiënten tevens lijden aan een andere auto-
immuunziekte, zoals reumatoïde artritis of systemische lupus erythematodes. 
 Het merendeel van de patiënten met SS ondervindt hinder van het gevoel van 
een droge mond (xerostomie) en droge ogen (keratoconjunctivitis sicca). Tevens zijn 
vaak een groot aantal andere manifestaties aanwezig, in het bijzonder, vermoeidheid, 
gewrichtspijn en spierpijn. Samen met de droogheidsklachten leiden deze manifestaties 
tot een beperking van de dagelijkse activiteiten en een verminderde kwaliteit van leven. 
 Kenmerkend voor het ziekteproces is dat de B-lymfocyten hyperactief zijn. Dit 
uit zich ondermeer in het feit dat patiënten met pSS een te hoge hoeveelheid 
immuunglobulinen (antilichamen) in hun bloed hebben (hypergammaglobulinemie), 
alsmede antilichamen gericht tegen ‘eigen’ lichaamscomponenten (autoantilichamen). 
Ook is de samenstelling van de B cel subpopulaties in het bloed veranderd, vergeleken 
met gezonde individuen. In de geïnfiltreerde speekselklieren leidt deze hyperactiviteit 
tot aanwezigheid van kiemcentra. Dit zjjn morfologisch herkenbare structuren waar 
geheugen B cellen gemaakt worden. Ook kunnen er klonale expansies van B cellen 
aangetroffen worden. Deze klonen kunnen ontsporen waardoor er een kwaadaardige 
woekering van B-lymfocyten optreedt. Patiënten met SS hebben dan ook een sterk 
verhoogd risico op het ontwikkelen van lymfomen. Dit betreft vooral het zogenaamde 
mucosa-associated lymfoid tissue (MALT) lymfoom. Studies hebben aangetoond dat 
het risico voor een SS patiënt om een MALT-lymfoom te ontwikkelen zes tot 20 keer 
hoger is dan het risico hierop in de algemene populatie. Ongeveer 7,5% van de SS 
patiënten ontwikkelt uiteindelijk een MALT lymfoom. Vooral in patiënten met pSS is de 
kans op het ontwikkelen van een dergelijk lymfoom verhoogd. 
 Er is nog geen erkende behandeling voor SS die direct ingrijpt in het ziekteproces;  het 
merendeel van de huidige behandelingen is gericht op het verlichten van de gevolgen 
van en klachten gerelateerd aan SS. Recent zijn nieuwe mogelijkheden geschapen 
om, door gebruik te maken van therapeutische monoklonale antilichamen, ook te 
interveniëren in het ziekteproces  zelf om zo de ziekteactiviteit van SS te remmen en 
verdere progressie te voorkomen. Deze monoklonale antilichamen grijpen vaak aan 
op specifieke eiwitten die zich op het celmembraan van B- en T-cellen bevinden of 
zijn gericht tegen communicatiemoleculen (cytokinen) van het immuunsysteem. Van 










in verschillende studies klinisch gunstige resultaten aangetoond in patiënten met pSS. 
Behandeling met rituximab leidt tot een daling van het aantal B cellen in het perifere 
bloed. In de tot dusver verrichte studies met rituximab is de meeste aandacht besteed 
aan klinische parameters, zoals ziekteactiviteit en kwaliteit van leven. Minder aandacht is 
besteed aan de immunopathologie van pSS tijdens B cel depletie. Nadere bestudering 
van de lokale en systemische effecten van B cel depletie therapie kan inzicht geven in het 
onderliggende immunopathogenetische mechanisme in pSS. In het in dit proefschrift 
beschreven onderzoek is de nadruk gelegd op de immunopathologische effecten van 
B cel gerichte therapie met rituximab in pSS, in het bijzonder op de effecten van een 
behandeling met rituximab op het cytokinen en chemokinen profiel in het bloed en 
de histopathologische veranderingen in het weefsel van de glandula parotidea (de 
oorspeekselklier). Daarnaast is nagegaan hoe een MALT-lymfoom in pSS patiënten het 
beste kan worden behandeld. In deze behandeling speelt rituximab eveneens een rol. 
 Genen en hun eiwitproducten kunnen worden onderverdeeld in functionele 
modules op geleide van de betrokken cellulaire processen en routes. Door middel 
van analyse technieken uit de systeembiologie kan inzicht worden verkregen in 
deze modules. Met behulp van microarrays kunnen van duizenden genen in een 
weefselmonster relatieve metingen op mRNA niveau worden gedaan. In hoofdstuk 2 
worden de uitkomsten van een dergelijke analyse van humaan (gl. parotidea) en muizen 
(gl. submandibularis/sublingualis en gl. parotidea) speekselklierweefsel beschreven. In 
dit onderzoek is weefsel van de oorspeekselklier gebruikt van zowel SS patiënten 
als van patiënten met monddroogheidsklachten die geen SS bleken te hebben (sicca 
patiënten) en gezonde controles. Uit deze analyse komen een zevental co-expressie 
modules (ziekte-gerelateerde gen-netwerken) naar voren waarbij de expressie van 
genen bij pSS anders is dan bij controle individuen. Bij 4 co-expressie modules komen 
de genen bij pSS significant verhoogd tot expressie en 3 co-expressie modules komen 
de genen juist verminderd tot expressie. Eén van deze modules vertoonde zowel 
bij humaan SS oorspeekselklierweefsel als bij speekselklierweefsel verkregen van een 
muizenmodel voor SS grote overeenkomsten tussen de tot expressie gebrachte genen 
en hun eiwitproducten. De sterke mate van overeenkomst in deze co-expressie module 
suggereert een gedeelde route in de ontwikkeling van SS. Deze gemeenschappelijke 
co-expressie module wordt gekenmerkt door genen die zijn betrokken bij de 
immuun- en inflammatoire respons. De betrokken genen coderen voor moleculen, 
zoals chemokinen, die een rol spelen bij het mobiliseren van specifieke lymfocyten 
en voor moleculen betrokken bij de vorming van kiemcentra. Genen die coderen 
voor B cellen bleken te zijn oververtegenwoordigd ten opzichte van genen coderend 
voor andere imuuncellen, zoals T cellen en dendritische cellen. Deze waarnemingen 
steunen de hypothese dat B cellen en B cel gerelateerde factoren, zoals de vorming 










belangrijke rol spelen in de pathogenese van pSS. De uit de systeembiologische analyse 
naar voren gekomen bevindingen hebben ons aangezet het immunoregulatoire aspect 
in pSS, met nadruk op de rol van B cellen en B cel gerelateerde factoren, nader te 
onderzoeken.
 Gezien het belang van de B cellen bij de destructie van de speekselklieren, werden 
de effecten van B cel depletie door rituximab op lokale ontstekingsparameters en 
regeneratieve mogelijkheden van het speekselklierweefsel bestudeerd. In hoofdstuk 
3 zijn de histopathologische uitkomsten van een dubbelblinde, gerandomiseerde, 
placebo gecontroleerde studie met rituximab in patiënten met pSS beschreven. 
Biopten van de oorspeekselklier van 30 pSS patiënten zijn bestudeerd. Van deze 
patiënten waren 20 patiënten behandeld met rituximab en 10 met een placebo. 
In tegenstelling tot de patiënten die een placebo kregen, werd in alle rituximab 
behandelde patiënten een aanzienlijke vermindering van de lymfocytaire infiltratie en 
de B/T-celverhouding waargenomen. In tegenstelling tot het bloed werd geen totale 
depletie van B cellen waargenomen in het weefsel van de oorspeekselklier. Het relatieve 
aantal lymphoepitheliale laesies (een bepaald type beschadiging van klierbuisjes in de 
speekselklier) en kiemcentrum-achtige structuren was significant verminderd in de 
rituximab behandelde patiënten, maar bleef onveranderd in de patiënten die een 
placebo hadden gekregen. Deze tekenen van een verminderde ontstekingsactiviteit 
en herstel van het weefsel van de oorspeekselklier in rituximab behandelde patiënten 
leidden niet tot significante verandering in de secretie van gestimuleerd speeksel 
door de oorspeekselklier. In patiënten die met een placebo waren behandeld, was de 
secretie van dit type speeksel juist gedaald. 
 
 De klinische effecten van rituximab monotherapie houden, na injectie met rituximab, 
6-9 maanden aan. De gerapporteerde resultaten in hoofdstuk 3, suggereren dat 
niet alle (autoreactieve) B cellen in de oorspeekselklier zijn gedepleteerd. Zowel het 
cytokine BAFF (B cel activerende factor) en het cytokine APRIL (een proliferatie-
inducerende ligand)  zijn factoren die een rol spelen in de activatie en overleving van 
B cellen. In hoofdstuk 4 wordt het effect van behandeling met rituximab op de BAFF 
en APRIL concentraties in serum beschreven. Ook is gekeken naar de lokalisatie van 
BAFF in de oorspeekselklier. Voorafgaand aan de behandeling met rituximab, bleken 
de serum concentraties van BAFF en APRIL in het bloed van pSS patiënten verhoogd 
vergeleken met gezonde controles. Behandeling met rituximab resulteerde in een 
sterke toename van BAFF concentratie in het bloed, terwijl de APRIL concentratie 
onveranderd bleef. BAFF kon zowel voor als na behandeling met rituximab in biopten 
van de oorspeekselklier worden aangetoond, namelijk in de lymfocytaire infiltraten 
rond de afvoerbuizen. Een duidelijk effect van rituximab op deze BAFF expressie kon 










deze studie werd geconcludeerd dat rituximab behandeling leidt tot een significante 
toename van BAFF in het bloed. Deze stijging in serum en de lokale aanwezigheid van 
BAFF op weefselniveau kunnen een rol spelen bij de terugkeer van B cellen in het 
bloed of een verklaring vormen voor de overleving van (autoreactieve) B cellen en het 
hernieuwd optreden van ziekteactiviteit. 
 De resultaten van de in hoofdstuk 2 beschreven studie duiden ook op een cruciale 
rol van cytokines en chemokines in de pathogenese van pSS. Uit de resultaten van de in 
hoofdstuk 4 beschreven studie komt naar voren dat B cel depletie leidt tot een stijging 
van BAFF concentratie in bloed en derhalve tot een BAFF gemoduleerde repopulatie 
van B cellen in bloed en speekselklieren van rituximab behandelde patiënten. 
 Op welke andere (pro-inflammatoire) cytokinen een behandeling met rituximab 
van invloed is, is beschreven in hoofdstuk 5. Vergeleken met gezonde controles, zijn 
in pSS patiënten de serumconcentraties van bijna alle geteste cytokines verhoogd. 
Deze bevinding past bij de toegenomen activiteit van het immuunsysteem in deze 
auto-immuunziekte. Behandeling met rituximab resulteert in een daling van niet 
alle cytokinen die onderzocht zijn, maar slechts een deel hiervan (8 van de 25). De 
cytokinen waarvan de serumconcentraties waren verlaagd, betroffen voornamelijk pro-
inflammatoire cytokinen (GM-CSF, IL-1Ra, IL-6, IL-10, IFN-α, TNF-α) en chemokinen 
(MIP-1β (CCL4), MIG (CXCL9)). Na een aanvankelijke daling van deze cytokinen en 
chemokinen, werden 36 weken na een behandeling met rituximab de uitgangswaarden 
weer bereikt. Met andere woorden, depletie van B cellen resulteert in een gelijktijdige 
tijdelijke verlaging van serumspiegels van vooral pro-inflammatoire cytokines. Het 
waargenomen klinisch gunstige effect van rituximab bij patiënten met pSS wordt 
mogelijk mede gemedieerd, hetzij direct, hetzij indirect door een daling van pro-
inflammatoire cytokinen producerende B cellen.
 
 Naast een daling van het aantal (autoreactieve) B cellen, kan behandeling met 
rituximab ook van invloed zijn op de frequentie en de functie van regulatoire T cellen 
(Tregs). Bij andere auto-immuunziekten (zoals reumatoïde artritis en systemische lupus 
erythematodes) resulteerde rituximab behandeling in een effect op de Tregs. Tregs 
zijn een subset van T cellen die een belangrijke rol spelen door onderdrukking van 
de proliferatie en functie van onder andere effector-T-cellen (Teffs). In hoofdstuk 6 
wordt een studie beschreven waarin het effect van rituximab op de frequentie en de 
functie van Tregs is onderzocht. In deze studie kon voorafgaand aan de behandeling 
geen significant verschil worden aangetoond tussen Tregs van gezonde controles en 
pSS patiënten. Tevens liet de functionele analyse van Tregs geen verandering zien in zijn 
onderdrukkende functie vóór en na behandeling met rituximab. Tenslotte werd ook 
op weefselniveau geen verschil in aantal Tregs waargenomen vóór en na rituximab 










niet samen te hangen met een verhoging of veranderde functie van perifere/lokale 
Tregs
 Een verscheidenheid van immuunfactoren (o.a. aanwezigheid van kiemcentra, 
verhoogde concentratie IL-6 en BAFF) wordt verondersteld een rol te spelen in de 
proliferatie van lymfocyten resulterend in de vorming van een MALT-lymfoom bij pSS. 
Over hoe een MALT-lymfoom bij pSS patiënten moet worden behandeld bleek echter 
geen eenduidigheid te bestaan. In hoofdstuk 7 wordt een retrospectieve studie 
beschreven op basis waarvan richtlijnen voor de behandeling van pSS patiënten met 
een MALT-lymfoom zijn ontwikkeld. Een groep van 329 SS patiënten werd geëvalueerd, 
35 van deze patiënten leden aan MALT-pSS. In alle gevallen was het MALT-lymfoom 
gelokaliseerd in de oorspeekselklier. Afhankelijk van het histopathologisch beeld en een 
aantal klinische en serologische parameters bestaat de behandeling van MALT-pSS uit 
“watchful waiting”, chirurgie, radiotherapie, chirurgie in combinatie met radiotherapie, 
alleen rituximab of rituximab in combinatie met chemotherapie. 
 In hoofdstuk 8 worden de implicaties van de bevindingen uit het onderhavige 










































The journey of a thousand miles begins with a single step - Lao Tzu
In 2008 werd de eerste stap van dit onderzoeksproject gezet,  en nu, ontelbare stappen 
berg op- en afwaarts later, leest u het Dankwoord. De afgelopen jaren heb ik met veel 
voldoening gewerkt aan de totstandkoming van dit proefschrift. Zoals bij velen was 
ook dit proefschrift niet tot stand gekomen zonder de onmisbare kennis en kunde 
van velen. Ik wil dan ook beginnen om een ieder te bedanken die een bijdrage heeft 
geleverd aan dit mooie proefschrift. Verder zijn er nog enkele mensen die ik persoonlijk 
wil bedanken.  
Allereerst wil ik graag prof. dr. L.G.M. de Bont bedanken voor de mogelijkheid die mij 
geboden is om dit onderzoek, gecombineerd met de studie Tandheelkunde, uit te 
voeren op een zeer prettige afdeling. 
 
Prof. dr. A. Vissink, beste Arjan, als eerste promotor stond jij aan de basis en bewaakte jij 
de voortgang van het onderzoek. Meerdere promovendi hebben jou al geroemd om 
jouw ongeëvenaarde snelheid in het corrigeren van manuscripten. Ook ik heb je, bijna 
bovennatuurlijke, snelheid van corrigeren mogen ervaren. Je enthousiasme over het 
onderwerp van dit proefschrift en het vertrouwen dat je mij hebt gegeven gedurende 
dit onderzoeksproject heb ik zeer gewaardeerd. Vaak wist je mij op het juiste pad te 
houden als ik een zijweg wilde inslaan. Met niet aflatende inzet heb je mij geholpen dit 
onderzoek tot een goed einde te brengen. Een betere eerste promotor had ik mij niet 
kunnen wensen. Ons congresavontuur in Brest zal ik niet snel vergeten. Bedankt voor 
je begeleiding. 
Prof. dr. F.G.M. Kroese, beste Frans, meerdere momenten hebben wij samen achter de 
computer gezeten om de tekst van een artikel te “finetunen”. Jouw kwaliteit om zeer 
complexe immunologische materie uit te leggen in begrijpelijke taal bewijst weer eens 
wat voor een goede docent jij bent. Tevens wist je, mede dankzij  je ontnuchterende 
opmerkingen, de onderzoeksbesprekingen van een plezierige, open sfeer te voorzien. 
Prof. dr. F.K.L. Spijkervet, beste Fred, van onderzoeksbegeleider en co-promotor ben 
jij inmiddels mijn promotor, afdelingshoofd en opleider geworden. Zonder jouw inzet 
betreffende de  parotisbiopten was dit proefschrift er niet geweest. Ik kon altijd bij je 
terecht voor overleg en wist je van een eventueel probleem een praktische oplossing 
aan te dragen. Ik dank je voor je begeleiding.   
Prof. dr. H. Bootsma, beste Hendrika, in 2008 begon onze prettige samenwerking en 
tot op heden ben ik dat als zodanig blijven ervaren. Jij was verantwoordelijk voor de 











langslopen voor overleg. Samen hebben we ook meerdere congressen bezocht welke 
ik leerzaam maar bovenal altijd heel gezellig heb bevonden. Bedankt voor je begeleiding. 
De leden van de beoordelingscommissie: geachte prof. dr. I. van der Waal en prof. dr. 
J.W.J. Bijlsma, ik ben u zeer erkentelijk dat u de tijd heeft genomen mijn proefschrift 
te beoordelen. Prof. dr. T. Dörner, thank you very much for your willingness to join the 
committee and time to review my thesis.
Prof. dr. S. Ihrler, dear Stephan, you were indispensible during the start of this research. 
The “münich” doublestainings have been demonstrated on conferences all over the 
world! I am very grateful for the boost that you gave to this research. Thank you for 
the kind hospitality during my stay in Münich. 
Prof. dr. C. Kallenberg, beste Cees, als voormalig afdelingshoofd van de afdeling 
Reumatologie en Klinische Immunologie had jij het overzicht over de verschillende 
studies. Ik dank je voor je vlotte en zeer grondige revisies (zelfs met oog op de komma’s 
en punten). 
Prof. dr. Ph. Kluin, beste Philip,  bedankt voor de mogelijkheid om altijd bij je binnen te 
kunnen lopen voor overleg. Met name aan het begin van dit onderzoekstraject heb ik 
kunnen putten uit jouw grote kennis van de (immuno-)pathologie. Dank voor je inzet 
voor het beoordelen van de histologische preparaten. 
Dr. J. E. van der Wall, beste Jacqueline, vanaf dag 1 ben je bij mijn onderzoek betrokken 
geweest en, ondanks je verhuizing van werkplek, is je betrokkenheid nog steeds 
gebleven. Ik dank je voor je input.   
Prof. dr. N. Bos,  beste Nico, met name aan het begin van dit onderzoekstraject hebben 
we nuttige discussies gehad over de te belopen weg. Dank hiervoor. 
Prof. dr. D. Wong, dr. S. Horvath and dr. S. Hu, dear David, Sven and Shen, thank you very 
much for the pleasant collaboration in the proteonomics and genomics project, which 
has resulted in a chapter in this thesis. 
Dr. G. van Imhoff en dr. J. Burgerhof, beste Gustaaf en Hans. Bedankt voor de plezierige 
samenwerking en jullie bijdragen aan de verschillende manuscripten. Prof. dr. J.L.N. 
Roodenburg, ik dank u voor uw bijdrage aan het mooie MALT-lymfoom manuscript. 
Dr.  W. Abdulahad, beste Wayel, veel heb ik van je geleerd over de praktische kant 











inzet en harde werkethos. Meerdere hoofdstukken waren zonder jou input niet in dit 
proefschrift verschenen. Hartelijk dank hiervoor.  
M. Huitema en J. Bijzet, beste Minke, ook jij was onmisbaar bij de totstandkoming van 
dit proefschrift, hartelijk dank voor je harde werk op het lab. Beste Johan, dank voor je 
hulp bij de logistiek op het lab. A. Visser en S. Beijer, beste Annie en Sylvia, bedankt voor 
jullie bijdrage aan dit proefschrift. 
Mijn mede Sjögren’s syndroom onderzoekers. Dr. W. W. I. Kalk en dr. J. Pijpe, beste Wouter 
en Justin, vanuit de door jullie opgezette onderzoekslijn is uiteindelijk dit proefschrift tot 
stand gekomen. Dr. J.M. Meijer, beste Jiska, ik heb je leren kennen vanaf mijn allereerste 
dag in Groningen. Je enthousiasme over het doen van onderzoek naar het syndroom 
van Sjögren heeft aanstekelijk gewerkt. Drs. P. M.  Meiners, beste Petra, samen zijn 
wij begonnen aan dit uitdagende traject. Vele uren hebben we samen doorgebracht 
op de faculteit, de onderzoeksbesprekingen en (internationale) congressen. Veel 
steun hebben we aan elkaar gehad. Inmiddels zijn wij ook allebei begonnen aan de 
specialisatie opleiding.  Ik wens je veel succes met de afronding van jouw laatste loodjes. 
Dr. N. Hamza, dear Nishath, several hours were spent behind the microtome together. 
You have already finished your PhD and fled the Netherlands. I wish you well. Nicole, 
Konstantina en Erlin wens ik veel succes met het vervolgonderzoek binnen deze leuke 
onderzoeksgroep.  
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